<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<Compounds>
  <Compound version="3.0.8">
    <Ids>
      <Id sources="cder-contrera" type="reg">LS-32</Id>
      <Id sources="list,isscan,rtecs,dsscpdb,epafhm,ntp,kd" type="cas">103-90-2</Id>
      <Id sources="kd" type="kd">KD-103-90-2</Id>
      <Id sources="rtecs" type="rtecs">AE4200000</Id>
      <Id sources="dsstox-2006-11-20" type="dsstox-sid">600</Id>
    </Ids>
    <OtherIds>
      <Id sources="dsstox-2006-11-20" type="dsstox-sid">600</Id>
      <Id sources="rtecs" type="oldcas">8055-08-1</Id>
      <Id sources="epafhm" type="dsstox_rid">21855</Id>
      <Id sources="dssfdamdd,dsscpdb,dssntphts,ntpbsi,epafhm" type="dsstox_cid">6</Id>
      <Id sources="dssfdamdd,dsscpdb,dssntphts,ntpbsi,epafhm" type="dsstox_generic_sid">20006</Id>
      <Id sources="dsscpdb" type="dsstox_rid">20006</Id>
      <Id sources="dssfdamdd" type="dsstox_rid">22542</Id>
      <Id sources="ntpbsi" type="dsstox_rid">30612</Id>
      <Id sources="dssntphts" type="dsstox_rid">33137</Id>
    </OtherIds>
    <Names>
      <Name sources="kd" type="activeIngredient">ACETAMINOPHEN</Name>
      <Name sources="chemidplus" type="chemName">Acetamide, N-(4-hydroxyphenyl)-</Name>
      <Name sources="rtecs" type="synonym">4-Hydroxyacetanilide</Name>
      <Name sources="rtecs" type="synonym">4-Hydroxyanilid kyseliny octove (Czech)</Name>
      <Name sources="rtecs,chemidplus" type="synonym">Acetaminophen</Name>
      <Name sources="ntp" type="synonym">ACETAMINOPHEN (4-HYDROXYACETANILIDE)</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Apap</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Abensanil</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Acamol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Acetagesic</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Acetalgin</Name>
      <Name sources="rtecs" type="synonym">Acetamide, N-(4-hydroxyphenyl)-</Name>
      <Name sources="rtecs,chemidplus" type="synonym">Acetamide, N-(p-hydroxyphenyl)-</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Acetaminofen</Name>
      <Name sources="chemidplus" type="synonym">Acetanilide, 4'-hydroxy-</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">algotropyl</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">alvedon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Amadil</Name>
      <Name sources="isscan" type="synonym">Anacin-3</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Anaflon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">anelix</Name>
      <Name sources="rtecs" type="synonym">Apamid</Name>
      <Name sources="rtecs,chemidplus" type="synonym">Apamide</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Ben-u-ron</Name>
      <Name sources="isscan,rtecs" type="synonym">Bickie-mol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Calpol</Name>
      <Name sources="isscan,rtecs" type="synonym">Cetadol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">clixodyne</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">datril</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Dial-a-gesic</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Dirox</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Dymadon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Eneril</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Febrilix</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">febro-gesic</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">febrolin</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">fendon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Finimal</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Hedex</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Homoolan</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">lestemp</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">liquagesic</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">lonarid</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Lyteca</Name>
      <Name sources="isscan,rtecs" type="synonym">lyteca syrup</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">multin</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">N-(4-Hydroxyphenyl)acetamide</Name>
      <Name sources="rtecs,chemidplus" type="synonym">N-Acetyl-p-aminophenol</Name>
      <Name sources="rtecs" type="synonym">NAPA (analgesic)</Name>
      <Name sources="rtecs,chemidplus" type="synonym">NCI-C55801</Name>
      <Name sources="isscan,rtecs" type="synonym">napafen</Name>
      <Name sources="isscan,rtecs" type="synonym">Napap</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Naprinol</Name>
      <Name sources="isscan,rtecs" type="synonym">Nobedon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Pacemo</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Panadol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Panets</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">paracetamol</Name>
      <Name sources="rtecs" type="synonym">Paracetamole</Name>
      <Name sources="rtecs" type="synonym">Paracetamolo (Italian)</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Parmol</Name>
      <Name sources="isscan,rtecs" type="synonym">pedric</Name>
      <Name sources="isscan,rtecs" type="synonym">phendon</Name>
      <Name sources="rtecs" type="synonym">Phenol, p-acetamido-</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">pyrinazine</Name>
      <Name sources="isscan,rtecs" type="synonym">sk-apap</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Tabalgin</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Tapar</Name>
      <Name sources="isscan,rtecs" type="synonym">Temlo</Name>
      <Name sources="isscan,rtecs" type="synonym">tempanal</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Tempra</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Tralgon</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">tussapap</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Tylenol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Valadol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">Valgesic</Name>
      <Name sources="rtecs,chemidplus" type="synonym">p-Acetamidophenol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">p-Acetaminophenol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">p-Acetylaminophenol</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">p-Hydroxyacetanilide</Name>
      <Name sources="kd" type="trade">ACEPHEN</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE #2</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE #3</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE #4</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN AND HYDROCODONE BITARTRATE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE #2</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE #4</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE NO. 2</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE NO. 3</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN W/ CODEINE PHOSPHATE #3</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, ASPIRIN AND CAFFEINE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, BUTALBITAL AND CAFFEINE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE</Name>
      <Name sources="kd" type="trade">ALLAY</Name>
      <Name sources="kd" type="trade">ANEXSIA</Name>
      <Name sources="kd" type="trade">ANEXSIA 10/660</Name>
      <Name sources="kd" type="trade">ANEXSIA 5/325</Name>
      <Name sources="kd" type="trade">ANEXSIA 7.5/325</Name>
      <Name sources="kd" type="trade">ANEXSIA 7.5/650</Name>
      <Name sources="kd" type="trade">ANOQUAN</Name>
      <Name sources="kd" type="trade">APAP W/ CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">BANCAP</Name>
      <Name sources="kd" type="trade">BANCAP HC</Name>
      <Name sources="kd" type="trade">BUCET</Name>
      <Name sources="kd" type="trade">BUTALBITAL AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">BUTALBITAL, ACETAMINOPHEN AND CAFFEINE</Name>
      <Name sources="kd" type="trade">BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE</Name>
      <Name sources="kd" type="trade">BUTALBITAL, ACETAMINOPHEN, CAFFEINE</Name>
      <Name sources="kd" type="trade">BUTALBITAL, APAP, AND CAFFEINE</Name>
      <Name sources="kd" type="trade">BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE</Name>
      <Name sources="kd" type="trade">BUTAPAP</Name>
      <Name sources="kd" type="trade">CAPITAL AND CODEINE</Name>
      <Name sources="kd" type="trade">CAPITAL WITH CODEINE</Name>
      <Name sources="kd" type="trade">CO-GESIC</Name>
      <Name sources="kd" type="trade">CODEINE PHOSPHATE AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">CODEINE, ASPIRIN, APAP FORMULA NO. 2</Name>
      <Name sources="kd" type="trade">CODEINE, ASPIRIN, APAP FORMULA NO. 3</Name>
      <Name sources="kd" type="trade">CODEINE, ASPIRIN, APAP FORMULA NO. 4</Name>
      <Name sources="kd" type="trade">DARVOCET</Name>
      <Name sources="kd" type="trade">DARVOCET-N 100</Name>
      <Name sources="kd" type="trade">DARVOCET-N 50</Name>
      <Name sources="kd" type="trade">DHC PLUS</Name>
      <Name sources="kd" type="trade">DOLENE AP-65</Name>
      <Name sources="kd" type="trade">DRIXORAL PLUS</Name>
      <Name sources="kd" type="trade">DURADYNE DHC</Name>
      <Name sources="kd" type="trade">EMPRACET W/ CODEINE PHOSPHATE #3</Name>
      <Name sources="kd" type="trade">EMPRACET W/ CODEINE PHOSPHATE #4</Name>
      <Name sources="kd" type="trade">ESGIC</Name>
      <Name sources="kd" type="trade">ESGIC-PLUS</Name>
      <Name sources="kd" type="trade">EXCEDRIN (MIGRAINE)</Name>
      <Name sources="kd" type="trade">FEMCET</Name>
      <Name sources="kd" type="trade">FIORICET</Name>
      <Name sources="kd" type="trade">FIORICET W/ CODEINE</Name>
      <Name sources="kd" type="trade">HY-PHEN</Name>
      <Name sources="kd" type="trade">HYDROCET</Name>
      <Name sources="kd" type="trade">HYDROCODONE BITARTRATE AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">INFANTS' FEVERALL</Name>
      <Name sources="kd" type="trade">INJECTAPAP</Name>
      <Name sources="kd" type="trade">LORCET-HD</Name>
      <Name sources="kd" type="trade">LORTAB</Name>
      <Name sources="kd" type="trade">MEDIGESIC PLUS</Name>
      <Name sources="kd" type="trade">NEOPAP</Name>
      <Name sources="kd" type="trade">NORCET</Name>
      <Name sources="kd" type="trade">NORCO</Name>
      <Name sources="kd" type="trade">OXYCET</Name>
      <Name sources="kd" type="trade">OXYCODONE 2.5/APAP 500</Name>
      <Name sources="kd" type="trade">OXYCODONE 5/APAP 500</Name>
      <Name sources="kd" type="trade">OXYCODONE AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">PAPA-DEINE #3</Name>
      <Name sources="kd" type="trade">PAPA-DEINE #4</Name>
      <Name sources="kd" type="trade">PENTAZOCINE HCL AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">PERCOCET</Name>
      <Name sources="kd" type="trade">PHENAPHEN W/ CODEINE NO. 2</Name>
      <Name sources="kd" type="trade">PHENAPHEN W/ CODEINE NO. 3</Name>
      <Name sources="kd" type="trade">PHENAPHEN W/ CODEINE NO. 4</Name>
      <Name sources="kd" type="trade">PHENAPHEN-650 W/ CODEINE</Name>
      <Name sources="kd" type="trade">PHRENILIN</Name>
      <Name sources="kd" type="trade">PHRENILIN FORTE</Name>
      <Name sources="kd" type="trade">PHRENILIN WITH CAFFEINE AND CODEINE</Name>
      <Name sources="kd" type="trade">PROPACET 100</Name>
      <Name sources="kd" type="trade">PROPOXYPHENE HCL AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN</Name>
      <Name sources="kd" type="trade">PROVAL #3</Name>
      <Name sources="kd" type="trade">ROXICET</Name>
      <Name sources="kd" type="trade">ROXICET 5/500</Name>
      <Name sources="kd" type="trade">ROXILOX</Name>
      <Name sources="kd" type="trade">SEDAPAP</Name>
      <Name sources="kd" type="trade">SYNALGOS-DC-A</Name>
      <Name sources="kd" type="trade">TALACEN</Name>
      <Name sources="kd" type="trade">TAVIST ALLERGY/SINUS/HEADACHE</Name>
      <Name sources="kd" type="trade">TENCON</Name>
      <Name sources="kd" type="trade">TRIAD</Name>
      <Name sources="kd" type="trade">TRIAPRIN</Name>
      <Name sources="kd" type="trade">TYCOLET</Name>
      <Name sources="kd" type="trade">TYLENOL</Name>
      <Name sources="kd" type="trade">TYLENOL W/ CODEINE</Name>
      <Name sources="kd" type="trade">TYLENOL W/ CODEINE NO. 1</Name>
      <Name sources="kd" type="trade">TYLENOL W/ CODEINE NO. 2</Name>
      <Name sources="kd" type="trade">TYLENOL W/ CODEINE NO. 3</Name>
      <Name sources="kd" type="trade">TYLENOL W/ CODEINE NO. 4</Name>
      <Name sources="kd" type="trade">TYLOX</Name>
      <Name sources="kd" type="trade">TYLOX-325</Name>
      <Name sources="kd" type="trade">ULTRACET</Name>
      <Name sources="kd" type="trade">VICODIN</Name>
      <Name sources="kd" type="trade">VICODIN ES</Name>
      <Name sources="kd" type="trade">VICODIN HP</Name>
      <Name sources="kd" type="trade">WYGESIC</Name>
      <Name sources="rtecs" type="rtecsPrimeName">Acetanilide, 4'-hydroxy-</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">4'-Hydroxyacetanilide</Name>
      <Name sources="isscan,rtecs,chemidplus" type="synonym">4-Acetamidophenol</Name>
      <Name sources="rtecs" type="synonym">N-Acetyl-para-aminophenol</Name>
      <Name sources="rtecs" type="synonym">Paracetamolum</Name>
      <Name sources="rtecs" type="rtecsMolecularFormula">C8H9NO2</Name>
      <Name sources="ccris,dssfdamdd,isscan,dsscpdb,dssntphts,chemidplus" type="chemName">Acetaminophen</Name>
      <Name sources="dssfdamdd,dsscpdb,dssntphts,ntpbsi,epafhm" type="IUPACName">N-(4-hydroxyphenyl)acetamide</Name>
      <Name sources="epafhm" type="chemName">4-acetamidophenol</Name>
      <Name sources="epafhm" type="chemName">N-(4-hydroxyphenyl)acetamide</Name>
      <Name sources="isscan" type="synonym">Arthralgen</Name>
      <Name sources="isscan" type="synonym">Bancap</Name>
      <Name sources="isscan,chemidplus" type="synonym">Disprol</Name>
      <Name sources="isscan" type="synonym">Calpol infant</Name>
      <Name sources="isscan" type="synonym">Capital</Name>
      <Name sources="isscan" type="synonym">Dafalgan</Name>
      <Name sources="isscan,chemidplus" type="synonym">Darvocet-n</Name>
      <Name sources="isscan,chemidplus" type="synonym">Doliprane</Name>
      <Name sources="isscan,chemidplus" type="synonym">Dolprone</Name>
      <Name sources="isscan" type="synonym">Dristan</Name>
      <Name sources="isscan" type="synonym">Dularin</Name>
      <Name sources="isscan" type="synonym">Elixodyne</Name>
      <Name sources="isscan,chemidplus" type="synonym">Enelfa</Name>
      <Name sources="isscan,chemidplus" type="synonym">Exdol</Name>
      <Name sources="isscan" type="synonym">G 1</Name>
      <Name sources="isscan,chemidplus" type="synonym">Gelocatil</Name>
      <Name sources="isscan" type="synonym">janupap</Name>
      <Name sources="isscan" type="synonym">Korum</Name>
      <Name sources="isscan" type="synonym">Liqiprine</Name>
      <Name sources="isscan,chemidplus" type="synonym">Liquiprin</Name>
      <Name sources="isscan,chemidplus" type="synonym">Momentum</Name>
      <Name sources="isscan" type="synonym">N-Acetyl-4-aminophenol</Name>
      <Name sources="isscan" type="synonym">NAPA</Name>
      <Name sources="isscan,chemidplus" type="synonym">Paldesic</Name>
      <Name sources="isscan" type="synonym">Panaleve</Name>
      <Name sources="isscan" type="synonym">Panex</Name>
      <Name sources="isscan" type="synonym">Panofen</Name>
      <Name sources="isscan" type="synonym">Percogesic</Name>
      <Name sources="isscan,chemidplus" type="synonym">Phenaphen</Name>
      <Name sources="isscan" type="synonym">Proxyphene/Acetamine</Name>
      <Name sources="isscan,chemidplus" type="synonym">Salzone</Name>
      <Name sources="isscan" type="synonym">Sinutab</Name>
      <Name sources="isscan" type="synonym">Parapan</Name>
      <Name sources="isscan" type="synonym">Paraspen</Name>
      <Name sources="isscan,chemidplus" type="synonym">Alpiny</Name>
      <Name sources="isscan" type="synonym">alpinyl</Name>
      <Name sources="isscan,chemidplus" type="synonym">Anhiba</Name>
      <Name sources="isscan" type="synonym">Anuphen</Name>
      <Name sources="isscan" type="synonym">apadon</Name>
      <Name sources="isscan" type="synonym">Apamide.</Name>
      <Name sources="dsscpdb,ntpbsi,ntp" type="chemName">Acetaminophen (4-hydroxyacetanilide)</Name>
      <Name sources="isscan" type="synonym">D oliprane</Name>
      <Name sources="isscan" type="synonym">Panale ve</Name>
      <Name sources="isscan" type="synonym">Ty lenol</Name>
      <Name sources="chemidplus" type="chemName">Acetanilide, 4'-hydroxy-</Name>
      <Name sources="chemidplus" type="chemName">Paracetamol</Name>
      <Name sources="chemidplus" type="synonym">222 AF</Name>
      <Name sources="chemidplus" type="synonym">4-(Acetylamino)phenol</Name>
      <Name sources="chemidplus" type="synonym">4-13-00-01091 (Beilstein Handbook Reference)</Name>
      <Name sources="chemidplus" type="synonym">4-Hydroxyanilid kyseliny octove [Czech]</Name>
      <Name sources="chemidplus" type="synonym">A-Per</Name>
      <Name sources="chemidplus" type="synonym">A.F. Anacin</Name>
      <Name sources="chemidplus" type="synonym">Abenol</Name>
      <Name sources="chemidplus" type="synonym">Abrol</Name>
      <Name sources="chemidplus" type="synonym">Abrolet</Name>
      <Name sources="chemidplus" type="synonym">Acenol</Name>
      <Name sources="chemidplus" type="synonym">Acenol (pharmaceutical)</Name>
      <Name sources="chemidplus" type="synonym">Acertol</Name>
      <Name sources="chemidplus" type="synonym">Acetaminophen [USP]</Name>
      <Name sources="chemidplus" type="synonym">Acetamol</Name>
      <Name sources="chemidplus" type="synonym">Acetofen</Name>
      <Name sources="chemidplus" type="synonym">Actifed Plus</Name>
      <Name sources="chemidplus" type="synonym">Actron</Name>
      <Name sources="chemidplus" type="synonym">Afebrin</Name>
      <Name sources="chemidplus" type="synonym">Afebryl</Name>
      <Name sources="chemidplus" type="synonym">Aferadol</Name>
      <Name sources="chemidplus" type="synonym">Algesidal</Name>
      <Name sources="chemidplus" type="synonym">Algina</Name>
      <Name sources="chemidplus" type="synonym">Algomol</Name>
      <Name sources="chemidplus" type="synonym">Anadin dla dzieci</Name>
      <Name sources="chemidplus" type="synonym">Analter</Name>
      <Name sources="chemidplus" type="synonym">Andox</Name>
      <Name sources="chemidplus" type="synonym">Anexsia</Name>
      <Name sources="chemidplus" type="synonym">Anti-Algos</Name>
      <Name sources="chemidplus" type="synonym">Antidol</Name>
      <Name sources="chemidplus" type="synonym">Apacet</Name>
      <Name sources="chemidplus" type="synonym">Apitrelal</Name>
      <Name sources="chemidplus" type="synonym">Arfen</Name>
      <Name sources="chemidplus" type="synonym">Asetam</Name>
      <Name sources="chemidplus" type="synonym">Asomal</Name>
      <Name sources="chemidplus" type="synonym">Aspac</Name>
      <Name sources="chemidplus" type="synonym">Aspirin-Free Anacin</Name>
      <Name sources="chemidplus" type="synonym">Asplin</Name>
      <Name sources="chemidplus" type="synonym">Atralidon</Name>
      <Name sources="chemidplus" type="synonym">Babikan</Name>
      <Name sources="chemidplus" type="synonym">Bacetamol</Name>
      <Name sources="chemidplus" type="synonym">Banesin</Name>
      <Name sources="chemidplus" type="synonym">Bayer Select Allergy-Sinus</Name>
      <Name sources="chemidplus" type="synonym">Bayer Select Head Cold</Name>
      <Name sources="chemidplus" type="synonym">Bayer Select Headache Pain</Name>
      <Name sources="chemidplus" type="synonym">Bayer Select Menstrual Multi-Symptom</Name>
      <Name sources="chemidplus" type="synonym">Bayer Select Sinus Pain Relief</Name>
      <Name sources="chemidplus" type="synonym">Benmyo</Name>
      <Name sources="chemidplus" type="synonym">Biocetamol</Name>
      <Name sources="chemidplus" type="synonym">CCRIS 3</Name>
      <Name sources="chemidplus" type="synonym">Cadafen</Name>
      <Name sources="chemidplus" type="synonym">Calapol</Name>
      <Name sources="chemidplus" type="synonym">Calmanticold</Name>
      <Name sources="chemidplus" type="synonym">Capital with Codeine</Name>
      <Name sources="chemidplus" type="synonym">Captin</Name>
      <Name sources="chemidplus" type="synonym">Causalon</Name>
      <Name sources="chemidplus" type="synonym">Cefalex</Name>
      <Name sources="chemidplus" type="synonym">Children's Acetaminophen Elixir Drops</Name>
      <Name sources="chemidplus" type="synonym">Children's Acetaminophen Elixir Solution</Name>
      <Name sources="chemidplus" type="synonym">Children's Acetaminophen Oral Solution</Name>
      <Name sources="chemidplus" type="synonym">Children's Tylenol Chewable</Name>
      <Name sources="chemidplus" type="synonym">Claradol Codeine</Name>
      <Name sources="chemidplus" type="synonym">Cod-Acamol Forte</Name>
      <Name sources="chemidplus" type="synonym">Codabrol</Name>
      <Name sources="chemidplus" type="synonym">Codalgin</Name>
      <Name sources="chemidplus" type="synonym">Codapane</Name>
      <Name sources="chemidplus" type="synonym">Codicet</Name>
      <Name sources="chemidplus" type="synonym">Codisal</Name>
      <Name sources="chemidplus" type="synonym">Codisal Forte</Name>
      <Name sources="chemidplus" type="synonym">Codoliprane</Name>
      <Name sources="chemidplus" type="synonym">Codral Pain Relief</Name>
      <Name sources="chemidplus" type="synonym">Cofamol</Name>
      <Name sources="chemidplus" type="synonym">Contac Cough &amp; Sore Throat Formula</Name>
      <Name sources="chemidplus" type="synonym">Contra-Schmerz P</Name>
      <Name sources="chemidplus" type="synonym">Coricidin</Name>
      <Name sources="chemidplus" type="synonym">Coricidin D</Name>
      <Name sources="chemidplus" type="synonym">Coricidin Sinus</Name>
      <Name sources="chemidplus" type="synonym">Cosutone</Name>
      <Name sources="chemidplus" type="synonym">Crocin</Name>
      <Name sources="chemidplus" type="synonym">Croix Blanche</Name>
      <Name sources="chemidplus" type="synonym">Cuponol</Name>
      <Name sources="chemidplus" type="synonym">Curadon</Name>
      <Name sources="chemidplus" type="synonym">Curpol</Name>
      <Name sources="chemidplus" type="synonym">Custodial</Name>
      <Name sources="chemidplus" type="synonym">DEA No. 9804</Name>
      <Name sources="chemidplus" type="synonym">DHCplus</Name>
      <Name sources="chemidplus" type="synonym">Dafalgan Codeine</Name>
      <Name sources="chemidplus" type="synonym">Darocet</Name>
      <Name sources="chemidplus" type="synonym">Daygrip</Name>
      <Name sources="chemidplus" type="synonym">Demilets</Name>
      <Name sources="chemidplus" type="synonym">Deminofen</Name>
      <Name sources="chemidplus" type="synonym">Democyl</Name>
      <Name sources="chemidplus" type="synonym">Demogripal</Name>
      <Name sources="chemidplus" type="synonym">Desfebre</Name>
      <Name sources="chemidplus" type="synonym">Dhamol</Name>
      <Name sources="chemidplus" type="synonym">Dol-Stop</Name>
      <Name sources="chemidplus" type="synonym">Dolcor</Name>
      <Name sources="chemidplus" type="synonym">Dolefin</Name>
      <Name sources="chemidplus" type="synonym">Dolegrippin</Name>
      <Name sources="chemidplus" type="synonym">Dolgesic</Name>
      <Name sources="chemidplus" type="synonym">Dolko</Name>
      <Name sources="chemidplus" type="synonym">Dolofugin</Name>
      <Name sources="chemidplus" type="synonym">Doloreduct</Name>
      <Name sources="chemidplus" type="synonym">Dolorfug</Name>
      <Name sources="chemidplus" type="synonym">Dolorol Forte</Name>
      <Name sources="chemidplus" type="synonym">Dolorstop</Name>
      <Name sources="chemidplus" type="synonym">Dolotec</Name>
      <Name sources="chemidplus" type="synonym">Dorocoff</Name>
      <Name sources="chemidplus" type="synonym">Dresan</Name>
      <Name sources="chemidplus" type="synonym">Dristan Cold No Drowsiness</Name>
      <Name sources="chemidplus" type="synonym">Dristancito</Name>
      <Name sources="chemidplus" type="synonym">Drixoral Cold &amp; Flu</Name>
      <Name sources="chemidplus" type="synonym">Drixoral Sinus</Name>
      <Name sources="chemidplus" type="synonym">Duaneo</Name>
      <Name sources="chemidplus" type="synonym">Duorol</Name>
      <Name sources="chemidplus" type="synonym">Duracetamol</Name>
      <Name sources="chemidplus" type="synonym">Durapan</Name>
      <Name sources="chemidplus" type="synonym">Dymadon Co</Name>
      <Name sources="chemidplus" type="synonym">Dymadon Forte</Name>
      <Name sources="chemidplus" type="synonym">EINECS 203-157-5</Name>
      <Name sources="chemidplus" type="synonym">Ecosetol</Name>
      <Name sources="chemidplus" type="synonym">Empracet</Name>
      <Name sources="chemidplus" type="synonym">Endecon</Name>
      <Name sources="chemidplus" type="synonym">Eu-Med</Name>
      <Name sources="chemidplus" type="synonym">Excipain</Name>
      <Name sources="chemidplus" type="synonym">Fanalgic</Name>
      <Name sources="chemidplus" type="synonym">Farmadol</Name>
      <Name sources="chemidplus" type="synonym">Febranine</Name>
      <Name sources="chemidplus" type="synonym">Febrectal</Name>
      <Name sources="chemidplus" type="synonym">Febrectol</Name>
      <Name sources="chemidplus" type="synonym">Febrex</Name>
      <Name sources="chemidplus" type="synonym">Febricet</Name>
      <Name sources="chemidplus" type="synonym">Febridol</Name>
      <Name sources="chemidplus" type="synonym">Febrin</Name>
      <Name sources="chemidplus" type="synonym">Fensum</Name>
      <Name sources="chemidplus" type="synonym">Fepanil</Name>
      <Name sources="chemidplus" type="synonym">Fever All</Name>
      <Name sources="chemidplus" type="synonym">Finiweh</Name>
      <Name sources="chemidplus" type="synonym">Fluparmol</Name>
      <Name sources="chemidplus" type="synonym">Fortalidon P</Name>
      <Name sources="chemidplus" type="synonym">Freka-cetamol</Name>
      <Name sources="chemidplus" type="synonym">Gattaphen T</Name>
      <Name sources="chemidplus" type="synonym">Geluprane</Name>
      <Name sources="chemidplus" type="synonym">Geralgine-P</Name>
      <Name sources="chemidplus" type="synonym">Gripin Bebe</Name>
      <Name sources="chemidplus" type="synonym">Grippostad</Name>
      <Name sources="chemidplus" type="synonym">Gynospasmine</Name>
      <Name sources="chemidplus" type="synonym">HSDB 3001</Name>
      <Name sources="chemidplus" type="synonym">Helon N</Name>
      <Name sources="chemidplus" type="synonym">Hy-Phen</Name>
      <Name sources="chemidplus" type="synonym">Hycomine Compound</Name>
      <Name sources="chemidplus" type="synonym">Ildamol</Name>
      <Name sources="chemidplus" type="synonym">Inalgex</Name>
      <Name sources="chemidplus" type="synonym">Infadrops</Name>
      <Name sources="chemidplus" type="synonym">Influbene N</Name>
      <Name sources="chemidplus" type="synonym">Intensin</Name>
      <Name sources="chemidplus" type="synonym">Jin Gang</Name>
      <Name sources="chemidplus" type="synonym">Junior Disprol</Name>
      <Name sources="chemidplus" type="synonym">Kataprin</Name>
      <Name sources="chemidplus" type="synonym">Kinder Finimal</Name>
      <Name sources="chemidplus" type="synonym">Kratofin simplex</Name>
      <Name sources="chemidplus" type="synonym">Labamol</Name>
      <Name sources="chemidplus" type="synonym">Lekadol</Name>
      <Name sources="chemidplus" type="synonym">Lemgrip</Name>
      <Name sources="chemidplus" type="synonym">Lemsip</Name>
      <Name sources="chemidplus" type="synonym">Liquigesic Co</Name>
      <Name sources="chemidplus" type="synonym">Lonarid Mono</Name>
      <Name sources="chemidplus" type="synonym">Lupocet</Name>
      <Name sources="chemidplus" type="synonym">Magnidol</Name>
      <Name sources="chemidplus" type="synonym">Malex N</Name>
      <Name sources="chemidplus" type="synonym">Malgis</Name>
      <Name sources="chemidplus" type="synonym">Malidens</Name>
      <Name sources="chemidplus" type="synonym">Maxadol</Name>
      <Name sources="chemidplus" type="synonym">Medinol Paediatric</Name>
      <Name sources="chemidplus" type="synonym">Medocodene</Name>
      <Name sources="chemidplus" type="synonym">Melabon Infantil</Name>
      <Name sources="chemidplus" type="synonym">Mexalen</Name>
      <Name sources="chemidplus" type="synonym">Midol Maximum Strength</Name>
      <Name sources="chemidplus" type="synonym">Midol PM Night Time Formula</Name>
      <Name sources="chemidplus" type="synonym">Midol Regular Strength</Name>
      <Name sources="chemidplus" type="synonym">Midol Teen Formula</Name>
      <Name sources="chemidplus" type="synonym">Migraleve Yellow</Name>
      <Name sources="chemidplus" type="synonym">Minafen</Name>
      <Name sources="chemidplus" type="synonym">Minoset</Name>
      <Name sources="chemidplus" type="synonym">Miralgin</Name>
      <Name sources="chemidplus" type="synonym">Mixture Name</Name>
      <Name sources="chemidplus" type="synonym">Mono Praecimed</Name>
      <Name sources="chemidplus" type="synonym">NCX 701</Name>
      <Name sources="chemidplus" type="synonym">NSC 109028</Name>
      <Name sources="chemidplus" type="synonym">Naldegesic</Name>
      <Name sources="chemidplus" type="synonym">Nebs</Name>
      <Name sources="chemidplus" type="synonym">Neo-Fepramol</Name>
      <Name sources="chemidplus" type="synonym">NeoCitran</Name>
      <Name sources="chemidplus" type="synonym">Neodol</Name>
      <Name sources="chemidplus" type="synonym">Neodolito</Name>
      <Name sources="chemidplus" type="synonym">Neuridon</Name>
      <Name sources="chemidplus" type="synonym">New Cortal for Children</Name>
      <Name sources="chemidplus" type="synonym">NilnOcen</Name>
      <Name sources="chemidplus" type="synonym">Nina</Name>
      <Name sources="chemidplus" type="synonym">No-Febril</Name>
      <Name sources="chemidplus" type="synonym">Nodolex</Name>
      <Name sources="chemidplus" type="synonym">Noral</Name>
      <Name sources="chemidplus" type="synonym">Oltyl</Name>
      <Name sources="chemidplus" type="synonym">Oralgan</Name>
      <Name sources="chemidplus" type="synonym">Ornex Severe Cold Formula</Name>
      <Name sources="chemidplus" type="synonym">Ortensan</Name>
      <Name sources="chemidplus" type="synonym">Oxycocet</Name>
      <Name sources="chemidplus" type="synonym">PCM Paracetamol Lichtenstein</Name>
      <Name sources="chemidplus" type="synonym">Paceco</Name>
      <Name sources="chemidplus" type="synonym">Pacemol</Name>
      <Name sources="chemidplus" type="synonym">Pacet</Name>
      <Name sources="chemidplus" type="synonym">Pacimol</Name>
      <Name sources="chemidplus" type="synonym">Paedialgon</Name>
      <Name sources="chemidplus" type="synonym">Paedol</Name>
      <Name sources="chemidplus" type="synonym">Pamol</Name>
      <Name sources="chemidplus" type="synonym">Panacete</Name>
      <Name sources="chemidplus" type="synonym">Panadeine</Name>
      <Name sources="chemidplus" type="synonym">Panadeine Co</Name>
      <Name sources="chemidplus" type="synonym">Panadiene</Name>
      <Name sources="chemidplus" type="synonym">Panado-Co</Name>
      <Name sources="chemidplus" type="synonym">Panado-Co Caplets</Name>
      <Name sources="chemidplus" type="synonym">Panamax</Name>
      <Name sources="chemidplus" type="synonym">Panasorbe</Name>
      <Name sources="chemidplus" type="synonym">Panodil</Name>
      <Name sources="chemidplus" type="synonym">Pantalgin</Name>
      <Name sources="chemidplus" type="synonym">Para-Suppo</Name>
      <Name sources="chemidplus" type="synonym">Para-Tabs</Name>
      <Name sources="chemidplus" type="synonym">Paracemol</Name>
      <Name sources="chemidplus" type="synonym">Paracenol</Name>
      <Name sources="chemidplus" type="synonym">Paracet</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol AL</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Antipanin P</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol BC</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Basics</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Dr. Schmidgall</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Fecofar</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Genericon</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Hanseler</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Harkley</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Heumann</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Hexal</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Italfarmaco</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Nycomed</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol PB</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Raffo</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Ratiopharm</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Rosch</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Saar</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol SmithKline Beecham</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Stada</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol Winthrop</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol [INN:BAN]</Name>
      <Name sources="chemidplus" type="synonym">Paracetamol von ct</Name>
      <Name sources="chemidplus" type="synonym">Paracetamolo</Name>
      <Name sources="chemidplus" type="synonym">Paracetamolo [Italian]</Name>
      <Name sources="chemidplus" type="synonym">Paracetamolum [INN-Latin]</Name>
      <Name sources="chemidplus" type="synonym">Paracetol</Name>
      <Name sources="chemidplus" type="synonym">Paracin</Name>
      <Name sources="chemidplus" type="synonym">Paracod</Name>
      <Name sources="chemidplus" type="synonym">Paracodol</Name>
      <Name sources="chemidplus" type="synonym">Parador</Name>
      <Name sources="chemidplus" type="synonym">Paradrops</Name>
      <Name sources="chemidplus" type="synonym">Parakapton</Name>
      <Name sources="chemidplus" type="synonym">Parake</Name>
      <Name sources="chemidplus" type="synonym">Paralen</Name>
      <Name sources="chemidplus" type="synonym">Paralief</Name>
      <Name sources="chemidplus" type="synonym">Paralink</Name>
      <Name sources="chemidplus" type="synonym">Paralyoc</Name>
      <Name sources="chemidplus" type="synonym">Paramol</Name>
      <Name sources="chemidplus" type="synonym">Paramolan</Name>
      <Name sources="chemidplus" type="synonym">Paranox</Name>
      <Name sources="chemidplus" type="synonym">Parasedol</Name>
      <Name sources="chemidplus" type="synonym">Parasin</Name>
      <Name sources="chemidplus" type="synonym">Parcetol</Name>
      <Name sources="chemidplus" type="synonym">Parogal</Name>
      <Name sources="chemidplus" type="synonym">Paroma</Name>
      <Name sources="chemidplus" type="synonym">Pe-Tam</Name>
      <Name sources="chemidplus" type="synonym">Pediapirin</Name>
      <Name sources="chemidplus" type="synonym">Pediatrix</Name>
      <Name sources="chemidplus" type="synonym">Percocet</Name>
      <Name sources="chemidplus" type="synonym">Percocet-5</Name>
      <Name sources="chemidplus" type="synonym">Percocet-Demi</Name>
      <Name sources="chemidplus" type="synonym">Percogesic with Codeine</Name>
      <Name sources="chemidplus" type="synonym">Perdolan Mono</Name>
      <Name sources="chemidplus" type="synonym">Phenaphen W/Codeine</Name>
      <Name sources="chemidplus" type="synonym">Phenipirin</Name>
      <Name sources="chemidplus" type="synonym">Phogoglandin</Name>
      <Name sources="chemidplus" type="synonym">Pinex</Name>
      <Name sources="chemidplus" type="synonym">Piramin</Name>
      <Name sources="chemidplus" type="synonym">Pirinasol</Name>
      <Name sources="chemidplus" type="synonym">Plicet</Name>
      <Name sources="chemidplus" type="synonym">Polmofen</Name>
      <Name sources="chemidplus" type="synonym">Predimol</Name>
      <Name sources="chemidplus" type="synonym">Predualito</Name>
      <Name sources="chemidplus" type="synonym">Prodol</Name>
      <Name sources="chemidplus" type="synonym">Prontina</Name>
      <Name sources="chemidplus" type="synonym">Propacet</Name>
      <Name sources="chemidplus" type="synonym">Puernol</Name>
      <Name sources="chemidplus" type="synonym">Pulmofen</Name>
      <Name sources="chemidplus" type="synonym">Pyregesic-C</Name>
      <Name sources="chemidplus" type="synonym">Pyrigesic</Name>
      <Name sources="chemidplus" type="synonym">Pyromed</Name>
      <Name sources="chemidplus" type="synonym">Quiet World</Name>
      <Name sources="chemidplus" type="synonym">Reliv</Name>
      <Name sources="chemidplus" type="synonym">Remedol</Name>
      <Name sources="chemidplus" type="synonym">Rhinex D-Lay Tablets</Name>
      <Name sources="chemidplus" type="synonym">Robitussin Night Relief</Name>
      <Name sources="chemidplus" type="synonym">Rockamol Plus</Name>
      <Name sources="chemidplus" type="synonym">Rounox</Name>
      <Name sources="chemidplus" type="synonym">RubieMol</Name>
      <Name sources="chemidplus" type="synonym">Rubophen</Name>
      <Name sources="chemidplus" type="synonym">Rupemol</Name>
      <Name sources="chemidplus" type="synonym">Sanicet</Name>
      <Name sources="chemidplus" type="synonym">Sanicopyrine</Name>
      <Name sources="chemidplus" type="synonym">Scanol</Name>
      <Name sources="chemidplus" type="synonym">Scentalgyl</Name>
      <Name sources="chemidplus" type="synonym">Scherzatabletten Rezeptur 534</Name>
      <Name sources="chemidplus" type="synonym">Schmerzex</Name>
      <Name sources="chemidplus" type="synonym">Sedalito</Name>
      <Name sources="chemidplus" type="synonym">Semolacin</Name>
      <Name sources="chemidplus" type="synonym">Servigesic</Name>
      <Name sources="chemidplus" type="synonym">Seskamol</Name>
      <Name sources="chemidplus" type="synonym">Setakop</Name>
      <Name sources="chemidplus" type="synonym">Setamol</Name>
      <Name sources="chemidplus" type="synonym">Setol</Name>
      <Name sources="chemidplus" type="synonym">Sifenol</Name>
      <Name sources="chemidplus" type="synonym">Sinaspril</Name>
      <Name sources="chemidplus" type="synonym">Sine-Aid, Maximum Strength</Name>
      <Name sources="chemidplus" type="synonym">Sine-Off Sinus Medicine Caplets</Name>
      <Name sources="chemidplus" type="synonym">Sinedol</Name>
      <Name sources="chemidplus" type="synonym">Sinmol</Name>
      <Name sources="chemidplus" type="synonym">Sinubid</Name>
      <Name sources="chemidplus" type="synonym">Spalt N</Name>
      <Name sources="chemidplus" type="synonym">Spalt fur die nacht</Name>
      <Name sources="chemidplus" type="synonym">St Joseph Aspirin-Free</Name>
      <Name sources="chemidplus" type="synonym">St Joseph Aspirin-Free for Children</Name>
      <Name sources="chemidplus" type="synonym">St. Joseph Cold Tablets for Children</Name>
      <Name sources="chemidplus" type="synonym">Stanback</Name>
      <Name sources="chemidplus" type="synonym">Stopain</Name>
      <Name sources="chemidplus" type="synonym">Sudafed Cold and Cough</Name>
      <Name sources="chemidplus" type="synonym">Sudafed Severe Cold Formula</Name>
      <Name sources="chemidplus" type="synonym">Sudafed Sinus</Name>
      <Name sources="chemidplus" type="synonym">Sunetheton</Name>
      <Name sources="chemidplus" type="synonym">Supac</Name>
      <Name sources="chemidplus" type="synonym">Supadol mono</Name>
      <Name sources="chemidplus" type="synonym">Supofen</Name>
      <Name sources="chemidplus" type="synonym">Suppap</Name>
      <Name sources="chemidplus" type="synonym">Supramol-M</Name>
      <Name sources="chemidplus" type="synonym">Tachiprina</Name>
      <Name sources="chemidplus" type="synonym">Tazamol</Name>
      <Name sources="chemidplus" type="synonym">Termacet</Name>
      <Name sources="chemidplus" type="synonym">Termalgin</Name>
      <Name sources="chemidplus" type="synonym">Termalgine</Name>
      <Name sources="chemidplus" type="synonym">Termofren</Name>
      <Name sources="chemidplus" type="synonym">TheraFlu</Name>
      <Name sources="chemidplus" type="synonym">Tiffy</Name>
      <Name sources="chemidplus" type="synonym">Titralgan</Name>
      <Name sources="chemidplus" type="synonym">Toximer P</Name>
      <Name sources="chemidplus" type="synonym">Treupel N</Name>
      <Name sources="chemidplus" type="synonym">Treupel mon</Name>
      <Name sources="chemidplus" type="synonym">Treuphadol</Name>
      <Name sources="chemidplus" type="synonym">Triaminic Sore Throat Formula</Name>
      <Name sources="chemidplus" type="synonym">Tricoton</Name>
      <Name sources="chemidplus" type="synonym">Tylenol Allergy Sinus</Name>
      <Name sources="chemidplus" type="synonym">Tylex</Name>
      <Name sources="chemidplus" type="synonym">Tylex CD</Name>
      <Name sources="chemidplus" type="synonym">Tylol</Name>
      <Name sources="chemidplus" type="synonym">Tylox</Name>
      <Name sources="chemidplus" type="synonym">Tymol</Name>
      <Name sources="chemidplus" type="synonym">Upsanol</Name>
      <Name sources="chemidplus" type="synonym">Utragin</Name>
      <Name sources="chemidplus" type="synonym">Vanquish</Name>
      <Name sources="chemidplus" type="synonym">Veralgina</Name>
      <Name sources="chemidplus" type="synonym">Vermidon</Name>
      <Name sources="chemidplus" type="synonym">Verpol</Name>
      <Name sources="chemidplus" type="synonym">Viclor Richet</Name>
      <Name sources="chemidplus" type="synonym">Vicodin</Name>
      <Name sources="chemidplus" type="synonym">Vips</Name>
      <Name sources="chemidplus" type="synonym">Viruflu</Name>
      <Name sources="chemidplus" type="synonym">Vivimed</Name>
      <Name sources="chemidplus" type="synonym">Volpan</Name>
      <Name sources="chemidplus" type="synonym">Zatinol</Name>
      <Name sources="chemidplus" type="synonym">Zolben</Name>
    </Names>
    <InChI>
      <InChI>
        <Code>1/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)</Code>
      </InChI>
    </InChI>
    <Descriptors>
      <SubstanceChemicalTypes>
        <SubstanceChemicalType>Defined organic</SubstanceChemicalType>
      </SubstanceChemicalTypes>
      <RtecsDescriptors>
        <Descriptor>tumorigen</Descriptor>
        <Descriptor>drug</Descriptor>
        <Descriptor>mutagen</Descriptor>
        <Descriptor>reproductive effector</Descriptor>
        <Descriptor>human data</Descriptor>
      </RtecsDescriptors>
    </Descriptors>
    <Manufacturers>
      <Manufacturer>AAIPHARMA LLC</Manufacturer>
      <Manufacturer>ABANA</Manufacturer>
      <Manufacturer>ABBOTT</Manufacturer>
      <Manufacturer>ABLE</Manufacturer>
      <Manufacturer>ALPHARMA</Manufacturer>
      <Manufacturer>ALPHARMA US PHARM</Manufacturer>
      <Manufacturer>AM THERAP</Manufacturer>
      <Manufacturer>AMARIN PHARMS</Manufacturer>
      <Manufacturer>AMIDE PHARM</Manufacturer>
      <Manufacturer>ASCHER</Manufacturer>
      <Manufacturer>BARR</Manufacturer>
      <Manufacturer>BRISTOL MYERS</Manufacturer>
      <Manufacturer>BRISTOL MYERS SQUIBB</Manufacturer>
      <Manufacturer>CARNRICK</Manufacturer>
      <Manufacturer>CENT PHARMS</Manufacturer>
      <Manufacturer>CLONMEL</Manufacturer>
      <Manufacturer>COREPHARMA</Manufacturer>
      <Manufacturer>DUNHALL</Manufacturer>
      <Manufacturer>DURAMED PHARM BARR</Manufacturer>
      <Manufacturer>ENDO PHARMS</Manufacturer>
      <Manufacturer>EON</Manufacturer>
      <Manufacturer>EVERYLIFE</Manufacturer>
      <Manufacturer>FOREST PHARMS</Manufacturer>
      <Manufacturer>G AND W LABS</Manufacturer>
      <Manufacturer>GENEVA PHARMS</Manufacturer>
      <Manufacturer>GILBERT LABS</Manufacturer>
      <Manufacturer>GLAXOSMITHKLINE</Manufacturer>
      <Manufacturer>GRAHAM DM</Manufacturer>
      <Manufacturer>HALSEY</Manufacturer>
      <Manufacturer>HI TECH PHARMA</Manufacturer>
      <Manufacturer>ICN</Manufacturer>
      <Manufacturer>IVAX PHARMS</Manufacturer>
      <Manufacturer>KV PHARM</Manufacturer>
      <Manufacturer>LEDERLE</Manufacturer>
      <Manufacturer>MALLINCKRODT</Manufacturer>
      <Manufacturer>MAYRAND</Manufacturer>
      <Manufacturer>MCNEIL CONS SPECLT</Manufacturer>
      <Manufacturer>MIKART</Manufacturer>
      <Manufacturer>MORTON GROVE</Manufacturer>
      <Manufacturer>MUTUAL PHARM</Manufacturer>
      <Manufacturer>MYLAN</Manufacturer>
      <Manufacturer>NOVARTIS</Manufacturer>
      <Manufacturer>ORTHO MCNEIL PHARM</Manufacturer>
      <Manufacturer>PERRIGO</Manufacturer>
      <Manufacturer>PHARM ASSOC</Manufacturer>
      <Manufacturer>PHARMERAL</Manufacturer>
      <Manufacturer>POLYMEDICA</Manufacturer>
      <Manufacturer>PURDUE FREDERICK</Manufacturer>
      <Manufacturer>PUREPAC PHARM</Manufacturer>
      <Manufacturer>ROBINS AH</Manufacturer>
      <Manufacturer>ROXANE</Manufacturer>
      <Manufacturer>SANOFI SYNTHELABO</Manufacturer>
      <Manufacturer>SCHERER LABS</Manufacturer>
      <Manufacturer>SCHERING PLOUGH</Manufacturer>
      <Manufacturer>SCHWARZ PHARMA</Manufacturer>
      <Manufacturer>SHIRE PHARM</Manufacturer>
      <Manufacturer>SOLVAY</Manufacturer>
      <Manufacturer>SUPERPHARM</Manufacturer>
      <Manufacturer>SUPPOSITORIA</Manufacturer>
      <Manufacturer>TEVA</Manufacturer>
      <Manufacturer>UCB</Manufacturer>
      <Manufacturer>US CHEM</Manufacturer>
      <Manufacturer>USL PHARMA</Manufacturer>
      <Manufacturer>VANGARD</Manufacturer>
      <Manufacturer>VINTAGE PHARMS</Manufacturer>
      <Manufacturer>VITARINE</Manufacturer>
      <Manufacturer>WARNER CHILCOTT</Manufacturer>
      <Manufacturer>WATSON LAB</Manufacturer>
      <Manufacturer>WATSON LABS</Manufacturer>
      <Manufacturer>WEST WARD</Manufacturer>
      <Manufacturer>WHITEWORTH TOWN PLSN</Manufacturer>
      <Manufacturer>WOMEN FIRST HLTHCARE</Manufacturer>
    </Manufacturers>
    <ToxicityStudies>
      <AcuteToxicityStudies>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Postgraduate Medical Journal.  (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1925-; Volume: 68, pp. 116, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>325.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>hallucinations, distorted perceptions</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Clinical Pediatrics (Philadelphia).  (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1962-; Volume: 33, pp. 42, 1994</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Child</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>591.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>blood: aplastic anemia</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicology, Clinical Toxicology.  (Marcel Dekker, 270 Madison Ave., New York, NY 10016)  V.19-    1982-; Volume: 29, pp. 223, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4.962</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>changes in structure or function of endocrine pancreas</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Human Toxicology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants., RG 21 2XS, UK) V.1- 1981-; Volume: 1, pp. 25, 1981</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-man</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>714.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Diseases of Children.  (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-80(3), 1911-50; V.100-    1960-; Volume: 137, pp. 386, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Infant</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1440.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>6.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>hypermotility, diarrhea</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>irritability</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>body temperature increase</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Medical Journal.  (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK)  V.1-    1857-; Volume: 282, pp. 199, 1981</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>143.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>general anesthetic</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pediatrics.  (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1-    1932-; Volume: 92, pp. 832, 1978</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Child</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>360.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>skin and appendages</Category>
                        <Description>skin (after systemic exposure) - dermatitis, not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>nausea or vomiting</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Pediatrics.  (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1-    1948-; Volume: 61, pp. 68, 1978</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Child</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>801.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>nausea or vomiting</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>general anesthetic</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Postgraduate Medical Journal.  (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1925-; Volume: 69, pp. 52, 1993</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-man</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>714.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Cardiac</Category>
                        <Description>ekg changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Lancet.  (7 Adam St., London WC2N 6AD, UK)  V.1-    1823-; Volume: 1, pp. 66, 1973</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>357.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>nausea or vomiting</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>anorexia (human)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>coma</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>JAMA, Journal of the American Medical Association.  (AMA, 535 N. Dearborn St., Chicago, IL 60610)  V.1-    1883-; Volume: 236, pp. 1874, 1976</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>260.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>nausea or vomiting</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>coma</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Southern Medical Journal.  (Southern Medical Assoc., POB 2446, Birmingham, AL 35205) V.1- 1908-; Volume: 71, pp. 906, 1978</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>490.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Medicine.  (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946-; Volume: 74, pp. 349, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-man</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>143.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>24.0</Value>
                      <Units>hour</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>jaundice, not otherwise specified or unclassified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>anorexia (human)</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Emergency Medicine.  (WB Saunders, Philadelphia, PA)  V.1-    1983-; Volume: 6, pp. 511, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>650.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>vascular: changes not otherwise specified</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Description>metabolic acidosis</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>blood pressure lowering not characterized in autonomic section</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Emergency Medicine.  (WB Saunders, Philadelphia, PA)  V.1-    1983-; Volume: 6, pp. 510, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Child</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Cardiac</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Respiratory</Category>
                        <Description>acute pulmonary edema</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicology, Clinical Toxicology.  (Marcel Dekker, 270 Madison Ave., New York, NY 10016)  V.19-    1982-; Volume: 35, pp. 325, 1997</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Description>metabolic alkalosis</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>coma</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Medical Journal of Australia.  (Australasian Medical Pub. Co. Ltd., 71-79 Arundel St., Glebe, N.S.W., Australia)  V.1-    1914-; Volume: 171, pp. 472, 1999</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Child</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>140.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>7.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>coma</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Allergy.  (Munksgaard International Publishers Ltd., POB 2148, 35 Norre Sogade, DK-1016 Copenhagen K, Denmark)  V.33-    1978-; Volume: 50(Suppl 26), pp. 206, 1995</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>13.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>excitement</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Allergy.  (Munksgaard International Publishers Ltd., POB 2148, 35 Norre Sogade, DK-1016 Copenhagen K, Denmark)  V.33-    1978-; Volume: 50(Suppl 26), pp. 206, 1995</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-man</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>9.286</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>sense organs and special senses</Category>
                        <Description>eye - changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>sense organs and special senses</Category>
                        <Description>ear - changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>skin and appendages</Category>
                        <Description>skin (after systemic exposure) - dermatitis, not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>United States Patent Document.  (U.S. Patent Office, Box 9, Washington, DC 20231) #4636513</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>1944.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1944.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Studi Sassaresi, Sezione 2.  (Societa Sassarese di Scienze Mediche e Naturali, Via Muroni 23-A, I-07100 Sassari, Italy)  V.42-    1964-; Volume: 57, pp. 561, 1979</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>1205.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1205.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>tremor</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 19, pp. 20, 1971</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>338.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>338.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-; Volume: 15, pp. 520, 1965</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>367.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>367.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>body temperature decrease</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Human Toxicology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants., RG 21 2XS, UK) V.1- 1981-; Volume: 3, pp. 13S, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>310.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>310.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Iyakuhin Kenkyu.  Study of Medical Supplies.  (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan)  V.1-    1970-; Volume: 24, pp. 602, 1993</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Dog</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Spleen</Category>
                        <Description>changes in spleen</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>altered sleep time (including change in righting reflex)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>body temperature decrease</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Archives Internationales de Pharmacodynamie et de Therapie.  (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium)  V.4-    1898-; Volume: 149, pp. 571, 1964</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Dog</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration directly into the vein by hypodermic needle</TestConditionComments>
                <RouteOfExposure>Injection - intravenous</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>826.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Veterinary and Human Toxicology.  (American College of Veterinary and Comparative Toxicology, Publication Office, Comparative Toxicology, Manhattan, KS 66506)  V.19-    1977-; Volume: 30, pp. 324, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Pig</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration directly into the vein by hypodermic needle</TestConditionComments>
                <RouteOfExposure>Injection - intravenous</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes AFOS</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - phosphatases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of the American Pharmaceutical Association, Scientific Edition.  (Washington, DC) V.29-49, 1940-60.  For publisher information, see JPMSAE.; Volume: 47, pp. 479, 1958</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Guinea pig</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>2620.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2620.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>altered sleep time (including change in righting reflex)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>tremor</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Archiv fuer Experimentelle Pathologie und Pharmakologie.  (Leipzig, Ger. Dem. Rep.)  V.1-109, 1873-1925.  For publisher information, see NSAPCC.; Volume: 33, pp. 216, 1894</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Frog</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Respiratory</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>altered sleep time (including change in righting reflex)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>ataxia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>United States Patent Document.  (U.S. Patent Office, Box 9, Washington, DC 20231) #4035499</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mammal - species unspecified</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>512.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Gigiena i Sanitariya.  For English translation, see HYSAAV.  (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR)  V.1-    1936-; Volume: 48(6), pp. 22, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mammal - species unspecified</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>891.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>891.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Cancer Letters (Shannon, Ireland).  (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland)  V.1-    1975-; Volume: 174, pp. 73, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biochemical Pharmacology.  (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523)  V.1-    1958-; Volume: 61, pp. 925, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Food and Chemical Toxicology.  (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523)  V.20-    1982-; Volume: 39, pp. 271, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Dehydrogenases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>JAT, Journal of Applied Toxicology.  (John Wiley &amp; Sons Ltd., Baffins Lane, Chichester, W. Sussex PO19 1UD, UK)  V.1-    1981-; Volume: 20, pp. 427, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Endocrine</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>tumor</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 65, pp. 135, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 65, pp. 135, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Nervous system</Category>
                        <Description>direct parasympathomimetic changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Acta Biochimica Polonica (Published by Polish Biochemical Society and the Committee of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa Panstwowe Wydawnictwo Naukowe, L.Pasteura 3 02-093 Warszawa, Poland) V.1-   1954-; Volume: 47, pp. 1129, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Oxidases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase - dealkylation, hydroxylation, etc.</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biological &amp; pharmaceutical bulletin. (Pharmaceutical Society of Japan, 2-12-15, Shibuya, Shibuya-ku, Tokyo 150-0002, Japan) V.1-   1993-; Volume: 24, pp. 1149, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rabbit</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>body temperature decrease</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Veterinary and Human Toxicology.  (American College of Veterinary and Comparative Toxicology, Publication Office, Comparative Toxicology, Manhattan, KS 66506)  V.19-    1977-; Volume: 42, pp. 146, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Medical Journal.  (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK)  V.1-    1857-; Volume: 288, pp. 50, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>166.7</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Pharmacology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK)  V.34-    1968-; Volume: 129, pp. 77, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Pharmacology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK)  V.34-    1968-; Volume: 129, pp. 77, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>499.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology Letters.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-    1977-; Volume: 135, pp. S130, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>151.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - peptidases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicology, Clinical Toxicology.  (Marcel Dekker, 270 Madison Ave., New York, NY 10016)  V.19-    1982-; Volume: 39, pp. 441, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>283.5</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>interstitial nephritis</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Contact Dermatitis. Environmental and Occupational Dermatitis.  (Munksgaard International Pub., c/o Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003)  V.1-    1975-; Volume: 43, pp. 60, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>headache</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Eksperimental'naya i Klinicheskaya Farmakologiya.  Experimental and Clinical Pharmacology. (Mezhdunarodnaya Kniga, ul. B. Yakimanka, 39, 117049 Moscow, Russia)  V.55-    1992-; Volume: 59, pp. 43, 1996</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Lipids</Category>
                        <Description>metabolism (intermediary) - lipids, including transport</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Clinical Pharmacology and Therapeutics. (American Society for Clinical Pharmacology and Therapeutics, St. Louis Mo Mosby-Year Book) V.1-   1960-; Volume: 67, pp. 591, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>8.3</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 10, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 303, pp. 468, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Molecular Carcinogenesis.  (John Wiley &amp; Sons, 605 Third Avenue, New York, NY 10158) V.1- 1988-; Volume: 60, pp. 907, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Molecular Carcinogenesis.  (John Wiley &amp; Sons, 605 Third Avenue, New York, NY 10158) V.1- 1988-; Volume: 60, pp. 907, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 303, pp. 340, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>57.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 195, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD - lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 196, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD - lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 196, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD - lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 196, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 191, pp. 211, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 192, pp. 119, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 65, pp. 135, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 181, pp. 106, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 181, pp. 133, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 184, pp. 27, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - oxidoreductases not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 184, pp. 27, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 189, pp. 173, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in both tubules and glomeruli</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Clinical Toxicology.  (New York, NY)  V.1-18, 1968-81.  For publisher information, see JTCTDW.; Volume: 39, pp. 441, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>307.2</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72(Suppl 1), pp. 350, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72(Suppl 1), pp. 340, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72(Suppl 1), pp. 350, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>370.4</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 73, pp. 220, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Ethnopharmacology.  (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland)  V.1-    1979-; Volume: 49, pp. 119, 1995</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 76, pp. 229, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology Letters.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-    1977-; Volume: 132, pp. 1, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Ethnopharmacology.  (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland)  V.1-    1979-; Volume: 56, pp. 193, 1997</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Pharmacology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK)  V.34-    1968-; Volume: 139, pp. 49, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Acta Anaesthesiologica Scandinavica.  (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.1-    1957-; Volume: 47, pp. 1145, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>416.7</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Hematology>
                      <ResultFindings>
                        <Category>Platelet</Category>
                        <Description>change in clotting factors</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Acta Anaesthesiologica Scandinavica.  (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.1-    1957-; Volume: 47, pp. 1145, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>474.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Acta Anaesthesiologica Scandinavica.  (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.1-    1957-; Volume: 47, pp. 1145, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-man</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>404.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Hematology>
                      <ResultFindings>
                        <Category>Platelet</Category>
                        <Description>change in clotting factors</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Pharmacology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK)  V.34-    1968-; Volume: 143, pp. 33, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 503, pp. 209, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration by more than one route</TestConditionComments>
                <RouteOfExposure>Multiple</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2.143</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 503, pp. 209, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the spinal cord</TestConditionComments>
                <RouteOfExposure>Intraspinal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2.143</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 503, pp. 209, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the cerebrum</TestConditionComments>
                <RouteOfExposure>Intracerebral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2.143</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 197, pp. 301, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 185, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>80.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <Immunological>
                      <ResultFindings>
                        <Description>decreased immune response</Description>
                      </ResultFindings>
                    </Immunological>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 205, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 12, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 13, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD - lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 13, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 13, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 14, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Oxidases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase - dealkylation, hydroxylation, etc.</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 14, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 27, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 47, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 214, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 215, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 215, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 11, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 105, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>specific route was not specified</TestConditionComments>
                <RouteOfExposure>Parenteral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 360, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Dehydrogenases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 379, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transferases not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 379, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 380, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 389, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 44, pp. 472, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 87, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>450.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 173, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>effect on specific coenzyme - NAD, NADP</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - xanthine, purine, or nucleotides including urate</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 173, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on cyclic nucleotides</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>other changes in urine composition</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 173, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Lipids</Category>
                        <Description>metabolism (intermediary) - lipids, including transport</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - amino acids (including renal excretion)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>other changes in urine composition</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 261, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Monkey</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 279, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 16, pp. 295, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Lipids</Category>
                        <Description>metabolism (intermediary) - lipids, including transport</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 118, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 167, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Respiratory</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 267, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 303, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Food and Chemical Toxicology.  (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523)  V.20-    1982-; Volume: 44, pp. 393, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>350.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Hematology>
                      <ResultFindings>
                        <Category>Platelet</Category>
                        <Description>change in clotting factors</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 306, pp. 478, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration directly into the vein by hypodermic needle</TestConditionComments>
                <RouteOfExposure>Injection - intravenous</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>430.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Description>changes in na</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>other changes in urine composition</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 362, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 363, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>900.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 364, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD30</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 346, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>900.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 352, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on mitochondrial function</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 60, pp. 352, 2001</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration directly into the vein by hypodermic needle</TestConditionComments>
                <RouteOfExposure>Injection - intravenous</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 210, pp. 157, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>350.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 17, pp. 1551, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>151.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 17, pp. 1551, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>529.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology Letters.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-    1977-; Volume: 160, pp. 204, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 307, pp. 67, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD - lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>peripheral nerve</Category>
                        <Description>sensory change involving peripheral nerve</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>changes in psychophysiological tests</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 305, pp. 755, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>116.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>eosinophilia</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Bone marrow</Category>
                        <Description>changes in bone marrow not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>changes in leucocyte (wbc) count</Description>
                      </ResultFindings>
                    </Hematology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 307, pp. 699, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>146.1</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>changes in psychophysiological tests</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 100, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 100, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 116, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>hypermotility, diarrhea</Description>
                      </ResultFindings>
                    </Histopathology>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 331, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 331, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 331, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 331, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 90, pp. 341, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 315, pp. 987, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in blood vessels or in circulation of kidney</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Zhongguo Yaoli Xuebao.  Acta Pharmacologica Sinica.  Chinese Journal of Pharmacology.  (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China)  V.1-    1980-; Volume: 23, pp. 503, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Pharmacology and Toxicology (Copenhagen).  (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.60-    1987-; Volume: 93, pp. 33, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>body temperature decrease</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 538, pp. 57, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>149.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 538, pp. 57, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration under the skin</TestConditionComments>
                <RouteOfExposure>Subdermal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 543, pp. 133, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>900.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 543, pp. 133, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>900.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Food and Chemical Toxicology.  (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523)  V.20-    1982-; Volume: 44, pp. 1138, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 316, pp. 507, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD80</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 211, pp. 157, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 219, pp. 187, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>European Journal of Pharmacology.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)  V.1-    1967-; Volume: 546, pp. 60, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>42.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 215, pp. 306, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - not otherwise specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 216, pp. 98, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology Letters.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-    1977-; Volume: 160, pp. 204, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Dehydrogenases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 318, pp. 792, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 318, pp. 792, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>150.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Proteins</Category>
                        <Description>metabolism (intermediary) - plasma proteins not involving coagulation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biological and Pharmaceutical Bulletin.  (Pharmaceutical Society of Japan, 2-12-15-201 Shibuya Shibuya-ku, Tokyo 150, Japan)  V.16-    1993-; Volume: 27, pp. 1792, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>change in gall bladder structure or function</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Clinical Toxicology.  (New York, NY)  V.1-18, 1968-81.  For publisher information, see JTCTDW.; Volume: 1, pp. 31, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>71.4</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biological and Pharmaceutical Bulletin.  (Pharmaceutical Society of Japan, 2-12-15-201 Shibuya Shibuya-ku, Tokyo 150, Japan)  V.16-    1993-; Volume: 29, pp. 1618, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Dehydrogenases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 223, pp. 56, 2007</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>350.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 92, pp. 33, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Dehydrogenases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - dehydrogenases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Human &amp; Experimental Toxicology.  (Macmillan Press Ltd., Brunel Road, Houndmills, Basingstoke, Hampshire, RG21 2XS, UK)     V.9-    1990-; Volume: 23, pp. 49, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>763.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Human &amp; Experimental Toxicology.  (Macmillan Press Ltd., Brunel Road, Houndmills, Basingstoke, Hampshire, RG21 2XS, UK)     V.9-    1990-; Volume: 23, pp. 49, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1089.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Pharmacology and Toxicology (Copenhagen).  (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.60-    1987-; Volume: 93, pp. 33, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>neurotransmitters or modulators (putative) - dopamine in striatum</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>body temperature decrease</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicological Sciences.  (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan)  V.1-    1976-; Volume: 31, pp. 491, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicological Sciences.  (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan)  V.1-    1976-; Volume: 31, pp. 491, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicological Sciences.  (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan)  V.1-    1976-; Volume: 31, pp. 49, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicological Sciences.  (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan)  V.1-    1976-; Volume: 31, pp. 23, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Journal of Toxicological Sciences.  (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan)  V.1-    1976-; Volume: 31, pp. 23, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Pharmacology.  (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK)  V.34-    1968-; Volume: 143, pp. 33, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 20, pp. 20, 2007</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>changes in leucocyte (wbc) count</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Spleen</Category>
                        <Description>changes in spleen</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 20, pp. 20, 2007</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>changes in leucocyte (wbc) count</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Spleen</Category>
                        <Description>changes in spleen</Description>
                      </ResultFindings>
                    </Histopathology>
                    <Immunological>
                      <ResultFindings>
                        <Description>decreased immune response</Description>
                      </ResultFindings>
                    </Immunological>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Chemical Research in Toxicology.  (American Chemical Soc., Distribution Office Dept. 223, POB 57/36, West End Station, Washington, DC 20037)  V.1-    1988-; Volume: 20, pp. 20, 2007</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Hematology>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>changes in leucocyte (wbc) count</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Spleen</Category>
                        <Description>changes in spleen</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biological and Pharmaceutical Bulletin.  (Pharmaceutical Society of Japan, 2-12-15-201 Shibuya Shibuya-ku, Tokyo 150, Japan)  V.16-    1993-; Volume: 29, pp. 472, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LDLo - lowest published lethal dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 549, pp. 147, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>6.0</Value>
                      <Units>hour</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 244, pp. 25, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                    <OrganWeight>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes in liver weight</Description>
                      </ResultFindings>
                    </OrganWeight>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 243, pp. 261, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>LD40</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 243, pp. 249, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>529.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 226, pp. 74, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Naunyn-Schmiedeberg's Archives of Pharmacology.  (Springer Verlag, Heidelberger, Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.)  V.272-    1972-; Volume: 369(Suppl 1), pp. R174, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Fundamental &amp; Clinical Pharmacology (Oxford : Blackwell Science) 2001-; Volume: 18(Suppl 1), pp. 121, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rabbit</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Fundamental &amp; Clinical Pharmacology (Oxford : Blackwell Science) 2001-; Volume: 19, pp. 239, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>unreported - dose, but not route, is specified in the reference</TestConditionComments>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Biorganic &amp; Medicinal Chemistry.  (Elsevier Science, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK)  V.1    1993-; Volume: 15, pp. 2206, 2007</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LD50</Type>
                    <Value>
                      <Value>559.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                  </EndPoint>
                </EndPoints>
                <RtecsTestType>LD50</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>559.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>changes in serum composition (e.g., tp, bilirubin, cholesterol)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Pharmacology and Toxicology (Vails Gate, N.Y. : Science Publications) V.1- 2006-; Volume: 1, pp. 17, 2006</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Proteins</Category>
                        <Description>metabolism (intermediary) - plasma proteins not involving coagulation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>acute toxicity</StudyType>
          <Background>
            <References>
              <Reference>Pharmacological reports : PR (Krako?w, Poland : Institute of Pharmacology, Polish Academy of Sciences) V.57-    2005-; Volume: 57, pp. 596, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - proteins other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </AcuteToxicityStudies>
      <AquaticToxicityStudies>
        <Study sources="epafhm">
          <StudyType>aquatic toxicity</StudyType>
          <Background>
            <References>
              <Reference>165_EPAFHM_v4b</Reference>
              <Reference>U.S. EPA Mid-Continent Ecology Division</Reference>
              <Reference>http://www.epa.gov/med/Prods_Pubs/fathead_minnow.htm</Reference>
              <Reference>Russom,C.L., Bradbury, S.P., Broderius, S.J., Hammermeister, D.E., Drummond, R.A., Environmental Toxicology and Chemistry, Vol. 16, No. 5, pp. 948-967, 1997</Reference>
              <Reference>Broderius, S., M. Kahl, and M. Hoglund (1995) Use of Joint Toxic Response to define the primary mode of toxic action for diverse industrial organic chemicals. Environ Toxicol Chem 14: 1591-1605.</Reference>
              <Reference>Veith, G. D., D.J. Call, and L.T. Brooke (1983) Structure-toxicity relationships for the fathead minnow, Pimephales promelas: narcotic industrial chemicals.  Can. J. Fish. Aquat. Sci. 40: 743-748.</Reference>
              <Reference>[McKim, J.M., P.K. Schmieder, R.W. Carlson, E.P. Hunt, and G.J. Niemi (1987) Use of respiratory-cardiovascular responses of rainbow trout (Salmo gairdneri) in identifying Fish Acute Toxicity Syndromes.  Part I.  Pentachlorophenol, 2,4-dinitrophenol, tricaine methanesulfonate, and 1-octanol.  Environ. Toxicol. Chem. 6: 295-312.];[McKim, J.M., P.K. Schmieder, G.J. Niemi, R.W. Carlson, and T.R. Henry (1987) Use of respiratory-cardiovascular responses of rainbow trout (Salmo gairdneri) in identifying Fish Acute Toxicity Syndromes. Part II. Malathion, carbaryl, acrolein, and benzaldehyde.  Environ. Toxicol. Chem. 6: 313-328.]</Reference>
              <Reference>Drummond, R.A. and C.L. Russom (1990)  Behavioral toxicity syndromes: A promising tool for assessing toxicity mechanisms in juvenile fathead minnows.  Environ. Toxicol. Chem. 9: 37-46.</Reference>
            </References>
            <PhysicalCharacteristics>
              <TestForm>parent</TestForm>
            </PhysicalCharacteristics>
            <TestSubstanceCharacterization>
              <PhysicalProperties>
                <Property>
                  <Value>
                    <Value>0.32</Value>
                    <Units>None</Units>
                  </Value>
                  <Type>CLogP</Type>
                  <Method>Measured</Method>
                  <Comments>LogP was obtained from the STARLIST database within the UDRIVE system version 3.53, 1988, from Pomona College Medicinal Chemistry Project, Claremont, CA.</Comments>
                </Property>
              </PhysicalProperties>
            </TestSubstanceCharacterization>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Pimephales promelas (fathead minnow)</Species>
              </TestSystem>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>LC50</Type>
                    <Description>72hr to 96hr LC50_Ratio</Description>
                    <Value>
                      <Value>814.0</Value>
                      <Units>micro-g/mL</Units>
                    </Value>
                    <EndPointComment>96 hours</EndPointComment>
                  </EndPoint>
                </EndPoints>
                <MOA>MOA not determined due to insufficient evidence: MOA not determined due to insufficient evidence</MOA>
                <ExcessToxicityIndex>5.2</ExcessToxicityIndex>
                <LC50Ratio>1.13</LC50Ratio>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>814.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>96.0</Value>
                      <Units>hours</Units>
                    </TreatmentTime>
                    <DoseDuration>
                      <Value>96.0</Value>
                      <Units>hours</Units>
                    </DoseDuration>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>919.8</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>24.0</Value>
                      <Units>hours</Units>
                    </TreatmentTime>
                    <DoseDuration>
                      <Value>24.0</Value>
                      <Units>hours</Units>
                    </DoseDuration>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </AquaticToxicityStudies>
      <BacterialMutagenesisStudies>
        <Study sources="ntp">
          <StudyType>bacterial mutagenesis</StudyType>
          <StudyCalls>
            <Call>Negative</Call>
          </StudyCalls>
          <Background>
            <StudyReportNumber>413793</StudyReportNumber>
            <StudyStartDate>19800101</StudyStartDate>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28835</ExperimentId>
                <TestId>28835</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>141.0</RevertantCount>
                      <RevertantCountSignificance>12.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Sodium Azide</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>2102.0</RevertantCount>
                      <RevertantCountSignificance>41.3</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>138.0</RevertantCount>
                    <RevertantCountSignificance>4.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>131.0</RevertantCount>
                    <RevertantCountSignificance>6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>145.0</RevertantCount>
                    <RevertantCountSignificance>6.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>140.0</RevertantCount>
                    <RevertantCountSignificance>12.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>119.0</RevertantCount>
                    <RevertantCountSignificance>13</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28836</ExperimentId>
                <TestId>28836</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>110.0</RevertantCount>
                      <RevertantCountSignificance>5.8</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Sodium Azide</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1190.0</RevertantCount>
                      <RevertantCountSignificance>57</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>104.0</RevertantCount>
                    <RevertantCountSignificance>11.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>115.0</RevertantCount>
                    <RevertantCountSignificance>6.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>94.0</RevertantCount>
                    <RevertantCountSignificance>2.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>106.0</RevertantCount>
                    <RevertantCountSignificance>10.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>93.0</RevertantCount>
                    <RevertantCountSignificance>6.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28837</ExperimentId>
                <TestId>28837</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>117.0</RevertantCount>
                      <RevertantCountSignificance>6.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1983.0</RevertantCount>
                      <RevertantCountSignificance>73.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>109.0</RevertantCount>
                    <RevertantCountSignificance>11.4</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>107.0</RevertantCount>
                    <RevertantCountSignificance>5.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>114.0</RevertantCount>
                    <RevertantCountSignificance>6.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>112.0</RevertantCount>
                    <RevertantCountSignificance>5.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>96.0</RevertantCount>
                    <RevertantCountSignificance>0.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28838</ExperimentId>
                <TestId>28838</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>91.0</RevertantCount>
                      <RevertantCountSignificance>5.7</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1262.0</RevertantCount>
                      <RevertantCountSignificance>13.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>95.0</RevertantCount>
                    <RevertantCountSignificance>2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>91.0</RevertantCount>
                    <RevertantCountSignificance>1.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>85.0</RevertantCount>
                    <RevertantCountSignificance>4</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>100.0</RevertantCount>
                    <RevertantCountSignificance>8.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>87.0</RevertantCount>
                    <RevertantCountSignificance>8.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28839</ExperimentId>
                <TestId>28839</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>145.0</RevertantCount>
                      <RevertantCountSignificance>13.5</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1731.0</RevertantCount>
                      <RevertantCountSignificance>125.8</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>143.0</RevertantCount>
                    <RevertantCountSignificance>6.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>132.0</RevertantCount>
                    <RevertantCountSignificance>5.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>141.0</RevertantCount>
                    <RevertantCountSignificance>8.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>141.0</RevertantCount>
                    <RevertantCountSignificance>3.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>137.0</RevertantCount>
                    <RevertantCountSignificance>4.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28840</ExperimentId>
                <TestId>28840</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>97.0</RevertantCount>
                      <RevertantCountSignificance>8</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1055.0</RevertantCount>
                      <RevertantCountSignificance>40.6</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>101.0</RevertantCount>
                    <RevertantCountSignificance>3.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>120.0</RevertantCount>
                    <RevertantCountSignificance>9.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>104.0</RevertantCount>
                    <RevertantCountSignificance>6.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>108.0</RevertantCount>
                    <RevertantCountSignificance>6.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>87.0</RevertantCount>
                    <RevertantCountSignificance>6.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28841</ExperimentId>
                <TestId>28841</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>17.0</RevertantCount>
                      <RevertantCountSignificance>3.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Sodium Azide</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1524.0</RevertantCount>
                      <RevertantCountSignificance>39.8</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>25.0</RevertantCount>
                    <RevertantCountSignificance>2.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>23.0</RevertantCount>
                    <RevertantCountSignificance>1.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>18.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>16.0</RevertantCount>
                    <RevertantCountSignificance>2.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>18.0</RevertantCount>
                    <RevertantCountSignificance>2.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28842</ExperimentId>
                <TestId>28842</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>17.0</RevertantCount>
                      <RevertantCountSignificance>2.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Sodium Azide</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>990.0</RevertantCount>
                      <RevertantCountSignificance>28.4</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>17.0</RevertantCount>
                    <RevertantCountSignificance>2.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>15.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>13.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>15.0</RevertantCount>
                    <RevertantCountSignificance>3.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>13.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28843</ExperimentId>
                <TestId>28843</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>12.0</RevertantCount>
                      <RevertantCountSignificance>2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>119.0</RevertantCount>
                      <RevertantCountSignificance>15.5</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>1.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>2.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>1.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28844</ExperimentId>
                <TestId>28844</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>8.0</RevertantCount>
                      <RevertantCountSignificance>1.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>74.0</RevertantCount>
                      <RevertantCountSignificance>2.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>3.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>12.0</RevertantCount>
                    <RevertantCountSignificance>2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>13.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28845</ExperimentId>
                <TestId>28845</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>10.0</RevertantCount>
                      <RevertantCountSignificance>1.7</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>68.0</RevertantCount>
                      <RevertantCountSignificance>8.7</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>12.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28846</ExperimentId>
                <TestId>28846</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>11.0</RevertantCount>
                      <RevertantCountSignificance>0.7</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>60.0</RevertantCount>
                      <RevertantCountSignificance>4.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>12.0</RevertantCount>
                    <RevertantCountSignificance>1.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>3.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28847</ExperimentId>
                <TestId>28847</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>5.0</RevertantCount>
                      <RevertantCountSignificance>0.6</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>9-Aminoacridine</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>199.0</RevertantCount>
                      <RevertantCountSignificance>24.5</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>2.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>1.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>4.0</RevertantCount>
                    <RevertantCountSignificance>0.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>4.0</RevertantCount>
                    <RevertantCountSignificance>0.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28848</ExperimentId>
                <TestId>28848</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>7.0</RevertantCount>
                      <RevertantCountSignificance>2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>9-Aminoacridine</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>383.0</RevertantCount>
                      <RevertantCountSignificance>20.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>2.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>5.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>1.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>5.0</RevertantCount>
                    <RevertantCountSignificance>0.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28849</ExperimentId>
                <TestId>28849</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>9.0</RevertantCount>
                      <RevertantCountSignificance>2.6</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>159.0</RevertantCount>
                      <RevertantCountSignificance>14.6</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>2.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>10.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>2.6</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28850</ExperimentId>
                <TestId>28850</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>8.0</RevertantCount>
                      <RevertantCountSignificance>2.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>124.0</RevertantCount>
                      <RevertantCountSignificance>6.3</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28851</ExperimentId>
                <TestId>28851</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>14.0</RevertantCount>
                      <RevertantCountSignificance>0.3</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>133.0</RevertantCount>
                      <RevertantCountSignificance>1.7</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>2.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>13.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>11.0</RevertantCount>
                    <RevertantCountSignificance>3.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28852</ExperimentId>
                <TestId>28852</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>9.0</RevertantCount>
                      <RevertantCountSignificance>2.8</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>67.0</RevertantCount>
                      <RevertantCountSignificance>0.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>7.0</RevertantCount>
                    <RevertantCountSignificance>2.4</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>11.0</RevertantCount>
                    <RevertantCountSignificance>1.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>6.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>8.0</RevertantCount>
                    <RevertantCountSignificance>1.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>9.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28853</ExperimentId>
                <TestId>28853</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>18.0</RevertantCount>
                      <RevertantCountSignificance>3.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Not specified</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1779.0</RevertantCount>
                      <RevertantCountSignificance>27.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>19.0</RevertantCount>
                    <RevertantCountSignificance>2.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>18.0</RevertantCount>
                    <RevertantCountSignificance>2.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>16.0</RevertantCount>
                    <RevertantCountSignificance>1.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>17.0</RevertantCount>
                    <RevertantCountSignificance>3.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>16.0</RevertantCount>
                    <RevertantCountSignificance>2.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28854</ExperimentId>
                <TestId>28854</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>14.0</RevertantCount>
                      <RevertantCountSignificance>1.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Not specified</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1440.0</RevertantCount>
                      <RevertantCountSignificance>77</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>14.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>20.0</RevertantCount>
                    <RevertantCountSignificance>2.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>14.0</RevertantCount>
                    <RevertantCountSignificance>1.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>16.0</RevertantCount>
                    <RevertantCountSignificance>0.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>14.0</RevertantCount>
                    <RevertantCountSignificance>0.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28855</ExperimentId>
                <TestId>28855</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>27.0</RevertantCount>
                      <RevertantCountSignificance>4.1</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1945.0</RevertantCount>
                      <RevertantCountSignificance>17.2</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>31.0</RevertantCount>
                    <RevertantCountSignificance>3.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>26.0</RevertantCount>
                    <RevertantCountSignificance>4.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>29.0</RevertantCount>
                    <RevertantCountSignificance>3.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>26.0</RevertantCount>
                    <RevertantCountSignificance>1.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>19.0</RevertantCount>
                    <RevertantCountSignificance>1.8</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Syrian hamster (mesocricetus auratus)</Species>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28856</ExperimentId>
                <TestId>28856</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <Cytotoxicity>1</Cytotoxicity>
                      <CytotoxicityComments>Yes</CytotoxicityComments>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1668.0</RevertantCount>
                      <RevertantCountSignificance>49.5</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>21.0</RevertantCount>
                    <RevertantCountSignificance>2.7</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>25.0</RevertantCount>
                    <RevertantCountSignificance>2.9</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>24.0</RevertantCount>
                    <RevertantCountSignificance>4.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>25.0</RevertantCount>
                    <RevertantCountSignificance>3.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>22.0</RevertantCount>
                    <RevertantCountSignificance>1.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28857</ExperimentId>
                <TestId>28857</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>26.0</RevertantCount>
                      <RevertantCountSignificance>5.3</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1657.0</RevertantCount>
                      <RevertantCountSignificance>37.9</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>27.0</RevertantCount>
                    <RevertantCountSignificance>2.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>34.0</RevertantCount>
                    <RevertantCountSignificance>2.1</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>28.0</RevertantCount>
                    <RevertantCountSignificance>3.2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>25.0</RevertantCount>
                    <RevertantCountSignificance>4</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>26.0</RevertantCount>
                    <RevertantCountSignificance>3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <Species>Rat</Species>
                  <Strain>Sprague-Dawley</Strain>
                  <Sex>Male</Sex>
                  <Tissue>Liver</Tissue>
                  <FinalConcentration>10 %</FinalConcentration>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>28858</ExperimentId>
                <TestId>28858</TestId>
                <AssayTechnique>Preincubation</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/plate</Units>
                      </Dose>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <RevertantCount>25.0</RevertantCount>
                      <RevertantCountSignificance>3.6</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>2-Aminoanthracene</ControlCompoundName>
                  <TreatmentGroup>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <RevertantCount>1022.0</RevertantCount>
                      <RevertantCountSignificance>28.3</RevertantCountSignificance>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>24.0</RevertantCount>
                    <RevertantCountSignificance>3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>30.0</RevertantCount>
                    <RevertantCountSignificance>2</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>24.0</RevertantCount>
                    <RevertantCountSignificance>4.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3333.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>24.0</RevertantCount>
                    <RevertantCountSignificance>4.5</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <RevertantCount>20.0</RevertantCount>
                    <RevertantCountSignificance>2.3</RevertantCountSignificance>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="dsscpdb">
          <StudyType>bacterial mutagenesis</StudyType>
          <Background>
            <References>
              <Reference>DSSTox Filename: 7_CPDBAS_v5d</Reference>
              <Reference>http://potency.berkeley.edu/chempages/ACETAMINOPHEN.html</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
              </TestSystem>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>bacterial mutagenesis</StudyType>
          <StudyCalls>
            <Call>Negative</Call>
          </StudyCalls>
          <Background>
            <References>
              <Reference>JASIEWICZ,ML AND RICHARDSON,JC; ABSENCE OF MUTAGENIC ACTIVITY OF BENORYLATE, PARACETAMOL AND ASPIRIN IN THE SALMONELLA/MAMMALIAN MICROSOME TEST; MUTAT. RES. 190(2):95-100, 1987</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA97</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA97</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>50000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>bacterial mutagenesis</StudyType>
          <StudyCalls>
            <Call>Negative</Call>
          </StudyCalls>
          <Background>
            <References>
              <Reference>OLDHAM,JW, PRESTON,RF AND PAULSON,JD; MUTAGENICITY TESTING OF SELECTED ANALGESICS IN AMES SALMONELLA STRAINS; J. APPL. TOXICOL. 6(4):237-243, 1986</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1538</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, AROCLOR 1254</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>5.0</LowValue>
                        <HighValue>5000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>bacterial mutagenesis</StudyType>
          <StudyCalls>
            <Call>Positive</Call>
          </StudyCalls>
          <Background>
            <References>
              <Reference>KUBOYAMA,N AND FUJII,A; MUTAGENICITY OF ANALGESICS, THEIR DERIVATIVES, AND ANTI-INFLAMMATORY DRUGS WITH S-9 MIX OF SEVERAL ANIMAL SPECIES; J. NIHON UNIV. SCH. DENT. 34(3):183-195, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Guinea pig</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>GUINEA PIG, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Absent</MetabolicActivation>
                <MetabolicActivationSystem>
                  <Comments>NONE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Mouse</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>MOUSE, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Guinea pig</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>GUINEA PIG, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Polychlorinated biphenyl (kanechlor 500; KC-500)</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Hamster (cricetinae)</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>HAMSTER, LIVER, S-9, PCB</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>DMSO</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>PREINCUBATION</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>100.0</LowValue>
                        <HighValue>10000.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>bacterial mutagenesis</StudyType>
          <StudyCalls>
            <Call>Negative</Call>
          </StudyCalls>
          <Background>
            <References>
              <Reference>BURKE,DA, WEDD,DJ, HERRIOTT,D, BAYLISS,MK, SPALDING,DJM AND WILCOX,P; EVALUATION OF PYRAZOLE AND ETHANOL INDUCED S9 FRACTION IN BACTERIAL MUTAGENICITY TESTING; MUTAGENESIS 9(1):23-29, 1994</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1535</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Pyrazole</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PYRAZOLE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA1537</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Pyrazole</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PYRAZOLE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Pyrazole</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PYRAZOLE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Pyrazole</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PYRAZOLE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA102</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Pyrazole</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, PYRAZOLE</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA98</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Ethanol</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, ETHANOL</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA100</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Ethanol</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, ETHANOL</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Salmonella typhimurium</Species>
                <Strain>TA102</Strain>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Ethanol</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                  <Comments>RAT, LIVER, S-9, ETHANOL</Comments>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>METHANOL</Substance>
                  </Substance>
                </SolventVehicle>
                <AssayTechnique>STANDARD PLATE</AssayTechnique>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>0.0</LowValue>
                        <HighValue>2500.0</HighValue>
                      </Value>
                      <Units>micro-g/plate</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </BacterialMutagenesisStudies>
      <CarcinogenicityStudies>
        <Study sources="dsscpdb">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <References>
              <Reference>DSSTox FileID : 7_CPDBAS_v5d</Reference>
              <Reference>http://potency.berkeley.edu/chempages/ACETAMINOPHEN.html</Reference>
              <Reference>TR 394; final call in CPDB differs due to additional data</Reference>
            </References>
            <PhysicalCharacteristics>
              <TestForm>Parent</TestForm>
            </PhysicalCharacteristics>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Sex>Male</Sex>
              </TestSystem>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>TD50</Type>
                    <Description>TD50 is harmonic mean of more than one positive test</Description>
                    <Value>
                      <Value>495.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                    <EndPointComment>TD50 is harmonic mean of more than one positive test</EndPointComment>
                    <TargetSites>
                      <TargetSite>Liver</TargetSite>
                      <TargetSite>System: Urinary Tract</TargetSite>
                    </TargetSites>
                  </EndPoint>
                </EndPoints>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>495.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>System: Urinary Tract</Category>
                        <SubCategory1>Urinary Bladder</SubCategory1>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Sex>Female</Sex>
              </TestSystem>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>TD50</Type>
                    <Description>TD50 is harmonic mean of more than one positive test</Description>
                    <Value>
                      <Value>495.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                    <EndPointComment>TD50 is harmonic mean of more than one positive test</EndPointComment>
                    <TargetSites>
                      <TargetSite>Liver</TargetSite>
                      <TargetSite>System: Urinary Tract</TargetSite>
                    </TargetSites>
                  </EndPoint>
                </EndPoints>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>495.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>System: Urinary Tract</Category>
                        <SubCategory1>Urinary Bladder</SubCategory1>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="dsscpdb">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <References>
              <Reference>DSSTox FileID : 7_CPDBAS_v5d</Reference>
              <Reference>http://potency.berkeley.edu/chempages/ACETAMINOPHEN.html</Reference>
              <Reference>TR 394; final call in CPDB differs due to additional data</Reference>
            </References>
            <PhysicalCharacteristics>
              <TestForm>Parent</TestForm>
            </PhysicalCharacteristics>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Sex>Male</Sex>
              </TestSystem>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>TD50</Type>
                    <Description>TD50 is harmonic mean of more than one positive test</Description>
                    <Value>
                      <Value>1620.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                    <EndPointComment>TD50 is harmonic mean of more than one positive test</EndPointComment>
                    <TargetSites>
                      <TargetSite>Liver</TargetSite>
                    </TargetSites>
                  </EndPoint>
                </EndPoints>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1620.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Sex>Female</Sex>
              </TestSystem>
              <TestResults>
                <EndPoints>
                  <EndPoint>
                    <Type>TD50</Type>
                    <Description>TD50 is harmonic mean of more than one positive test</Description>
                    <Value>
                      <Value>1620.0</Value>
                      <Units>mg/kg</Units>
                    </Value>
                    <EndPointComment>TD50 is harmonic mean of more than one positive test</EndPointComment>
                    <TargetSites>
                      <TargetSite>Liver</TargetSite>
                    </TargetSites>
                  </EndPoint>
                </EndPoints>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1620.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                  <Results>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="isscan">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <References>
              <Reference>DSSTox Filename: ISSCAN_v3a_1153_19Sept08_ISSCANv3a_parsed_utf8.xls</Reference>
              <Reference>Data Source: NTP394</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Sex>Male</Sex>
              </TestSystem>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Sex>Female</Sex>
              </TestSystem>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
            </Test>
          </Tests>
        </Study>
        <Study sources="isscan">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <References>
              <Reference>DSSTox Filename: ISSCAN_v3a_1153_19Sept08_ISSCANv3a_parsed_utf8.xls</Reference>
              <Reference>Data Source: NTP394</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Sex>Male</Sex>
              </TestSystem>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
            </Test>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Sex>Female</Sex>
              </TestSystem>
              <TestResults>
                <TestCalls>
                  <Call>Equivocal</Call>
                </TestCalls>
              </TestResults>
            </Test>
          </Tests>
        </Study>
        <Study sources="ntp">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <StudyReportNumber>TR-394</StudyReportNumber>
            <StudyTitle>Toxicology and Carcinogenesis Studies of Acetaminophen (CAS No. 103-90-2) in F344 Rats and B6C3F</StudyTitle>
            <PerformingLaboratory>T.S.I. Mason Laboratories, Inc.</PerformingLaboratory>
            <References>
              <Reference>TR-394</Reference>
            </References>
            <Duration>
              <Value>104.0</Value>
              <Units>week</Units>
            </Duration>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <TestId>1</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestResultComments>KIDNEY: NEPHROPATHY; TUBULAR HYPERPLASIA; PARATHYROID GLAND: HYPERPLASIA</TestResultComments>
                <TestCalls>
                  <Call>No evidence</Call>
                </TestCalls>
              </TestResults>
            </Test>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <TestId>2</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestResultComments>HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 9/50 17/50 15/50 24/50; KIDNEY: NEPHROPATHY</TestResultComments>
                <TestCalls>
                  <Call>Equivocal evidence</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <NonNeoplasticLesions>
                        <ResultFindings>
                          <Category>System: Hematopoietic</Category>
                          <SubCategory2>Mononuclear</SubCategory2>
                          <SubCategory3>Leukemia</SubCategory3>
                          <SubCategory4>Benign</SubCategory4>
                          <IncidentRate>9/50</IncidentRate>
                        </ResultFindings>
                        <ResultFindings>
                          <Category>System: Hematopoietic</Category>
                          <SubCategory2>Mononuclear</SubCategory2>
                          <SubCategory3>Leukemia</SubCategory3>
                          <SubCategory4>Benign</SubCategory4>
                          <IncidentRate>17/50</IncidentRate>
                        </ResultFindings>
                        <ResultFindings>
                          <Category>System: Hematopoietic</Category>
                          <SubCategory2>Mononuclear</SubCategory2>
                          <SubCategory3>Leukemia</SubCategory3>
                          <SubCategory4>Benign</SubCategory4>
                          <IncidentRate>15/50</IncidentRate>
                        </ResultFindings>
                        <ResultFindings>
                          <Category>System: Hematopoietic</Category>
                          <SubCategory2>Mononuclear</SubCategory2>
                          <SubCategory3>Leukemia</SubCategory3>
                          <SubCategory4>Benign</SubCategory4>
                          <IncidentRate>24/50</IncidentRate>
                        </ResultFindings>
                      </NonNeoplasticLesions>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>B6C3F1</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <TestId>3</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestResultComments>THYROID GLAND: FOLLICULAR CELL HYPERPLASIA</TestResultComments>
                <TestCalls>
                  <Call>No evidence</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>6000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                  <Results>
                    <NonNeoplasticLesions>
                      <ResultFindings>
                        <Category>Thyroid</Category>
                        <SubCategory2>Follicular Cells</SubCategory2>
                        <SubCategory3>Hyperplasia</SubCategory3>
                        <SubCategory4>Benign</SubCategory4>
                      </ResultFindings>
                    </NonNeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>B6C3F1</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <TestId>4</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestResultComments>THYROID GLAND: FOLLICULAR CELL HYPERPLASIA</TestResultComments>
                <TestCalls>
                  <Call>No evidence</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>6000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>R&amp;M:0,.06,.3,.6%/60 PER GROUP</DoseComments>
                  </DosageRegimen>
                  <IndividualSubjectCount>60</IndividualSubjectCount>
                  <Results>
                    <NonNeoplasticLesions>
                      <ResultFindings>
                        <Category>Thyroid</Category>
                        <SubCategory2>Follicular Cells</SubCategory2>
                        <SubCategory3>Hyperplasia</SubCategory3>
                        <SubCategory4>Benign</SubCategory4>
                      </ResultFindings>
                    </NonNeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <StudyTitle>INDUCTION OF LIVER CELL TUMOURS IN IF MICE BY PARACETAMOL</StudyTitle>
            <References>
              <Reference>FLAKS,A AND FLAKS,B; INDUCTION OF LIVER CELL TUMOURS IN IF MICE BY PARACETAMOL; CARCINOGENESIS 4:363-368, 1983</Reference>
            </References>
            <Duration>
              <Value>18.0</Value>
              <Units>month</Units>
            </Duration>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>IF</Strain>
                <Sex>Both</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>1</ExperimentId>
                <TestId>1</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>%</Units>
                      </Dose>
                      <DoseComments>0.5; 1.0% IN DIET FOR 18 MO</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0.5; 1.0% IN DIET FOR 18 MO</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0.5; 1.0% IN DIET FOR 18 MO</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultComments>LIVER: HEPATOCELLULAR ADENOMA, CARCINOMA</TreatmentResultComments>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory3>Carcinoma</SubCategory3>
                        <SubCategory4>Malignant</SubCategory4>
                      </ResultFindings>
                    </NeoplasticLesions>
                    <NonNeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory3>Adenoma</SubCategory3>
                        <SubCategory4>Benign</SubCategory4>
                      </ResultFindings>
                    </NonNeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>IF</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>2</ExperimentId>
                <TestId>2</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>%</Units>
                      </Dose>
                      <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultComments>LIVER: HEPATOCELLULAR CARCINOMA, HEPATOCELLULAR ADENOMA OR CARCINOMA</TreatmentResultComments>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory2>Hepatocellular</SubCategory2>
                        <SubCategory3>Carcinoma</SubCategory3>
                        <SubCategory4>Malignant</SubCategory4>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory2>Hepatocellular</SubCategory2>
                        <SubCategory3>Adenoma</SubCategory3>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory2>Hepatocellular</SubCategory2>
                        <SubCategory3>Carcinoma</SubCategory3>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>IF</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>3</ExperimentId>
                <TestId>3</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>%</Units>
                      </Dose>
                      <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.5; 1% IN DIET FOR 18 MO (STUDY DURATION: 18 MO)</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultComments>LIVER: HEPATOCELLULAR CARCINOMA OR ADENOMA</TreatmentResultComments>
                    <NeoplasticLesions>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory2>Hepatocellular</SubCategory2>
                        <SubCategory3>Adenoma</SubCategory3>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <SubCategory2>Hepatocellular</SubCategory2>
                        <SubCategory3>Carcinoma</SubCategory3>
                      </ResultFindings>
                    </NeoplasticLesions>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <StudyTitle>THE CHRONIC HEPATOTOXIC, TUMOR-PROMOTING, AND CARCINOGENIC EFFECTS OF ACETAMINOPHEN IN MALE B6C3F1 MICE</StudyTitle>
            <References>
              <Reference>HAGIWARA,A AND WARD,JM; THE CHRONIC HEPATOTOXIC, TUMOR-PROMOTING, AND CARCINOGENIC EFFECTS OF ACETAMINOPHEN IN MALE B6C3F1 MICE; FUNDAM. APPL. TOXICOL. 7:376-386, 1986</Reference>
            </References>
            <Duration>
              <Value>72.0</Value>
              <Units>week</Units>
            </Duration>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>B6C3F1</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>1</ExperimentId>
                <TestId>1</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>ppm</Units>
                      </Dose>
                      <DoseComments>0; 5000; 10000 PPM IN DIET BEGINNING AT 6 WK OF AGE AND CONTINUING FOR 70 WK (STUDY DURATION: 72 WK)</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 5000; 10000 PPM IN DIET BEGINNING AT 6 WK OF AGE AND CONTINUING FOR 70 WK (STUDY DURATION: 72 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 5000; 10000 PPM IN DIET BEGINNING AT 6 WK OF AGE AND CONTINUING FOR 70 WK (STUDY DURATION: 72 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="ccris">
          <StudyType>carcinogenicity</StudyType>
          <Background>
            <StudyTitle>CARCINOGENICITY TESTING OF ACETAMINOPHEN IN F344 RATS</StudyTitle>
            <References>
              <Reference>HIRAGA,K AND FUJII,T; CARCINOGENICITY TESTING OF ACETAMINOPHEN IN F344 RATS; JPN. J. CANCER RES. (GANN) 76(2):79-85, 1985</Reference>
            </References>
            <Duration>
              <Value>130.0</Value>
              <Units>week</Units>
            </Duration>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>1</ExperimentId>
                <TestId>1</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>%</Units>
                      </Dose>
                      <DoseComments>0; 0.45; 0.9% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4500.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.45; 0.9% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>9000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.45; 0.9% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Diet</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>2</ExperimentId>
                <TestId>2</TestId>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Negative</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Diet</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>%</Units>
                      </Dose>
                      <DoseComments>0; 0.65; 1.3% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>6500.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.65; 1.3% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>13000.0</Value>
                      <Units>ppm</Units>
                    </Dose>
                    <DoseComments>0; 0.65; 1.3% IN DIET FOR 104 WK (STUDY DURATION: 130 WK)</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </CarcinogenicityStudies>
      <InVitroChromosomeAberrationStudies>
        <Study sources="ntp">
          <StudyType>in vitro chromosome aberration</StudyType>
          <StudyCalls>
            <Call>Positive</Call>
          </StudyCalls>
          <Background>
            <StudyReportNumber>034886</StudyReportNumber>
            <StudyStartDate>19861104</StudyStartDate>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Chinese hamster</Species>
                <TargetCell>CHO-W-B1</TargetCell>
                <MetabolicActivation>Absent</MetabolicActivation>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>1</ExperimentId>
                <TestId>1</TestId>
              </TestCondition>
              <TestResults>
                <TestResultComments>Total Aberrations Probability = 0.011 : Total Aberrations Trend = 2.307</TestResultComments>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Not specified</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>6</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>10.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>6</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Mitomycin C</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.05</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>38</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Mitomycin C</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.08</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>20.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>25</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>20</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1257.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>60</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>60</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2513.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>58</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>27</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3750.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>75</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>50</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>20.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>200</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>30</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Chinese hamster</Species>
                <TargetCell>CHO-W-B1</TargetCell>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>2</ExperimentId>
                <TestId>2</TestId>
              </TestCondition>
              <TestResults>
                <TestResultComments>Total Aberrations Probability = 0 : Total Aberrations Trend = 3.726</TestResultComments>
                <TestCalls>
                  <Call>Weakly positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Not specified</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>3</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>10.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>5</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Cyclophosphamide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>7.5</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>200</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>15</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Cyclophosphamide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>37.5</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>25</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>10</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2513.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>200</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>6</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3750.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>200</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>13</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>200</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>31</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Chinese hamster</Species>
                <TargetCell>CHO-W-B1</TargetCell>
                <MetabolicActivation>Present</MetabolicActivation>
                <MetabolicActivationSystem>
                  <SystemType>S9</SystemType>
                  <InducingAgents>
                    <Substance>
                      <Substance>Aroclor 1254</Substance>
                    </Substance>
                  </InducingAgents>
                  <Species>Rat</Species>
                  <Tissue>Liver</Tissue>
                </MetabolicActivationSystem>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>Dimethylsulfoxide</Substance>
                  </Substance>
                </SolventVehicle>
                <ExperimentId>3</ExperimentId>
                <TestId>3</TestId>
              </TestCondition>
              <TestResults>
                <TestResultComments>Total Aberrations Probability = 0.002 : Total Aberrations Trend = 2.935</TestResultComments>
                <TestCalls>
                  <Call>Weakly positive</Call>
                </TestCalls>
              </TestResults>
              <NegativeTestControls>
                <TestControl>
                  <ControlCompoundName>Not specified</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>0.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>100</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>1</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Dimethylsulfoxide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>10.0</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <TotalCellsScored>100</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>2</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <PositiveTestControls>
                <TestControl>
                  <ControlCompoundName>Cyclophosphamide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>7.5</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>100</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>17</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
                <TestControl>
                  <ControlCompoundName>Cyclophosphamide</ControlCompoundName>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <Dose>
                        <Value>37.5</Value>
                        <Units>micro-g/mL</Units>
                      </Dose>
                      <TreatmentTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </TreatmentTime>
                      <HarvestTime>
                        <Value>12.0</Value>
                        <Units>hrs</Units>
                      </HarvestTime>
                    </DosageRegimen>
                    <ControlType>Positive</ControlType>
                    <Results>
                      <TotalCellsScored>25</TotalCellsScored>
                      <StructureAberrationCellsWithoutGaps>20</StructureAberrationCellsWithoutGaps>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </PositiveTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3800.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>100</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>10</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4400.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>100</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>10</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5000.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </TreatmentTime>
                    <HarvestTime>
                      <Value>12.0</Value>
                      <Units>hrs</Units>
                    </HarvestTime>
                  </DosageRegimen>
                  <Results>
                    <TotalCellsScored>100</TotalCellsScored>
                    <StructureAberrationCellsWithoutGaps>15</StructureAberrationCellsWithoutGaps>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </InVitroChromosomeAberrationStudies>
      <InVitroMicronucleusStudies>
        <Study sources="ccris">
          <StudyType>in vitro micronucleus</StudyType>
          <StudyCalls>
            <Call>Positive</Call>
          </StudyCalls>
          <Background>
            <References>
              <Reference>MATSUSHIMA,T HAYASHI,M MATSUOKA,A ISHIDATE,M MIURA,KF SHIMIZU,H SUZUKI,Y MORIMOTO,K OGURA MURE,K KOSHI,K AND SOFUNI,T; VALIDATION OF THE IN VITRO MICRONUCLEUS TEST IN A CHINESE HAMSTER LUNG CELL LINE (CHL/IU); MUTAGENESIS 14(6):569-580, 1999</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Chinese hamster</Species>
                <TargetCell>Chl</TargetCell>
              </TestSystem>
              <TestCondition>
                <SolventVehicle>
                  <Substance>
                    <Substance>SALINE</Substance>
                  </Substance>
                </SolventVehicle>
              </TestCondition>
              <TestResults>
                <TestCalls>
                  <Call>Positive</Call>
                </TestCalls>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>
                        <LowValue>15.0</LowValue>
                        <HighValue>120.0</HighValue>
                      </Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <TreatmentTime>
                      <Value>48.0</Value>
                      <Units>hour</Units>
                    </TreatmentTime>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </InVitroMicronucleusStudies>
      <MultipleDoseStudies>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Kiso to Rinsho.  Clinical Report.  (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan)  V.1-    1960-; Volume: 4, pp. 2536, 1970</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>35.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>chronic: death in the "nutritional and gross metabolic" data type field</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>National Toxicology Program Technical Report Series.  (Research Triangle Park, NC 27709) No.206-; 1992 NTP-TR-394</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>747.25275</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <OrganWeight>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes in bladder weight</Description>
                      </ResultFindings>
                    </OrganWeight>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Iyakuhin Kenkyu.  Study of Medical Supplies.  (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan)  V.1-    1970-; Volume: 24, pp. 615, 1993</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>320.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>19.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>WBC</Category>
                        <Description>changes in leucocyte (wbc) count</Description>
                      </ResultFindings>
                    </Hematology>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <OrganWeight>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes in liver weight</Description>
                      </ResultFindings>
                    </OrganWeight>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Ukrainskii Biokhimicheskii Zhurnal. Ukranian Biochemical Journal.  (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR)  V.50-    1978-; Volume: 68(6), pp. 92, 1996</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>800.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Oxidases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase - dealkylation, hydroxylation, etc.</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Enzymes Oxidases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - cytochrome oxidases - including oxidative phosphorylation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>National Toxicology Program Technical Report Series.  (Research Triangle Park, NC 27709) No.206-; 1992 NTP-TR-394</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1494.5055</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <OrganWeight>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes in bladder weight</Description>
                      </ResultFindings>
                    </OrganWeight>
                    <BodyWeightChange>
                      <ResultFindings>
                        <Description>weight loss or decreased weight gain</Description>
                      </ResultFindings>
                    </BodyWeightChange>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 96, pp. 494, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>40.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <OrganWeight>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes in liver weight</Description>
                      </ResultFindings>
                    </OrganWeight>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. #PB85204667/AS</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>14.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <FoodConsumption>
                      <ResultFindings>
                        <Description>behavioral: food intake (animal)</Description>
                      </ResultFindings>
                    </FoodConsumption>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Farmakologiya i Toksikologiya (Moscow).  For English translation, see PHTXA6 and RPTOAN. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR)  V.2-    1939-; Volume: 47, pp. 105, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>multiple effects</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Contact Dermatitis. Environmental and Occupational Dermatitis.  (Munksgaard International Pub., c/o Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003)  V.1-    1975-; Volume: 43, pp. 60, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>0.95238096</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>3.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>skin and appendages</Category>
                        <Description>skin (after systemic exposure) - dermatitis, allergic</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                    <Immunological>
                      <ResultFindings>
                        <Description>hypersensitivity delayed</Description>
                      </ResultFindings>
                    </Immunological>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Eksperimental'naya i Klinicheskaya Farmakologiya.  Experimental and Clinical Pharmacology. (Mezhdunarodnaya Kniga, ul. B. Yakimanka, 39, 117049 Moscow, Russia)  V.55-    1992-; Volume: 61, pp. 48, 1998</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes AFOS</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - phosphatases</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Lipids</Category>
                        <Description>metabolism (intermediary) - lipids, including transport</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>liver function tests impaired</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 72, pp. 235, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>28.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Annals of Pharmacotherpy.  (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992-; Volume: 38, pp. 1432, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>12.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>5.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Hematology>
                      <ResultFindings>
                        <Category>Blood</Category>
                        <Description>hemorrhage</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Platelet</Category>
                        <Description>change in clotting factors</Description>
                      </ResultFindings>
                    </Hematology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Hong Kong Medical Journal (Published by the Hong Kong Academy of Medicine and the Hong Kong Medical Association, 10th Floor, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong, China)-; Volume: 10, pp. 61, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Infant</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration by more than one route</TestConditionComments>
                <RouteOfExposure>Multiple</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>77.333336</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>3.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>vascular</Category>
                        <Description>thrombosis distant from injection site</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>The Journal of emergency medicine (New York : Pergamon Press) V.1-    1983-; Volume: 23, pp. 253, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>6.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 78, pp. 105, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>10.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Tranaminases</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - transaminases</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 116, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>3.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - enzymes other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 116, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>250.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>3.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Enzymes Other</Category>
                        <Description>enzyme inhibition, induction, or change in blood or tissue levels - enzymes other than specified</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 305, pp. 123, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>30.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>renal function tests depressed</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Urinary bladder</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmacology and Experimental Therapeutics.  (Williams &amp; Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-; Volume: 315, pp. 987, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>525.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>4.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in blood vessels or in circulation of kidney</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>tolerance</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicology.  (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1-    1973-; Volume: 243, pp. 261, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>750.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>7.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Kidney</Category>
                        <Description>changes in tubules (including acute renal failure, acute tubular necrosis)</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>chronic: death in the "nutritional and gross metabolic" data type field</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 226, pp. 46, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>3.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Spleen</Category>
                        <Description>changes in spleen</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 226, pp. 46, 2008</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>60.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>4.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Immunological>
                      <ResultFindings>
                        <Description>decreased immune response</Description>
                      </ResultFindings>
                    </Immunological>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>American Journal of Emergency Medicine.  (WB Saunders, Philadelphia, PA)  V.1-    1983-; Volume: 23, pp. 94, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Infant</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>25.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>7.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Digestive  system</Category>
                        <Description>nausea or vomiting</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), diffuse</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>somnolence (general depressed activity)</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Naunyn-Schmiedeberg's Archives of Pharmacology.  (Springer Verlag, Heidelberger, Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.)  V.272-    1972-; Volume: 369(Suppl 1), pp. R174, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>7.0</Value>
                      <Units>day</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>degenerative changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Fundamental &amp; Clinical Pharmacology (Oxford : Blackwell Science) 2001-; Volume: 18(Suppl 1), pp. 89, 2004</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>130.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>1.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <ClinicalChemistry>
                      <ResultFindings>
                        <Category>Other</Category>
                        <Description>metabolism (intermediary) - effect on inflammation or mediation of inflammation</Description>
                      </ResultFindings>
                    </ClinicalChemistry>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Brain</Category>
                        <Description>changes in cerebral spinal fluid</Description>
                      </ResultFindings>
                    </Histopathology>
                    <ClinicalSigns>
                      <ResultFindings>
                        <Description>analgesia</Description>
                      </ResultFindings>
                    </ClinicalSigns>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>multiple dose</StudyType>
          <Background>
            <References>
              <Reference>Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK)  V.1-    1980-; Volume: 26, pp. 689, 2005</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>720.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>2.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </MultipleDoseStudies>
      <ReproductiveStudies>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Archives of Disease in Childhood.  (British Medical Journal, POB 560B, Kennebunkport, ME 04046)  V.1-    1926-; Volume: 58, pp. 631, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>650.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>29W preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - apgar score (human only)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - neonatal measures or effects other than specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - postnatal measures or effects other than specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Obstetrics and Gynaecology.  (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK)  V.82-    1975-; Volume: 91, pp. 286, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>417.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>20W preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - craniofacial (including nose and tongue)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - hepatobiliary system</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>British Journal of Obstetrics and Gynaecology.  (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK)  V.82-    1975-; Volume: 96, pp. 491, 1989</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human-woman</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>31-32W preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>maternal effects - effects on female not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - neonatal measures or effects other than specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Zhejiang Yike Daxue Xuebao.  Journal of Zhejiang Medical University.  (Zhejiang Yike Daxue, Yan'an Lu, Hanzhou, Zhejiang, Peop. Rep. China)  V.1-    1972(?)-; Volume: 27, pp. 49, 1998</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>3D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmaceutical Sciences.  (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037)  V.50-    1961-; Volume: 66, pp. 111, 1977</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>8-19D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on fertility - post-implantation mortality</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - fetotoxicity (except death, e.g., stunted fetus)</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Teratology, The International Journal of Abnormal Development.  (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-; Volume: 26(1), pp. 42A, 1982</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>12500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>14D pre/1-11D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - cytological changes (including somatic cell genetic material)</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Zhejiang Yike Daxue Xuebao.  Journal of Zhejiang Medical University.  (Zhejiang Yike Daxue, Yan'an Lu, Hanzhou, Zhejiang, Peop. Rep. China)  V.1-    1972(?)-; Volume: 22, pp. 196, 1993</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>3D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - growth statistics (e.g. reduced weight gain)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - behavioral</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - postnatal measures or effects other than specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Archives of Toxicology, Supplement.  (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094)  No.1-    1978-; Volume: 7, pp. 164, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>35000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>70D male</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>paternal effects - testes, epididymis, sperm duct</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>paternal effects - effects on male not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Cytobios. (Faculty Press, 88 Regent St., Cambridge, UK)  V.1-    1969-; Volume: 27, pp. 27, 1980</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>25.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>1D male</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>paternal effects - spermatogenesis</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 4, pp. 170, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>600.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>1D male</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>paternal effects - spermatogenesis</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>paternal effects - testes, epididymis, sperm duct</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 4, pp. 166, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>6-15D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - fetotoxicity (except death, e.g., stunted fetus)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - craniofacial (including nose and tongue)</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - musculoskeletal system</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 4, pp. 166, 1984</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>6-15D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - urogenital system</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 56, pp. 150, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1430.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>2D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>maternal effects - effects on female not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Toxicological Sciences (Oxford University Press,  6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41,   Jan. 1998-; Volume: 56, pp. 150, 2000</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>15730.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>8D pre/1-3D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on fertility - measures of fertility not otherwise specified</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Fertility and Sterility.  (American Fertility Soc., 608 13th Ave. S, Birmingham, AL 35282) V.1-    1950-; Volume: 38, pp. 238, 1982</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rabbit</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>2000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>1D pre</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on fertility - measures of fertility not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. #PB85204667/AS</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>49000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>7D male/7D pre/21D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on fertility - litter size</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. #PB85204667/AS</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>370.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>multigenerations</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on newborn - growth statistics (e.g. reduced weight gain)</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. #PB85204667/AS</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>multigenerations</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - urogenital system</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. #PB85204667/AS</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>multigenerations</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>specific developmental abnormalities - hepatobiliary system</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>reproductive</StudyType>
          <Background>
            <References>
              <Reference>Teratology Society. Poster Sessions Abstracts; pp. 258, 2003</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>24.5</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseComments>8-14D preg</DoseComments>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>reproductive</Category>
                        <Description>effects on embryo or fetus - fetotoxicity (except death, e.g., stunted fetus)</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </ReproductiveStudies>
      <RTECSMutationStudies>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Journal of Nihon University School of Dentistry.  (Nihon University School of Dentistry, 1-8-13 Surugadai, Kanda, Chiyoda-ku, Tokyo, 101, Japan)  V.1-    1958-; Volume: 34, pp. 183, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Bacteria - salmonella typhimurium</Species>
              </TestSystem>
              <TestResults>
                <RtecsTestType>mutation in microorganisms</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>micro-g/disc</Units>
                    </Dose>
                    <DoseComments>+S9</DoseComments>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 227, pp. 147, 1989</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>micronucleus test</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>42.86</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>8.0</Value>
                      <Units>hour</Units>
                    </DoseDuration>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 261, pp. 1, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
                <TargetCell>lymphocyte</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>inhibition of dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>0.3</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Nippon Eiseigaku Zasshi.  Japanese Journal of Hygiene.  (Nippon Eisei Gakkai, c/o Kyoto Daigaku Igakubu, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606, Japan)  V.1-    1946-; Volume: 37, pp. 673, 1982</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
                <TargetCell>lymphocyte</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>mutation system not otherwise specified</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Nippon Eiseigaku Zasshi.  Japanese Journal of Hygiene.  (Nippon Eisei Gakkai, c/o Kyoto Daigaku Igakubu, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606, Japan)  V.1-    1946-; Volume: 37, pp. 673, 1982</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
                <TargetCell>lymphocyte</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 209, pp. 161, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>42.86</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 261, pp. 1, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>sister chromatid exchange</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>42.86</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 261, pp. 1, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Human</Species>
                <TargetCell>lymphocyte</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>sister chromatid exchange</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 189, pp. 299, 1987</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <TargetCell>kidney</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>micronucleus test</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 164, pp. 167, 1986</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <TargetCell>liver</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>unscheduled dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 320, pp. 189, 1994</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>unscheduled dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>500.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Journal of Pharmaceutical Sciences.  (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037)  V.50-    1961-; Volume: 80, pp. 761, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>micronucleus test</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>100.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 164, pp. 167, 1986</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <TargetCell>liver</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>unscheduled dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>7.5</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Cancer Research. (Public Ledger Building, Suit 816, 6th &amp; Chestnut Sts., Philadelphia, PA 19106)  V.1-    1941-; Volume: 49, pp. 1038, 1989</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <TargetCell>embryo</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>morphological transformation</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1000.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 111, pp. 242, 1991</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <TargetCell>liver</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>dna damage</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Toxicology and Applied Pharmacology.  (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-    1959-; Volume: 96, pp. 494, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>unscheduled dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>84000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>40.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Cytobios. (Faculty Press, 88 Regent St., Cambridge, UK)  V.1-    1969-; Volume: 27, pp. 27, 1980</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 278, pp. 253, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 278, pp. 253, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>sister chromatid exchange</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Caryologia.  (Via G. LaPira 4, 50121 Florence, Italy)  V.1-    1948-; Volume: 38, pp. 347, 1985</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>sex chromosome loss and nondisjunction</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>25.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 272, pp. 223, 1992</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>micronucleus test</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>50.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-; Volume: 204, pp. 333, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>dna damage</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1-    1986-; Volume: 3, pp. 51, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>inhibition of dna synthesis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>0.16</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Toxicology In Vitro.  (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-   1987-; Volume: 3, pp. 13, 1989</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>mutation system not otherwise specified</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Progress in Clinical and Biological Research.  (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1975-; Volume: 209A, pp. 365, 1986</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>ovary</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>70.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>24.0</Value>
                      <Units>hour</Units>
                    </DoseDuration>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Eisei Shikenjo Hokoku.  Bulletin of the Institute of Hygienic Sciences.  (Kokuritsu Eisei Shikenjo Kagaku, 18-1 Bushitsu Johobu, Setagaya-ku, Tokyo 158, Japan)  V.1-    1886-; Volume: (96), pp. 55, 1978</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>fibroblast</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>60.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Archives of Toxicology, Supplement.  (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094)  No.1-    1978-; Volume: 4, pp. 41, 1980</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>cytogenetic analysis</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>10.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Progress in Clinical and Biological Research.  (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1975-; Volume: 209A, pp. 365, 1986</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>ovary</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>sister chromatid exchange</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>200.0</Value>
                      <Units>micro-g/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1-    1986-; Volume: 3, pp. 51, 1988</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Hamster</Species>
                <TargetCell>lung</TargetCell>
              </TestSystem>
              <TestResults>
                <RtecsTestType>sister chromatid exchange</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1.0</Value>
                      <Units>micro-mol/mL</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>RTECS mutation</StudyType>
          <Background>
            <References>
              <Reference>Toxicologist.  (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-; Volume: 66, pp. 362, 2002</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>administration into the peritoneal cavity</TestConditionComments>
                <RouteOfExposure>Injection - intraperitoneal</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>dna damage</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>300.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                  </DosageRegimen>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </RTECSMutationStudies>
      <SubchronicStudies>
        <Study sources="ntp">
          <StudyType>subchronic</StudyType>
          <Background>
            <References>
              <Reference>Technical Report 394, 1993</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <DoseDuration>
                        <Value>13.0</Value>
                        <Units>week</Units>
                      </DoseDuration>
                    </DosageRegimen>
                    <IndividualSubjectCount>10</IndividualSubjectCount>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <SurvivalRate>all/10</SurvivalRate>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>67.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>130.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>280.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>520.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1160.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Inflammation, subchronic active hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3330.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>8/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Inflammation, subchronic active hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
                <Strain>Fischer 344</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <DoseDuration>
                        <Value>13.0</Value>
                        <Units>week</Units>
                      </DoseDuration>
                    </DosageRegimen>
                    <IndividualSubjectCount>10</IndividualSubjectCount>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <SurvivalRate>all/10</SurvivalRate>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>73.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>140.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>280.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>560.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1060.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>3830.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>8/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Inflammation, subchronic active hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>B6C3F1</Strain>
                <Sex>Male</Sex>
              </TestSystem>
              <TestCondition>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <DoseDuration>
                        <Value>13.0</Value>
                        <Units>week</Units>
                      </DoseDuration>
                    </DosageRegimen>
                    <IndividualSubjectCount>10</IndividualSubjectCount>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <SurvivalRate>all/10</SurvivalRate>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>170.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>370.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>790.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>9/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1320.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Calcification, hepatic, focal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Pigmentation, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>4910.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>8/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Calcification, hepatic, focal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Pigmentation, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>11540.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>9/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Calcification, hepatic, focal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Pigmentation, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
                <Strain>B6C3F1</Strain>
                <Sex>Female</Sex>
              </TestSystem>
              <TestCondition>
                <RouteOfExposure>Oral - dietary</RouteOfExposure>
              </TestCondition>
              <NegativeTestControls>
                <TestControl>
                  <TreatmentGroup>
                    <DosageRegimen>
                      <DoseDuration>
                        <Value>13.0</Value>
                        <Units>week</Units>
                      </DoseDuration>
                    </DosageRegimen>
                    <IndividualSubjectCount>10</IndividualSubjectCount>
                    <ControlType>Negative</ControlType>
                    <Results>
                      <SurvivalRate>9/10</SurvivalRate>
                    </Results>
                  </TreatmentGroup>
                </TestControl>
              </NegativeTestControls>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>220.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>9/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>410.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>830.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>1780.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>9/10</SurvivalRate>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>5420.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>all/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Calcification, hepatic, focal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Pigmentation, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>12700.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseFrequency>
                      <FrequencyCount>1.0</FrequencyCount>
                      <FrequencyPeriod>
                        <Value>1.0</Value>
                        <Units>day</Units>
                      </FrequencyPeriod>
                    </DoseFrequency>
                    <DoseDuration>
                      <Value>13.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <IndividualSubjectCount>10</IndividualSubjectCount>
                  <Results>
                    <SurvivalRate>9/10</SurvivalRate>
                    <Histopathology>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Hepatocytomegaly</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Necrosis, hepatic</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Calcification, hepatic, focal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>Liver</Category>
                        <Description>Pigmentation, hepatic</Description>
                      </ResultFindings>
                    </Histopathology>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </SubchronicStudies>
      <TumorigenicStudies>
        <Study sources="rtecs">
          <StudyType>tumorigenic</StudyType>
          <Background>
            <References>
              <Reference>Acta Pathologica, Microbiologica et Immunologica Scandinavica, Section A: Pathology. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.90-95, 1982-87.; Volume: 93, pp. 367, 1985</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>164000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>78.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>tumorigenic</Category>
                        <Description>carcinogenic by rtecs criteria</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>kidney, ureter and bladder</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>tumorigenic</StudyType>
          <Background>
            <References>
              <Reference>Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK)  V.1-    1980-; Volume: 4, pp. 363, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>135000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>77.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>tumorigenic</Category>
                        <Description>carcinogenic by rtecs criteria</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>liver</Category>
                        <Description>hepatitis (hepatocellular necrosis), zonal</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>liver</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>tumorigenic</StudyType>
          <Background>
            <References>
              <Reference>Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK)  V.1-    1980-; Volume: 4, pp. 363, 1983</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Mouse</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TD - toxic dose (other than lowest)</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>270000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>77.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>tumorigenic</Category>
                        <Description>equivocal tumorigenic agent by rtecs criteria</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>liver</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>endocrine</Category>
                        <Description>changes not otherwise specified</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>tumorigenic</StudyType>
          <Background>
            <References>
              <Reference>Acta Pathologica, Microbiologica et Immunologica Scandinavica, Section A: Pathology. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark)  V.90-95, 1982-87.; Volume: 93, pp. 367, 1985</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TD - toxic dose (other than lowest)</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>329000.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>78.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>tumorigenic</Category>
                        <Description>carcinogenic by rtecs criteria</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>liver</Category>
                        <Description>tumors</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
        <Study sources="rtecs">
          <StudyType>tumorigenic</StudyType>
          <Background>
            <References>
              <Reference>National Technical Information Service.  (Springfield, VA 22161)  Formerly U.S. Clearinghouse for Scientific &amp; Technical Information. PB93-227478</Reference>
            </References>
          </Background>
          <Tests>
            <Test>
              <TestSystem>
                <Species>Rat</Species>
              </TestSystem>
              <TestCondition>
                <TestConditionComments>per os, intragastric feeding, or introduction with drinking water</TestConditionComments>
                <RouteOfExposure>Oral</RouteOfExposure>
              </TestCondition>
              <TestResults>
                <RtecsTestType>TDLo - lowest published toxic dose</RtecsTestType>
              </TestResults>
              <Treatments>
                <TreatmentGroup>
                  <DosageRegimen>
                    <Dose>
                      <Value>218400.0</Value>
                      <Units>mg/kg</Units>
                    </Dose>
                    <DoseDuration>
                      <Value>104.0</Value>
                      <Units>week</Units>
                    </DoseDuration>
                  </DosageRegimen>
                  <Results>
                    <TreatmentResultFindings>
                      <ResultFindings>
                        <Category>tumorigenic</Category>
                        <Description>carcinogenic by rtecs criteria</Description>
                      </ResultFindings>
                      <ResultFindings>
                        <Category>blood</Category>
                        <Description>leukemia</Description>
                      </ResultFindings>
                    </TreatmentResultFindings>
                  </Results>
                </TreatmentGroup>
              </Treatments>
            </Test>
          </Tests>
        </Study>
      </TumorigenicStudies>
    </ToxicityStudies>
    <KnownDrugInformation>
      <Pharmacology>
        <PharmacologicalActions>
          <PharmacologicalAction>Analgesics, Non-Narcotic</PharmacologicalAction>
        </PharmacologicalActions>
        <CategoryPaths>
          <CategoryPath>Physiological Effects of Drugs : Peripheral Nervous System Agents : Sensory System Agents : Analgesics : Analgesics, Non-Narcotic</CategoryPath>
          <CategoryPath>Therapeutic Uses : Central Nervous System Agents : Analgesics : Analgesics, Non-Narcotic</CategoryPath>
        </CategoryPaths>
      </Pharmacology>
      <DrugProducts>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>NEOPAP</TradeName>
          <Applicant>POLYMEDICA</Applicant>
          <NdaNumber>016401</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19681107</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>TYLENOL</TradeName>
          <Applicant>MCNEIL CONS</Applicant>
          <NdaNumber>017756</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19760526</ApprovalDate>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>TYLENOL</TradeName>
          <Applicant>MCNEIL CONS</Applicant>
          <NdaNumber>017756</NdaNumber>
          <ProductNumber>002</ProductNumber>
          <ApprovalDate>19760526</ApprovalDate>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>100MG/ML</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>INJECTABLE; INJECTION</RouteOfAdministration>
          <TradeName>INJECTAPAP</TradeName>
          <Applicant>ORTHO MCNEIL PHARM</Applicant>
          <NdaNumber>017785</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>018060</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19780209</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>018060</NdaNumber>
          <ProductNumber>002</ProductNumber>
          <ApprovalDate>19780209</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>325MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>018060</NdaNumber>
          <ProductNumber>003</ProductNumber>
          <ApprovalDate>19780209</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ACTAVIS MID ATLANTIC</Applicant>
          <NdaNumber>018337</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19800422</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>325MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ACTAVIS MID ATLANTIC</Applicant>
          <NdaNumber>018337</NdaNumber>
          <ProductNumber>002</ProductNumber>
          <ApprovalDate>19800422</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ACTAVIS MID ATLANTIC</Applicant>
          <NdaNumber>018337</NdaNumber>
          <ProductNumber>003</ProductNumber>
          <ApprovalDate>19800422</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>80MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>INFANTS' FEVERALL</TradeName>
          <Applicant>ACTAVIS MID ATLANTIC</Applicant>
          <NdaNumber>018337</NdaNumber>
          <ProductNumber>004</ProductNumber>
          <ApprovalDate>19800422</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>TABLET, EXTENDED RELEASE; ORAL</RouteOfAdministration>
          <TradeName>TYLENOL (CAPLET)</TradeName>
          <Applicant>MCNEIL CONS</Applicant>
          <NdaNumber>019872</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19940608</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>TABLET, EXTENDED RELEASE; ORAL</RouteOfAdministration>
          <TradeName>TYLENOL (GELTAB)</TradeName>
          <Applicant>MCNEIL CONS</Applicant>
          <NdaNumber>019872</NdaNumber>
          <ProductNumber>002</ProductNumber>
          <ApprovalDate>19940608</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>SUPPOSITORIA</Applicant>
          <NdaNumber>070607</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19870406</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>SUPPOSITORIA</Applicant>
          <NdaNumber>070608</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19861201</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ROXANE</Applicant>
          <NdaNumber>071010</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ROXANE</Applicant>
          <NdaNumber>071011</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>072218</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19920327</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>072237</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19920327</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>325MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACEPHEN</TradeName>
          <Applicant>G AND W LABS</Applicant>
          <NdaNumber>072344</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>19920327</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>120MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ABLE</Applicant>
          <NdaNumber>073106</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>325MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ABLE</Applicant>
          <NdaNumber>073107</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>SUPPOSITORY; RECTAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>ABLE</Applicant>
          <NdaNumber>073108</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <DrugProductType>Discontinued</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>TABLET, EXTENDED RELEASE; ORAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>PERRIGO</Applicant>
          <NdaNumber>075077</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>20000225</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
        <DrugProduct sources="FDAOrangeBook,DrugsAtFDA">
          <ActiveIngredients>
            <ActiveIngredient>
              <Ingredient>ACETAMINOPHEN</Ingredient>
              <Strength>650MG</Strength>
            </ActiveIngredient>
          </ActiveIngredients>
          <RouteOfAdministration>TABLET, EXTENDED RELEASE; ORAL</RouteOfAdministration>
          <TradeName>ACETAMINOPHEN</TradeName>
          <Applicant>COREPHARMA</Applicant>
          <NdaNumber>076200</NdaNumber>
          <ProductNumber>001</ProductNumber>
          <ApprovalDate>20020319</ApprovalDate>
          <DrugProductType>OverTheCounter</DrugProductType>
          <DrugCompoundType>Single Active Ingredient</DrugCompoundType>
        </DrugProduct>
      </DrugProducts>
      <PDRReferences>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1082</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
                <TradeName>ARTHRALGEN-PR TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1145</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1203</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>COPLEXEN LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1430</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1431</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB PEDIATRIC SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1437</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBSTER</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL H.M.B. TABLETS</TradeName>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS</TradeName>
                <TradeName>BANCAPS-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>1470</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>581</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BORDEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIAL-A-GESIC SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>585</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>606</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TETREX-AP SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>609</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>626</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>SIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>633</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>683</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN TABLETS &amp; ELIXIR</TradeName>
                <TradeName>DULARIN TH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>687</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>688</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOVAHISTINE SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>704</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
                <TradeName>PERCOGESIC-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>736</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>737</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>738</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>742</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>752</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KEY PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMLO</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>765</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>870</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>COVANGESIC LIQUID</TradeName>
                <TradeName>COVANGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>890</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE</TradeName>
                <TradeName>TYLENOL ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>903</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>904</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>24</PDRVolume>
          <PDRYear>1970</PDRYear>
          <PDRPages>956</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1086</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
                <TradeName>ARTHRALGEN-PR TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1148</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1199</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCOTT/CORD</CompanyName>
              <MarketedTradeNames>
                <TradeName>SCOTGESIC CAPSULES</TradeName>
                <TradeName>SCOTGESIC ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1222</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>COPLEXEN LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1235</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1352</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>STUART</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROLAIRE-B</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1465</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1466</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER-CHILEOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1471</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBSTER</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1472</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL H.M.B. TABLETS</TradeName>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1473</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS</TradeName>
                <TradeName>BANCAPS-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>1497</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>588</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>608</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TETREX-AP SYRUP.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>611</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>635</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN TABLETS &amp; SYRUP</TradeName>
                <TradeName>DULARIN TH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>684</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>685</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOVAHISTINE SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>688</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENLAP ELIXIR</TradeName>
                <TradeName>TENLAP SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>700</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>705</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>706</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>738</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>740</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>755</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KEY PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMLO</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>770</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>894</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>895</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>896</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>909</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>964</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>25</PDRVolume>
          <PDRYear>1971</PDRYear>
          <PDRPages>975</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTEGA</CompanyName>
              <MarketedTradeNames>
                <TradeName>T-CAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1000</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PANAMERICAN PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEBREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1110</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1181</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1245</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCOTT-ALISON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DENGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1246</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCOTT/CORD</CompanyName>
              <MarketedTradeNames>
                <TradeName>SCOTGESIC CAPSULES</TradeName>
                <TradeName>SCOTGESIC ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1280</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1286</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1383</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID, CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1402</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TPR PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1497</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB-LL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1498</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1504</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL H.M.B. TABLETS</TradeName>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS</TradeName>
                <TradeName>BANCAPS-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>1537</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>608</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TETREX-AP SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>615</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>638</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>643</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
                <TradeName>DIALOG W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>667</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COASTAL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COASTALDYNE</TradeName>
                <TradeName>COASTALGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN TABLETS &amp; SYRUP</TradeName>
                <TradeName>DULARIN TH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>689</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>690</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOVAHISTINE SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>704</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBS ANALGESIC LIQUID</TradeName>
                <TradeName>NEBS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>712</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>713</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>743</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>749</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>761</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KEY PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMLO</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>776</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>889</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>MALLAGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>908</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>911</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE</TradeName>
                <TradeName>TYLENOL ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>924</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
                <TradeName>TRIND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MED SPEC</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUO-3X</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MED SPEC</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPPRESS 300</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>26</PDRVolume>
          <PDRYear>1972</PDRYear>
          <PDRPages>986</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1151</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1224</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1287</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCOTT-ALISON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DENGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SCOTT/CORD</CompanyName>
              <MarketedTradeNames>
                <TradeName>SCOTGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1288</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCOTT/CORD</CompanyName>
              <MarketedTradeNames>
                <TradeName>SCOTGESIC ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID, CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TPR PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1503</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1504</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1511</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBSTER</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1512</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL H.M.B. TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WESTERFTELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS-C</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>1539</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>656</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL W/CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>663</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>693</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COASTAL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COASTALDYNE</TradeName>
                <TradeName>COASTALGESIC</TradeName>
                <TradeName>PAVADON ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>711</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN TABLETS &amp; SYRUP</TradeName>
                <TradeName>DULARIN TH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>714</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>716</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOVAHISTINE SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>730</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBS ANALGESIC LIQUID</TradeName>
                <TradeName>NEBS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>736</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDECON</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
                <TradeName>PERCOGESIC W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>743</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>767</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>768</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>773</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>786</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KEY PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMLO</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>801</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>855</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX TY-MED</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>920</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MARCEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>OSSONATE-PLUS CAPSULETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>938</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>942</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>943</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>944</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>959</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>960</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>27</PDRVolume>
          <PDRYear>1973</PDRYear>
          <PDRPages>961</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MED SPEC</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUO-3X</TradeName>
                <TradeName>SUPPRESS 300</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1055</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1059</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1131</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PENNWALT</CompanyName>
              <MarketedTradeNames>
                <TradeName>STRASCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1196</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1264</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1372</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1440</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1543</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1544</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1555</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBCON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1556</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>1585</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>640</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>666</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>668</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>673</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>729</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>734</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBA ANALGESIC TABLETS</TradeName>
                <TradeName>NEBS ANALGESIC LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>749</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>751</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDECON</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>753</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>754</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>757</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>785</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>786</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>787</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>792</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>897</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>949</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MARTEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>OSSONATE-PLUS CAPSULETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>954</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPEP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>968</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>972</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>973</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>974</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>989</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>28</PDRVolume>
          <PDRYear>1974</PDRYear>
          <PDRPages>990</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1012</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1013</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1072</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>METRO MED</CompanyName>
              <MarketedTradeNames>
                <TradeName>METROGESIC, METROGESIC #2, METROGESIC #3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1079</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1080</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MITCHUM-THAYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>LIQUIPRIN DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1083</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1153</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PENNWALT</CompanyName>
              <MarketedTradeNames>
                <TradeName>STRASCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACRAFT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1213</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1289</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEBRIGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1388</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1394</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1461</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1575</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1576</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER/CHLICOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1583</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBCON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1585</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP</TradeName>
                <TradeName>BANCAP WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>1607</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEO-SYNEPHRINE COMPOUND COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>656</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>657</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>683</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>685</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>690</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>720</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANUPHEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>750</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIAMINICIN TABLETS</TradeName>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>760</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>769</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NABS ANALGESIC LIQUID</TradeName>
                <TradeName>NABS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>774</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>776</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDECON</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
                <TradeName>PERCOGESIC W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>784</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>811</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>812</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>813</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>818</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST-ROUSSEL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>852</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>919</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LILTY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>968</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MARCEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>OSSONATE-PLUS CAPSULETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>974</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>988</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA FOR CHILDREN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>994</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEII</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>29</PDRVolume>
          <PDRYear>1975</PDRYear>
          <PDRPages>997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1004</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1010</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA FOR CHILDREN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1015</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1017</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1018</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH CAPSULES</TradeName>
                <TradeName>TYLENOL WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1033</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1034</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1102</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>METRO MED</CompanyName>
              <MarketedTradeNames>
                <TradeName>METROGESIC, METROGESIC # 2, METROGESIC # 3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1104</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1110</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1111</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORCLIFF THAYER INC.</CompanyName>
              <MarketedTradeNames>
                <TradeName>LIQUIPRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1114</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1230</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACRAFT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1255</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1438</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>OMEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1443</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1509</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1544</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TUTAG</CompanyName>
              <MarketedTradeNames>
                <TradeName>X-OTAG PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1606</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1633</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1634</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1641</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WEBCON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPRETTES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1643</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESTERFIELD</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP</TradeName>
                <TradeName>BANCAP WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>1707</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>662</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>692</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>693</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>694</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODIMAL TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>695</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTURY PHARMACEUTICALS, INC.</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETA WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>702</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>733</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COASTAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COASTALGESIC</TradeName>
                <TradeName>PAVADON ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>735</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATLC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANUPHEN SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>769</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>778</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NABS ANALGESIC LIQUID</TradeName>
                <TradeName>NABS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>794</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>799</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>803</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>839</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST-ROUSSEL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>862</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>882</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>911</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX TY-MED</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>30</PDRVolume>
          <PDRYear>1976</PDRYear>
          <PDRPages>931</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N</TradeName>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1020</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MARLOP</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLMAR CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1022</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDSPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEI1</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL LIQUID COLD FORMULA FOR CHILDREN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1031</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1034</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH CAPSULES AND TABLETS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1035</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS AND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1051</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1055</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERCHANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1123</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINACON TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1130</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1133</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORCLIFF THAYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>LIQUIPRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1136</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP</TradeName>
                <TradeName>BANCAP WITH CODEINE</TradeName>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1256</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACRAFT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1267</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN, USP ELIXIR, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1272</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-PROVIDENT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROVAL #3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1282</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1292</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN</TradeName>
                <TradeName>PHENAPHEN WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1453</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEBRIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1475</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1481</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1554</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1594</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TUTAG</CompanyName>
              <MarketedTradeNames>
                <TradeName>X-OTAG PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1655</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1682</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHIICOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1683</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER/CHLCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>1756</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>642</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>670</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>701</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>702</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>703</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODIMAL TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>705</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTURY PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETA WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>713</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COASTAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COASTALGESIC</TradeName>
                <TradeName>PAVADON ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>745</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANUPHEN SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>781</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>791</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>800</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBS ANALGESIC LIQUID</TradeName>
                <TradeName>NEBS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>806</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>811</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>815</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>844</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
                <TradeName>GAYSAL-S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>845</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>846</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>851</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOECHST-ROUSSEL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>877</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>897</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>927</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX TY-MED</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>31</PDRVolume>
          <PDRYear>1977</PDRYear>
          <PDRPages>948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1077</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCKESSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1078</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1079</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL LIQUID COLD FORMULA FOR CHILDREN</TradeName>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH CAPSULES</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH TABLETS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1084</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1086</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1095</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON NUTRITIONAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1196</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1199</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORCLIFF THAYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>LIQUIPRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1202</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP</TradeName>
                <TradeName>BANCAP WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1203</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1325</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACRAFT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN, USP ELIXIR, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1345</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-PROVIDENT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROVAL #3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1355</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1365</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN</TradeName>
                <TradeName>PHENAPHEN WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1445</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1551</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEBRIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1572</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1576</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP ELIXIR</TradeName>
                <TradeName>SK-APAP TABLETS</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1628</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1729</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>VITARINE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN DROPS &amp; SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN TABLETS [FEBRINOL]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1759</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1760</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB W/CODEINE</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>1845</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN-TH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS</TradeName>
                <TradeName>TYLENOL CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH CAPSULES</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON NUTRITIONAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-PROVIDENT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROVAL #3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>426</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN</TradeName>
                <TradeName>PHENAPHEN WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>438</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>440</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>675</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>704</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>705</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL 500</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>717</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>735</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL TABLETS</TradeName>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>736</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>749</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANUPHEN SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>814</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN-TH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>822</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>842</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EATON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEBS ANALGESIC LIQUID</TradeName>
                <TradeName>NEBS ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>849</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>857</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>858</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>861</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>875</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
                <TradeName>GAYSAL-S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>893</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>895</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>977</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX D.LAY</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>32</PDRVolume>
          <PDRYear>1978</PDRYear>
          <PDRPages>997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1007</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1089</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1090</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA FOR CHILDREN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1091</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL CHILDREN'S STRENGTH CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH CAPSULES</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH TABLETS</TradeName>
                <TradeName>TYLENOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1092</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1095</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1097</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1107</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEAD JOHNSON NUTRITIONAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TEMPRA</TradeName>
                <TradeName>TRIND</TradeName>
                <TradeName>TRIND-DM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1128</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEDICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1222</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1226</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORCLIFF THAYER</CompanyName>
              <MarketedTradeNames>
                <TradeName>LIQUIPRIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1238</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1239</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1364</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACRAFT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINAREST TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1381</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1401</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1496</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1513</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>S-PAINACET</TradeName>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1622</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1625</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP ELIXIR</TradeName>
                <TradeName>SK-APAP TABLETS</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1626</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1789</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VITARINE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN DROPS &amp; SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN TABLETS [FEBRINOL]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1822</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB EXTRA STRENGTH TABLETS</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1823</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>1896</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN-TH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>439</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER/CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
                <TradeName>SINUTAB</TradeName>
                <TradeName>SINUTAB EXTRA STRENGTH TABLETS</TradeName>
                <TradeName>SINUTAB W/CODEINE</TradeName>
                <TradeName>SINUTAB-II</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>440</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>679</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>724</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>725</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
                <TradeName>DATRIL</TradeName>
                <TradeName>DATRIL 500</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>756</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>757</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>759</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>760</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>772</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>796</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANUPHEN SUPPOSITORIES</TradeName>
                <TradeName>ORAPHEN-PD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOONER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DULARIN-TH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>842</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>TUSSAGESIC TABLETS &amp; SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>849</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOVAHISTINE SINUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>854</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>861</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EMKO</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>867</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>869</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>872</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>885</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FRYE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>907</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
                <TradeName>GAYSAL-S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>908</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>910</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>938</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>942</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>33</PDRVolume>
          <PDRYear>1979</PDRYear>
          <PDRPages>987</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX D.LAY</TradeName>
                <TradeName>RHINSPEC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1004</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX D.LAY</TradeName>
                <TradeName>RHINSPEC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1026</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1099</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA [WITH COUGH SUPPRESSANT]</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1100</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1101</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1104</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1106</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1131</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEDIC MEDICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MEDICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1132</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERCHANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1226</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1243</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1398</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1431</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1432</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1517</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1533</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>S-PAINACET</TradeName>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1542</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>CORICIDIN SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1571</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1628</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1633</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP TABLETS &amp; ELIXIR</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1688</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1733</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>FLEXAPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1793</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1794</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAYCARE DAYTIME COLDS MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1795</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
                <TradeName>VICKS NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>1898</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERRT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>430</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>CORICIDIN SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ORNEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>439</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>562</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALBA-TEMP SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>563</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MYOFORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>AMERICAN PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>FENDON TABLETS, ELIXIR</TradeName>
                <TradeName>ROMEX DECONGESTANT COUGH, COLD CAPSULES &amp; TROCHES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>736</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
                <TradeName>DATRIL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>737</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL 500</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>750</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>773</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>776</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MINOTAL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>777</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>812</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>COMATIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN WITH CODEINE ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>861</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>875</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>876</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>880</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FRYE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>912</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
                <TradeName>GAYSAL-S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>913</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERRT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>919</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-2 TABLETS</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>957</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>961</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>34</PDRVolume>
          <PDRYear>1980</PDRYear>
          <PDRPages>999</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
                <TradeName>SPASGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1028</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX D.LAY</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1050</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1111</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
                <TradeName>ANATUSS TABLETS &amp; SYRUP W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1112</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1113</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1114</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1115</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1118</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1120</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1121</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1153</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEDICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1154</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MEDICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1265</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1290</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1291</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1387</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1444</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1466</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1477</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1478</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1566</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROTEX</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1583</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1593</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>CORICIDIN COUGH SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1626</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP TABLETS &amp; ELIXIR</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1787</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>FLEXAPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1847</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1848</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAYCARE DAYTIME COLDS MEDICINE-LIQUID</TradeName>
                <TradeName>DAYCARE MULTI-SYMPTOM COLDS MEDICINE-CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1849</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
                <TradeName>VICKS NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1885</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANITOL TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>1959</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VALADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>439</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>573</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALBA-TEMP SUPPOSITORIES</TradeName>
                <TradeName>MYOFORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>684</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>736</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
                <TradeName>DATRIL</TradeName>
                <TradeName>DATRIL 500</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>737</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>752</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>783</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>784</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MINOTAL TABLETS</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>795</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CIBA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIALOG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>867</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DOW PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>883</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>884</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>885</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>889</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>920</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXASONE W/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>922</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL</TradeName>
                <TradeName>GAYSAL-S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>923</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>932</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-2 TABLETS</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>976</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>980</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>981</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>35</PDRVolume>
          <PDRYear>1981</PDRYear>
          <PDRPages>982</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1022</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1028</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1029</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1071</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
                <TradeName>SPASGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1075</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>RHINEX D.LAY</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1094</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1153</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1154</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1155</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCFAL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL LIQUID COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1156</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1157</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1161</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1163</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1164</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1200</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERCHANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1340</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1367</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1368</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1469</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1517</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHILIPS ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>OXYCODONE HYDROCHLORIDE &amp; ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>PHILIPS ROXENE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1533</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PUREPAC</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1551</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ARTHRALGEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1563</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1649</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1671</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROTEX</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1672</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1690</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1700</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>CORICIDLN SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1740</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUNRIL PREMENSTRUAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACUCRON TABLETS</TradeName>
                <TradeName>LOBAC CAPSULES</TradeName>
                <TradeName>VENTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1809</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP TABLETS &amp; ELIXIR</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1810</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1869</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VAPADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1913</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>FLEXAPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1915</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>U.S.CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1974</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1976</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAYCARE DAYTIME COLDS MEDICINE-LIQUID</TradeName>
                <TradeName>DAYCARE MULTI-SYMPTOM COLDS MEDICINE-CAPSULES</TradeName>
                <TradeName>HEADWAY CAPSULES, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>1977</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NYQULL NIGHTTIME COLDS MEDICINE</TradeName>
                <TradeName>VICKS NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>2006</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WESLEY</CompanyName>
              <MarketedTradeNames>
                <TradeName>CETASED, IMPROVED</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>2016</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WILLIAMS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MUS-LAX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>2018</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WILLIAMS</CompanyName>
              <MarketedTradeNames>
                <TradeName>T-GESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>2087</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENLLIN TABLETS</TradeName>
                <TradeName>SINULLN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>426</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>429</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>431</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHERING</CompanyName>
              <MarketedTradeNames>
                <TradeName>CORICIDLN SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>LOBAC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SQUIBB</CompanyName>
              <MarketedTradeNames>
                <TradeName>VAPADOL TABLETS, LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>440</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>588</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMERICAN PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>FENDON TABLETS, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>702</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>758</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPLRIN LIQUID COLD MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>759</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL</TradeName>
                <TradeName>DATRIL 500</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>778</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>817</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>818</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENLLIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>819</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULLN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>866</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>894</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EDWARDS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BLANEX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>905</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>911</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>913</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC</TradeName>
                <TradeName>PEREOGESIC WITH CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>918</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>931</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FRYE</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>951</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHLORZOXASONE W/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>953</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GERIATRIC</CompanyName>
              <MarketedTradeNames>
                <TradeName>GAYSAL-S TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>954</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>963</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>OLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>36</PDRVolume>
          <PDRYear>1982</PDRYear>
          <PDRPages>966</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-1 CAPSULES</TradeName>
                <TradeName>G-2 CAPSULES</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1014</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HYREX</CompanyName>
              <MarketedTradeNames>
                <TradeName>TWO-DYNE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1048</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1054</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1055</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1099</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1121</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1172</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODEGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1185</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASTAR</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
                <TradeName>ANATUSS TABLETS &amp; SYRUP W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1187</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD FORMULA TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1188</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>COTYLENOL LIQUID COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1189</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1190</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1191</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1194</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1202</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1203</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1369</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1401</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
                <TradeName>BANCAPS HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1539</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1610</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RHO MU</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1631</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1724</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1749</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROTEX</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROGESIC #3 TABLETS</TradeName>
                <TradeName>ROGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1750</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1755</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>OXYCODONE HYDROCHLORIDE &amp; ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1778</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHEIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP 300 MG. WITH CODEINE TABS</TradeName>
                <TradeName>APAP EXTRA STRENGTH CAPSULES &amp; TABLETS</TradeName>
                <TradeName>APAP TABLETS</TradeName>
                <TradeName>APAP WITH CODEINE ELIXIR</TradeName>
                <TradeName>CHLORZONE FORTE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE &amp; APAP TABLETS 65/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1881</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACUCRON TABLETS</TradeName>
                <TradeName>LOBAC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1909</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP TABLETS &amp; ELIXIR</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>1921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SPRINGBOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>STOPAYNE CAPSULES</TradeName>
                <TradeName>STOPAYNE SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2011</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>AMAPHEN WITH CODEINE #3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2012</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>KORIGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>U.S. CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2077</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2079</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAYCARE DAYTIME COLDS MEDICINE-LIQUID</TradeName>
                <TradeName>DAYCARE MULTI-SYMPTOM COLDS MEDICINE-CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2080</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HEADWAY CAPSULES, TABLETS</TradeName>
                <TradeName>NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
                <TradeName>VICKS NYQUIL NIGHTTIME COLDS MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2121</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WILLIAMS</CompanyName>
              <MarketedTradeNames>
                <TradeName>T-GESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2135</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>2202</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DI-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>COTYLENOL COLD FORMULA TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>421</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>428</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>431</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>442</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>443</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>587</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMERICAN PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>FENDON TABLETS, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>706</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DEMEROL APAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>767</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>768</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL-</TradeName>
                <TradeName>EXCEDRIN</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
                <TradeName>EXTRA-STRENGTH DATRIL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>785</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>836</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DI-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>883</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>918</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EDWARDS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BLANEX CAPSULES</TradeName>
                <TradeName>DOUBLE-A</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>932</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>938</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET-5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>940</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>945</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>977</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXASONE W/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>979</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>37</PDRVolume>
          <PDRYear>1983</PDRYear>
          <PDRPages>994</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-1 CAPSULES</TradeName>
                <TradeName>G-2 CAPSULES</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1009</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HOLLOWAY</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1014</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HYRAX</CompanyName>
              <MarketedTradeNames>
                <TradeName>TWO-DYNE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1046</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1053</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1054</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP</TradeName>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1099</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1121</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1163</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLARD</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOQUAN</TradeName>
                <TradeName>PHENATE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1176</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASTER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANATUSS TABLETS &amp; SYRUP</TradeName>
                <TradeName>ANATUSS WITH CODEINE SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1177</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYREND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPEP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1178</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1179</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1180</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULER STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1181</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1193</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1194</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1352</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1384</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1404</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1523</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1580</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1584</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>READ-PROVIDENT LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1604</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1697</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1729</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COLREX COMPOUND CAPSULES</TradeName>
                <TradeName>COLREX COMPOUND ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1734</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>OXYCODONE HYDROCHLORIDE &amp; ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>175</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHEIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP 300 MG. WITH CODEINE TABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1755</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SARON</CompanyName>
              <MarketedTradeNames>
                <TradeName>SAROFLEX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1758</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHEIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP WITH CODEINE ELIXIR</TradeName>
                <TradeName>CHLORZONE FORTE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE &amp; APAP TABLETS 65/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1890</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
                <TradeName>SK-OXYCODONE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1903</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SPRINGBOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>STOPAYNE CAPSULES</TradeName>
                <TradeName>STOPAYNE SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1985</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMACODONE CAPSULES</TradeName>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>AMAPHEN WITH CODEINE #3</TradeName>
                <TradeName>KORIGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>1986</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>U.S. CHEMICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>20</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ULTRA COLDS FORMULA ASPIRIN-FREE ANALGESIC/DECONGESTANT/ANTIHISTAMINE/ COUGH SUPPRESSANT NIGHTTIME LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2054</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2058</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS PHARMACY PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2096</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2099</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ULTRA COLDS FORMULA ASPIRIN-FREE ANALGESIC/DECONGESTENT/ANTIHISTEMINE/ COUGH SUPPRESSANT TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2102</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WILLIAMS</CompanyName>
              <MarketedTradeNames>
                <TradeName>T-GESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2116</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>2183</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRECET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
                <TradeName>DI-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULER STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>NEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>426</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>428</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>READ-PROVIDENT LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>429</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>432</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RORER</CompanyName>
              <MarketedTradeNames>
                <TradeName>GEMNISYN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>4419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>442</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIS CAPSULES</TradeName>
                <TradeName>DRISTAN ULTRA COLDS FORMULA ASPIRIN-FREE ANALGESIC/DECONGESTANT/ANTIHISTAMINE/ COUGH SUPPRESSANT NIGHTTIME LIQUID</TradeName>
                <TradeName>DRISTAN ULTRA COLDS FORMULA ASPIRIN-FREE ANALGESIC/DECONGESTENT/ANTIHISTEMINE/ COUGH SUPPRESSANT TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>443</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>444</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>596</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ARLO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESPESMOTEX TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>606</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCODAPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>628</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>770</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>771</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA-STRENGTH DATRIL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>791</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRECET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>8</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ULTRA COLDS FORMULA ASPIRIN-FREE ANALGESIC/DECONGESTANT/ANTIHISTAMINE/ COUGH SUPPRESSANT NIGHTTIME LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>834</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>882</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>927</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>933</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EDWARDS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BLANEX CAPSULES</TradeName>
                <TradeName>DOUBLE-A TABLETS</TradeName>
                <TradeName>HYDROGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>943</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>972</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP W/CODEINE #3</TradeName>
                <TradeName>APAP W/CODEINE #4</TradeName>
                <TradeName>APAP W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXASONE W/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>990</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES &amp; TABLETS</TradeName>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>38</PDRVolume>
          <PDRYear>1984</PDRYear>
          <PDRPages>993</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-1 CAPSULES</TradeName>
                <TradeName>G-2 CAPSULES</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1001</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
                <TradeName>G-1 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HYREX</CompanyName>
              <MarketedTradeNames>
                <TradeName>TWO-DYNE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1068</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1071</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAMBDA</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP</TradeName>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID, IMPROVED FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1120</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1122</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN WITH CODEINE TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1136</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1181</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLARD</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOQUAN</TradeName>
                <TradeName>PHENATE</TradeName>
                <TradeName>SALETO</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1196</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1197</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1198</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1199</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1200</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS, CAPSULES &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1201</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1206</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1214</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1385</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1420</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1444</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP CAPSULES</TradeName>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>BANCAP WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1445</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADYNE DHC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1569</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1632</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1637</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-PROVIDENT LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1656</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>OXYCODONE HYDROCHLORIDE &amp; ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1828</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHEIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP WITH CODEINE ELIXIR</TradeName>
                <TradeName>CHLORZONE FORTE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE &amp; APAP TABLETS 65/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SCHEM</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP 300 MG. WITH CODEINE CAPSULES &amp; TABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1971</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
                <TradeName>SK-OXYCODONE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>1985</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SPRINGBOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>STOPAYNE CAPSULES</TradeName>
                <TradeName>STOPAYNE SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2067</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMACODONE TABLETS</TradeName>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>AMAPHEN WITH CODEINE #3</TradeName>
                <TradeName>KORIGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2069</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET</TradeName>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2144</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2147</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS PHARMACY PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2184</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2185</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC CAPSULES</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2227</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>2297</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>404</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA</TradeName>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS, CAPSULES &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN SWALLOWABLE TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>NEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>421</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERRELL DOW</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>O'NEAL, JONES &amp; FELDMAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-PROVIDENT LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>428</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>442</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS PHARMACY PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>443</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC CAPSULES</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>444</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>445</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>634</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>705</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>769</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX</TradeName>
                <TradeName>CONGESPIRIN ASPIRIN-FREE CHEWABLE COLD TABLETS FOR CHILDREN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>770</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN LIQUID COLD MEDICINE</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH</TradeName>
                <TradeName>EXCEDRIN P.M.</TradeName>
                <TradeName>EXTRA-STRENGTH DATRIL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>789</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>834</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>836</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>837</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>887</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>909</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>919</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>942</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>973</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP W/CODEINE #3</TradeName>
                <TradeName>APAP W/CODEINE #4</TradeName>
                <TradeName>APAP W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXASONE W/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>975</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GILBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>39</PDRVolume>
          <PDRYear>1985</PDRYear>
          <PDRPages>998</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1033</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1034</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN WITH CODEINE TABLETS AND CAPSULES</TradeName>
                <TradeName>PROPACET 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1041</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1073</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLARD</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOQUAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1083</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP #3 CAPSULES</TradeName>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1084</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1085</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA AND CHEWABLE COLD TABLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1086</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1087</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN SWALLOWABLE TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1088</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN, TABLETS, CAPSULES &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1089</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS ,&amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1093</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1095</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1096</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1132</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MANLEY &amp; JAMES</CompanyName>
              <MarketedTradeNames>
                <TradeName>TELDRIN MULTI-SYMPTOM ALLERGY RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1246</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>METRO MED</CompanyName>
              <MarketedTradeNames>
                <TradeName>BETA-PHED CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1267</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1388</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1441</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1446</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-ROWELL, INC.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1461</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1462</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1569</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>OXYCODONE HYDROCHLORIDE &amp; ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1606</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHEIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP 300 MG. WITH CODEINE CAPSULES &amp; TABS</TradeName>
                <TradeName>APAP WITH CODEINE ELIXIR</TradeName>
                <TradeName>CHLORZONE FORTE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE &amp; APAP TABLETS 65/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1722</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1723</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
                <TradeName>SK-OXYCODONE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1735</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SPRINGBOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPAIN HC CAPSULES</TradeName>
                <TradeName>STOPAYNE CAPSULES</TradeName>
                <TradeName>STOPAYNE SYRUP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1807</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMACODONE TABLETS</TradeName>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>AMAPHEN WITH CODEINE # 3</TradeName>
                <TradeName>KORIGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1808</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUCET</TradeName>
                <TradeName>LORCET</TradeName>
                <TradeName>LORCET-HD</TradeName>
                <TradeName>TRIAD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1866</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1869</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS PHARMACY PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1897</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1898</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1899</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ ANALGESIC CAPSULES</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1996</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>1999</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ZENITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE &amp; ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>404</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
                <TradeName>HYDROCET</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LAKESIDE</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPACET 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA AND CHEWABLE COLD TABLET</TradeName>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPSULES</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPSULES</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN, TABLETS, CAPSULES &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN SWALLOWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS ,&amp; CAPSULES</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>420</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-ROWELL, INC.</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VICKS PHARMACY PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ ANALGESIC CAPSULES</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>589</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCODAPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>611</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>654</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BART</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>674</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>727</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPSULES/LIQUID</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER [NEW FORMULA]</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE LIQUID COLD MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>728</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL EXTRA-STRENGTH TABLETS &amp; CAPSULES</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS &amp; CAPSULES</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>743</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>779</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL WITH CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>781</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>784</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>785</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>830</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>847</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>855</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>860</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>875</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>884</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>887</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES &amp; TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>928</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
                <TradeName>G-1 CAPSULES</TradeName>
                <TradeName>G-2 CAPSULES</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HYREX</CompanyName>
              <MarketedTradeNames>
                <TradeName>TWO-DYNE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>984</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>991</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LAKESIDE</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINGLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP</TradeName>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID, IMPROVED FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>40</PDRVolume>
          <PDRYear>1986</PDRYear>
          <PDRPages>993</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, ELIXIR</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1000</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1001</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>G-1 CAPSULES</TradeName>
                <TradeName>G-2 CAPSULES</TradeName>
                <TradeName>G-3 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1061</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1074</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LASALLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS</TradeName>
                <TradeName>PROTID, IMPROVED FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1076</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1122</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1124</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE TABLETS</TradeName>
                <TradeName>PROPACET 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1132</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1172</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLARD</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOQUAN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1173</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLARD</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENATE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1180</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAMACET-P</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1182</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP #3 CAPSULES</TradeName>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1183</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1184</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA, CHEWABLE COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1185</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1187</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMERPRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1188</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CON PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1195</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1198</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1199</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1375</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>METRO MED</CompanyName>
              <MarketedTradeNames>
                <TradeName>BETA-PHED CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1402</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1539</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1601</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>161</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1610</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>163</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1632</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1758</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1765</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1774</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1924</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-APAP WITH CODEINE TABLETS</TradeName>
                <TradeName>SK-OXYCODONE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>1925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITH KLINE &amp; FRENCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>SK-65 APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2010</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TRIMEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>AMACODONE TABLETS</TradeName>
                <TradeName>AMAPHEN CAPSULES</TradeName>
                <TradeName>AMAPHEN WITH CODEINE #3</TradeName>
                <TradeName>KORIGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2011</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUCET</TradeName>
                <TradeName>LORCET</TradeName>
                <TradeName>LORCET-HD</TradeName>
                <TradeName>TRIAD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2012</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2071</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHERSMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2104</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2105</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM-COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2106</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC CAPLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2139</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>2217</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ZENITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE &amp; ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL AND CODEINE TABLETS</TradeName>
                <TradeName>HYDROCET</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN [NEW FORMULATION]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES, TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPACET 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAMACET-P</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CON PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA, CHEWABLE COLD TABLETS</TradeName>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMERPRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PARAFON FORTE TABLETS</TradeName>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS, CAPSULES</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>421</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>423</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>REID-ROWELL</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMPAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM-COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC CAPLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WINTHROP-BREON</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>437</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>606</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>677</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>OXYCODONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>679</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BART</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>710</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>770</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>771</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE LIQUID COLD MEDICINE</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>772</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>786</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>823</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>CAPITAL AND CODEINE TABLETS</TradeName>
                <TradeName>HYDROCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>824</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>825</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>826</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN [NEW FORMULATION]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>828</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>829</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DIA-GESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>876</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DORSEY LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>900</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>905</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>910</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>913</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EDWARDS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BLANEX CAPSULES</TradeName>
                <TradeName>HYDROGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>940</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>941</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>41</PDRVolume>
          <PDRYear>1987</PDRYear>
          <PDRPages>998</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH PANADOL CAPSULES, TABLETS &amp; CAPLETS</TradeName>
                <TradeName>VANQUISH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1000</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN/CODEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1033</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1034</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS &amp; CAPLETS</TradeName>
                <TradeName>PANADOL JR. CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1035</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1037</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
                <TradeName>G-1 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1110</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1128</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1129</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPLETS</TradeName>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1175</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEEMING</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM DUAL RELIEF</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
                <TradeName>SPASGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1185</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1229</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1231</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP #3 CAPSULES</TradeName>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1232</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA AND CHEWABLE COLD TABLET</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1234</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1235</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1236</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1237</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1248</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1249</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>134</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>METRO MED</CompanyName>
              <MarketedTradeNames>
                <TradeName>BETA-PHED CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1466</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1488</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1597</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIE</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1661</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1676</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1692</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1693</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1843</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1850</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1852</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1854</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ CONSUMER HEALTH</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>1866</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2003</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SHOALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEGAMOR CAPSULES</TradeName>
                <TradeName>TENCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2107</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUCET</TradeName>
                <TradeName>LORCET</TradeName>
                <TradeName>LORCET PLUS</TradeName>
                <TradeName>LORCET-HD</TradeName>
                <TradeName>TRIAD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2108</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2152</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2192</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HCL AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2193</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2213</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2214</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2249</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>2324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS &amp; CAPLETS</TradeName>
                <TradeName>PANADOL JR. CAPLETS</TradeName>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COTYLENOL CHILDREN'S LIQUID COLD FORMULA AND CHEWABLE COLD TABLET</TradeName>
                <TradeName>COTYLENOL COLD MEDICATION TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COTYLENOL LIQUID COLD MEDICATION</TradeName>
                <TradeName>EXTRA-STRENGTH SINE-AID SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID EXTRA-STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS &amp; CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC TABLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>436</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>590</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
                <TradeName>GELPIRIN-CCF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>612</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>682</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>OXYCODONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>684</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BART</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALBA-TEMP 300</TradeName>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>716</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>781</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/ LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX A/S MULTI-SYMPTOM ALLERGY- SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE LIQUID COLD MEDICINE</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>783</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>799</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>EMPRACET WITH CODEINE PHOSPHATE NOS. 3 &amp; 4</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>843</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>844</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>846</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>847</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>849</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>897</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>924</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>930</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>935</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>949</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>968</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>972</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>42</PDRVolume>
          <PDRYear>1988</PDRYear>
          <PDRPages>973</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1005</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS PREMENSTRUAL SYNDROME FORMULA</TradeName>
                <TradeName>ORIGINAL MIDOL MULTI-SYMPTOM FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1006</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH PANADOL</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1007</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1015</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
                <TradeName>G-1 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1085</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1097</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPLETS</TradeName>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1156</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEEMING</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM DUAL RELIEF</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1157</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
                <TradeName>SPASGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1171</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1206</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1227</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1229</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP-10 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S COTYLENOL LIQUID COLD FORMULA AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1231</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1232</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1233</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1234</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1235</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1236</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1243</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1244</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1467</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1469</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1489</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1631</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMAFAIR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1666</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1689</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1699</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1700</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1857</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1863</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1866</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1868</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ CONSUMER HEALTH</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>1878</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2034</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SHOALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEGAMOR CAPSULES</TradeName>
                <TradeName>TENCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2146</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUCET</TradeName>
                <TradeName>LORCET PLUS</TradeName>
                <TradeName>LORCET-HD</TradeName>
                <TradeName>TRIAD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2147</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2192</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHERSMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2213</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS NO. 2, NO. 3 &amp; NO. 4</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER CHITCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HCL AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2227</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2229</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2268</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>2390</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA</TradeName>
                <TradeName>ANEXSIA 7.5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp;CAPLETS.</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SINUS TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH PANADOL</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS PREMENSTRUAL SYNDROME FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ORIGINAL MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S COTYLENOL LIQUID COLD FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS, ELIXIR, INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>426</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN ADVANCED FORMULA DECONGESTANT/ANTIHISTAMINE/ANALGESIC COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>437</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>614</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AIRS, LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN-CCF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>625</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>650</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>OXYCODONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>652</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BART</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALBA-TEMP 300</TradeName>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>657</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>658</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 7.5</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>683</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>754</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>755</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX A/S MULI-SYMPTOM ALLERGY /SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE LIQUID COLD MEDICINE</TradeName>
                <TradeName>COUGH FORMULA COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>756</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp;CAPLETS.</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS</TradeName>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>802</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SINUS TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>817</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>819</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>821</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CODEINE NO. 3</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>823</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>825</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>877</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DANBURY</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>907</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>915</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>934</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>935</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>949</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>956</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>957</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>43</PDRVolume>
          <PDRYear>1989</PDRYear>
          <PDRPages>990</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN/CODEINE TABLETS</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN &amp; CAFFEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1003</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN/CODEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1018</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS PREMENSTRUAL SYNDROME FORMULA</TradeName>
                <TradeName>REGULAR STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1019</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH PANADOL</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1021</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1035</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1121</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1122</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1133</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1134</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID, ELIXIR</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL &amp; ACETAMINOPHEN</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1191</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEEMING</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM DUAL RELIEF NIGHTTIME SLEEP AID/ANALGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1192</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEGERE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETACO TABLETS</TradeName>
                <TradeName>SPASGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1193</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEMMON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>PROPACET 100 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>RHINEX D.LAY TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1207</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1248</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1272</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1274</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1277</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1278</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1279</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL LIQUID COLD FORMULA AND CHEWABLE COLD TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1280</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1281</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION, MAXIMUM STRENGTH, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1282</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS MEDICATION, MAXIMUM STRENGTH, TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1289</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1291</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1521</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1522</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1543</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1680</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMAFAIR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1722</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALGISIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1745</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1757</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1758</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1905</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1911</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1914</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUGBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP WITH CODEINE ELIXIR &amp; TABLETS</TradeName>
                <TradeName>APAP WITH OXYCODONE CAPSULES</TradeName>
                <TradeName>HYDROCODONE WITH APAP TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH APAP TABLETS</TradeName>
                <TradeName>PROPOXYPHENE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1920</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEMCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5 TABLETS</TradeName>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>DORCOL CHILDREN'S FEVER &amp; PAIN REDUCER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>1936</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2207</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUCET</TradeName>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2208</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES/TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>UAD LABS.</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2255</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
                <TradeName>FEVERNOL SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2276</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS AND CAPLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS NO. 2, NO. 3 &amp; NO. 4</TradeName>
                <TradeName>PROPOXYPHENE HCL AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2293</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ALCOHOL-FREE LIQUID, AND INFANTS' DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2294</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2296</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN DECONGESTANT/ANTIHISTAMINE/ ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>2452</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500</TradeName>
                <TradeName>ANEXSIA 7.5/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/ LIQUID/LIQUI-GELS</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>411</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GLENBROOK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S PANADOL CHEWABLE TABLETS, LIQUID, INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH PANADOL</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH MIDOL PMS PREMENSTRUAL SYNDROME FORMULA</TradeName>
                <TradeName>MAXIMUM STRENGTH PANADOL TABLETS AND CAPLETS</TradeName>
                <TradeName>REGULAR STRENGTH MIDOL MULTI-SYMPTOM FORMULA</TradeName>
                <TradeName>VANQUISH ANALGESIC CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
                <TradeName>VICODIN ES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL LIQUID COLD FORMULA AND CHEWABLE COLD TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION, MAXIMUM STRENGTH, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS MEDICATION, MAXIMUM STRENGTH, TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5 TABLETS</TradeName>
                <TradeName>LORTAB 5 TABLETS</TradeName>
                <TradeName>LORTAB 7 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ALCOHOL-FREE LIQUID, AND INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ANTIHISTAMINE/ ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>438</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>608</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
                <TradeName>GELPIRIN-CCF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>623</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>651</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>OXYCODONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>656</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>657</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 7.5/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLPRN #3 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>760</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/ LIQUID/LIQUI-GELS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>761</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>COUGH FORMULA COMTREX</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>762</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>4-WAY COLD TABLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS AND CAPLETS</TradeName>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>825</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>826</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>829</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>919</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>927</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>934</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>936</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>940</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>941</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>958</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>965</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>44</PDRVolume>
          <PDRYear>1990</PDRYear>
          <PDRPages>966</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1030</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN &amp; CAFFEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1052</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
                <TradeName>TENCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>REDUTEMP TAB.</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1156</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1158</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1160</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1161</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS, LIQUID</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>DOLENE AP-65 TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1223</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1275</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1326</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1327</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDRENS CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT-LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1329</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION FAST ACTING EFFERVESCENT TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1330</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1331</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS &amp; TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS, CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1564</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1565</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1582</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1704</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM DUAL RELIEF NIGHTTIME SLEEP AID/ANALGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1790</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICHARDSON-VICKS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOGESIC ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1802</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1803</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1922</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPSULES [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1931</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>1946</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAUDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2214</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS</TradeName>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES/TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2266</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL SPRINKLE CAPS</TradeName>
                <TradeName>FEVERALL SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2287</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS AND CAPLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS NO. 2, NO. 3 &amp; NO. 4</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ALCOHOL-FREE LIQUID, AND INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2314</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2350</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>2466</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500</TradeName>
                <TradeName>ANEXSIA 7.5/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY SINUS COMTREX MULTI-SYMPTOM ALLERGY/SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/ LIQUI-GELS/LIQUID</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>410</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDRENS CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS &amp; TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION FAST ACTING EFFERVESCENT TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN CAPLETS, GELCAPS, TABLETS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION TABLETS, CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RUSS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SAUDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANACIN-3 CHILDREN'S ACETAMINOPHEN CHEWABLE TABLETS, ALCOHOL-FREE LIQUID, AND INFANTS' DROPS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ANACIN-3 MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>ANACIN-3 REGULAR STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED CAPLETS</TradeName>
                <TradeName>DRISTAN DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>436</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>438</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>589</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
                <TradeName>GELPIRIN-CCF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>605</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>635</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARR</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE W/ ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>OXYCODONE W/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>641</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>642</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BEECHAM LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 7.5/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>740</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/ LIQUI-GELS/LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>741</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY SINUS COMTREX MULTI-SYMPTOM ALLERGY/SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COUGH FORMULA COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>742</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>743</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>4-WAY COLD TABLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS AND LIQUID</TradeName>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>821</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>822</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>824</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>826</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>830</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>910</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>919</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>935</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHLORZOXAZONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>941</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>943</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>973</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>980</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>45</PDRVolume>
          <PDRYear>1991</PDRYear>
          <PDRPages>981</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1001</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1002</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1050</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN/CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1079</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DOLACET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1080</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HAUCK</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1130</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>REDUTEMP TAB.</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1187</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1189</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1191</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LANNETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODALAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1192</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LEDERLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN CAPSULES, TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN W/CODEINE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE WITH ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1254</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1358</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1360</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1365</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1367</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1368</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1369</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1370</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1371</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1372</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS AND GELCAPS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID WITH DECONGESTANT, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID, MAXIMUM STRENGTH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1373</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1381</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS,</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1382</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1614</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1616</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1629</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1774</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM DUAL RELIEF NIGHTTIME SLEEP AID/ANALGESIC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1865</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1866</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1983</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>1992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2006</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2070</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2196</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2197</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2316</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS</TradeName>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2318</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES/TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2374</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN UNISERTS SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL SPRINKLE CAPS</TradeName>
                <TradeName>FEVERALL SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2393</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS AND CAPLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS NO. 2, NO. 3 &amp; NO. 4</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE ANACIN MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE ANACIN MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN COLD NASAL DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2420</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NO DROWSINESS DRISTAN COLD NASAL DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>2540</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>403</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABANA</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/ LIQUID</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS</TradeName>
                <TradeName>DAY &amp; NIGHT COMTREX</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>NON-DROWSY COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC PLUS TABLETS</TradeName>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>412</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MASON</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS AND GELCAPS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID WITH DECONGESTANT, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS,</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>A.H. ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>429</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>432</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>434</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE ANACIN MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE ANACIN MAXIMUM STRENGTH ACETAMINOPHEN FILM COATED TABLETS</TradeName>
                <TradeName>DRISTAN COLD NASAL DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>NO DROWSINESS DRISTAN COLD NASAL DECONGESTANT/ANALGESIC COATED CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>437</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>502</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABANA</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>590</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>614</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ASCHER</CompanyName>
              <MarketedTradeNames>
                <TradeName>HY-PHEN TABLETS [FORMERLY HYCODAPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>744</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>745</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/ LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>746</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>COUGH FORMULA COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>747</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>DAY &amp; NIGHT COMTREX</TradeName>
                <TradeName>NON-DROWSY COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>748</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>DATRIL EXTRA-STRENGTH ANALGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>749</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>750</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>4-WAY COLD TABLETS</TradeName>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>836</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>838</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>840</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>846</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>941</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>950</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>970</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACODA #3</TradeName>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>972</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>46</PDRVolume>
          <PDRYear>1992</PDRYear>
          <PDRPages>999</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1000</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1030</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1033</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 [HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1214</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1288</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1408</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1413</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S SUSPENSION LIQUID</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1415</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH LIQUID FORMULA</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1419</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1420</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1421</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS AND GELCAPS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID WITH DECONGESTANT, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID, MAXIMUM STRENGTH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1422</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1430</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1431</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1819</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PARKE-DAVIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUBID EXTENDED-RELEASE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1829</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1947</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>1948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2100</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2101</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2166</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2287</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2288</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2489</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEVERALL SPRINKLE CAPS</TradeName>
                <TradeName>FEVERALL SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2523</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2532</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN COLD &amp; FLU</TradeName>
                <TradeName>DRISTAN COLD NASAL DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2533</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN JUICE MIX-IN</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN COLD GEL CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2534</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH DRISTAN COLD NO DROWSINESS FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>2657</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>406</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/LIQUID</TradeName>
                <TradeName>DAY &amp; NIGHT COMTREX</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>NON-DROWSY COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>409</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>414</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>416</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>417</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION CAPLETS AND GELCAPS, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID WITH DECONGESTANT, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION LIQUID, MAXIMUM STRENGTH</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER CAPLETS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>428</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>430</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SMITHKLINE BEECHAM PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 [HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>435</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WHITEHALL</CompanyName>
              <MarketedTradeNames>
                <TradeName>DRISTAN COLD &amp; FLU</TradeName>
                <TradeName>DRISTAN COLD NASAL DECONGESTANT/ ANTIHISTAMINE/ ANALGESIC COATED TABLETS</TradeName>
                <TradeName>DRISTAN JUICE MIX-IN</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN COLD GEL CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH DRISTAN COLD NO DROWSINESS FORMULA</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>438</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>761</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>762</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>763</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COUGH FORMULA COMTREX</TradeName>
                <TradeName>DAY &amp; NIGHT COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>764</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
                <TradeName>NON-DROWSY COMTREX</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>765</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>766</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>767</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>4-WAY COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>858</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>859</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>861</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>863</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>960</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>970</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>47</PDRVolume>
          <PDRYear>1993</PDRYear>
          <PDRPages>973</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1005</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN/CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1080</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>REDUTEMP</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1115</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KENWOOD</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN COLD &amp; ALLERGY CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1143</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1144</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1216</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1272</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1339</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S SUSPENSION LIQUID</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS' SUSPENSION DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1340</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1343</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM PLUS COUGH LIQUID FORMULA</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1344</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1345</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1346</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1347</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH MEDICATION MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MAXIMUM STRENGTH LIQUID WITH DECONGESTANT</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1348</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1364</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ORAL SOLUTION</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1615</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MISSION</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUPAC</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1618</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1621</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORTHAMPTON MEDICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEMCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NUTRIPHARM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ISOCOM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1821</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1893</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>1894</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2017</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS, SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2027</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2050</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2117</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2388</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2389</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2392</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2463</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEVERALL CHILDREN'S SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL INFANT'S SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL JUNIOR STRENGTH SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL SPRINKLE CAPS POWDER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2484</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS AND CAPLETS, USP</TradeName>
                <TradeName>ACETAMINOPHEN WITH CODEINE PHOSPHATE TABLETS NO. 2, NO. 3 &amp; NO. 4</TradeName>
                <TradeName>HYDROCODONE WITH APAP TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2498</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2627</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>2642</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>306</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/LIQUID</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM NON-DROWSY CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED PLUS CAPLETS</TradeName>
                <TradeName>ACTIFED PLUS TABLETS</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS [DAYTIME]</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS [NIGHTTIME]</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME TABLETS [DAYTIME]</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME TABLETS [NIGHTTIME]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BURROUGHS WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SEVERE COLD FORMULA TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN</TradeName>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>315</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>317</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM PLUS COUGH LIQUID FORMULA</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU NO DROWSINESS HOT MEDICATION, PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION EFFERVESCENT TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME MEDICATION LIQUID</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MAXIMUM STRENGTH LIQUID WITH DECONGESTANT</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS' SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>318</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE ORAL SOLUTION</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>325</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
                <TradeName>PHENAPHEN-650 WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>327</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>334</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>494</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP ELIXIR</TradeName>
                <TradeName>GELPIRIN CCF TABLETS</TradeName>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>569</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ATHENA NEUROSCIENCES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ATARIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>624</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOEHRINGER MANNHEIM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>678</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUFFERIN AF NITE TIME ANALGESIC/SLEEPING AID CAPLETS</TradeName>
                <TradeName>COMTREX MULTI-SYMPTOM COLD RELIEVER TABLETS/CAPLETS/LIQUI-GELS/LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>679</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>680</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MULTI-SYMPTOM NON-DROWSY CAPLETS</TradeName>
                <TradeName>CONGESPIRIN FOR CHILDREN ASPIRIN FREE CHEWABLE COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>682</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>4-WAY COLD TABLETS</TradeName>
                <TradeName>SINUS EXCEDRIN ANALGESIC, DECONGESTANT TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>779</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>780</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>784</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>789</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>883</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMA MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>893</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMA MULTI-SOURCE PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>898</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DU PONT PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>906</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>PANACET 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>920</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>924</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>952</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>48</PDRVolume>
          <PDRYear>1994</PDRYear>
          <PDRPages>954</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1027</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1090</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1172</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>REDUTEMP</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1211</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KENWOOD</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN COLD &amp; ALLERGY CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1241</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1242</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1320</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1376</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1437</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1447</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS NIGHTTIME MEDICINE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1448</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S SUSPENSION LIQUID</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS' SUSPENSION DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEILCONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1449</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1450</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1451</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID CAPLETS, GELCAPS, GELTABS, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1452</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM PLUS COUGH LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL COLD HOT MEDICATION PACKETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1453</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1454</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, HOT MEDICATION</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1455</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION</TradeName>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION WITH DECONGESTANT</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1456</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1457</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1473</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1474</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1718</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1721</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NORTHAMPTON MEDICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEMCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1871</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER HEALTH CARE</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1899</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>POLYMEDICA</CompanyName>
              <MarketedTradeNames>
                <TradeName>NEOPAP SUPPOSITORIES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1932</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>1987</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICO PHARMACAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2010</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS COMPANY</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2127</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2138</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2157</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2158</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2230</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2236</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2513</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2514</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2519</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2520</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2597</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UPSHER-SMITH</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEVERALL CHILDREN'S SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL INFANT'S SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL JUNIOR STRENGTH SUPPOSITORIES</TradeName>
                <TradeName>FEVERALL SPRINKLE CAPS POWDER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2617</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN TABLETS AND CAPLETS, USP</TradeName>
                <TradeName>HYDROCODONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2618</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED PLUS TABLETS AND CAPLETS</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS AND TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>BENADRYL COLD/FLU TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2620</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB MAXIMUM STRENGTH SINUS ALLERGY TABLETS</TradeName>
                <TradeName>SINUTAB REGULAR STRENGTH WITHOUT DROWSINESS TABLET</TradeName>
                <TradeName>SINUTAB SINUS MAXIMUM STRENGTH WITHOUT DROWSINESS TABLET</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2621</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2631</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>2755</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>305</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOEHRINGER MANNHEIM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>306</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>COMTREX MAXIMUM STRENGTH MULTI-SYMPTOM COLD RELIEVERTABLETS/CAPLETS/LIQUI-GELS/ LIQUID</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>NON-DROWSY COMTREX MAXIMUM STRENGTH CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC TABLETS &amp; CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>314</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>316</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>318</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM PLUS COUGH LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S CHEWABLE TABLETS &amp; ELIXIR</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN CHILDREN'S SUSPENSION LIQUID</TradeName>
                <TradeName>TYLENOL COLD HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION</TradeName>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION WITH DECONGESTANT</TradeName>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS' SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS NIGHTTIME MEDICINE</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, HOT MEDICATION</TradeName>
                <TradeName>TYLENOL INFANTS' DROPS AND INFANTS' SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID CAPLETS, GELCAPS, GELTABS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEILCONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>334</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UAD LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>336</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WHITBY</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>498</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP ELIXIR</TradeName>
                <TradeName>GELPIRIN CCF TABLETS</TradeName>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>592</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARRE-NATIONAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION</TradeName>
                <TradeName>APAP DROPS</TradeName>
                <TradeName>APAP ELIXIR-CHERRY OR GRAPE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>648</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BOEHRINGER MANNHEIM</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>701</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>COMTREX MAXIMUM STRENGTH MULTI-SYMPTOM COLD RELIEVERTABLETS/CAPLETS/LIQUI-GELS/ LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>702</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALLERGY-SINUS COMTREX MULTI-SYMPTOM ALLERGY SINUS FORMULA TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>703</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS</TradeName>
                <TradeName>NON-DROWSY COMTREX MAXIMUM STRENGTH CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>704</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>841</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>842</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>843</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>845</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>847</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>852</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>957</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>971</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>DURADRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
                <TradeName>PANACET 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
                <TradeName>REPAN-CF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>49</PDRVolume>
          <PDRYear>1995</PDRYear>
          <PDRPages>997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1010</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>BANCAP HC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1013</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES AND TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1018</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
                <TradeName>LORCET-HD</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1283</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>RELAGESIC</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KENWOOD</CompanyName>
              <MarketedTradeNames>
                <TradeName>DUADACIN COLD, FLU &amp; ALLERGY CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1356</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1357</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1433</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
                <TradeName>DARVOCET-N 50</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1487</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCO-PAP CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1543</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYRAND</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1554</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1555</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL ACETAMINOPHEN DROPS AND SUSPENSION DROPS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS NIGHTTIME MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1556</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT &amp; FEVER-REDUCER DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1557</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM HOT MEDICATION LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1558</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1559</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1560</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID CAPLETS, GELTABS, GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1561</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1562</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH FLU NIGHTTIME HOT MEDICATION PACKETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1563</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1564</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1565</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION WITH DECONGESTANT</TradeName>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1566</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, GELCAPS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1583</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1584</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1781</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MONARCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MONARCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
                <TradeName>ANEXSIA 7.5/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1790</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1934</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>1993</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2038</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>RICO PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIGRALAM CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2066</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2228</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2244</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2258</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2260</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2339</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2566</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>FEMCET CAPSULES</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2576</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2679</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE WITH APAP TABLETS</TradeName>
                <TradeName>HYDROCODONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS TABLETS AND CAPLETS</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2680</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS MAXIMUM STRENGTH WITHOUT DROWSINESS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS REGULAR STRENGTH WITHOUT DROWSINESS TABLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED SINUS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2682</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>2891</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MAXIMUM STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS AND GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES AND TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650</TradeName>
                <TradeName>LORCET PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT &amp; FEVER-REDUCER DROPS</TradeName>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, ACETAMINOPHEN GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH, ACETAMINOPHEN CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM LIQUID FORMULA AND CHEWABLE TABLETS</TradeName>
                <TradeName>INFANTS' TYLENOL ACETAMINOPHEN DROPS AND SUSPENSION DROPS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM FORMULA MEDICATION TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM HOT MEDICATION LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION</TradeName>
                <TradeName>TYLENOL COUGH MULTI-SYMPTOM MEDICATION WITH DECONGESTANT</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH, HEADACHE PLUS PAIN RELIEVER WITH ANTACID CAPLETS</TradeName>
                <TradeName>TYLENOL FLU MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH, GELCAPS</TradeName>
                <TradeName>TYLENOL JUNIOR STRENGTH, ACETAMINOPHEN COATED CAPLETS, GRAPE AND FRUIT CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS MEDICATION GELCAPS AND CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH ALLERGY SINUS NIGHTTIME MEDICATION CAPLETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH FLU NIGHTTIME HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL MAXIMUM STRENGTH, SINUS MEDICATION GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL PM EXTRA STRENGTH PAIN RELIEVER/SLEEP AID CAPLETS, GELTABS, GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>325</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MONARCH</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA 5/500 ELIXIR</TradeName>
                <TradeName>ANEXSIA 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>485</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA</CompanyName>
              <MarketedTradeNames>
                <TradeName>APAP ELIXLR</TradeName>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>581</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BARRE-NATIONAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>APAP DROPS</TradeName>
                <TradeName>APAP ELIXIR-CHERRY OR GRAPE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>668</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>732</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS AND GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS &amp; CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>733</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS, LIQUIGELS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>782</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>783</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>785</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>787</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>792</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>794</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PEDIAPAP ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>932</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>938</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>949</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>958</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>DURADRIN CAPSULES</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>959</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
                <TradeName>PANACET 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>971</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>976</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN TABLETS AND CAPSULES</TradeName>
                <TradeName>REPAN-CF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>50</PDRVolume>
          <PDRYear>1996</PDRYear>
          <PDRPages>982</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1000</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1012</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1016</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1331</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>INTERNATIONAL ETHICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>RELAGESIC</TradeName>
                <TradeName>TENCON CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1403</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1404</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1405</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1473</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1544</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1559</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, SUSPENSION LIQUID, AND SUSPENSION DROPS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL ACETAMINOPHEN SUSPENSION DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1560</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1561</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT &amp; FEVER-REDUCER DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1562</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>JUNIOR STRENGTH TYLENOL ACETAMINOPHEN COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1570</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1571</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1572</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM HOT LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1573</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD SEVERE CONGESTION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1574</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1575</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUME</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH GELCAPS, CAPLETS, GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1576</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1592</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1593</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1826</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/850 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1836</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>1991</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2055</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2148</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2239</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>232</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2348</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR, TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION [OXYCODONE &amp; ACETAMINOPHEN]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2386</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2387</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2464</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2469</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2612</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CETA PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>LOBAC CAPSULES</TradeName>
                <TradeName>LOBAC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2613</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENAKE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2748</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS [CIII]</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS [CIII]</TradeName>
                <TradeName>PROPACET 100 [PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN] TABLETS [CIV]</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS [CIV]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2751</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2765</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2787</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, UPSA</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS [USP]</TradeName>
                <TradeName>HYDROCODONE BITARTRATE WITH APAP TABLETS</TradeName>
                <TradeName>HYDROCODONE WITH APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS TABLETS AND CAPLETS</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS AND TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2789</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS MS WITHOUT DROWSINESS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS RS WITHOUT DROWSINESS TABLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2790</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER WELLCOME</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SINUS MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>2930</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>306</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS AND GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS, CAPLETS, AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>320</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABORATORIES</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ACETAMINOPHEN CHEWABLE TABLETS, ELIXIR, SUSPENSION LIQUID, AND SUSPENSION DROPS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL ACETAMINOPHEN SUSPENSION DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT &amp; FEVER-REDUCER DROPS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, TABLETS</TradeName>
                <TradeName>TYLENOL ACETAMINOPHEN REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUME</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL ACETAMINOPHEN COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS HEADACHE GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM HOT LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH GELCAPS, CAPLETS, GELTABS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>329</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANDOZ PHARMACEUTICALS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SANOFI WINTHROP</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>338</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>481</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALPHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>APAP DROPS</TradeName>
                <TradeName>APAP ELIXIR-CHERRY OR GRAPE</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>484</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>511</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>666</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>734</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS AND GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS, CAPLETS, AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>735</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SLEEPING AID TABLETS, CAPLETS, LIQUIGELS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>787</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>788</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>790</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>792</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>809</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>811</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CENTRAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>PEDIAPAP ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>955</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>967</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DUPONT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>979</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>DURADRIN CAPSULES</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>988</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII [OXYCODONE HCL 5 MG, ACETAMINOPHEN 325 MG]</TradeName>
                <TradeName>HYDROCODONE/APAP TABLETS, USP CIII 5/500 MG, 7.5/650 MG, 7.5/750 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>51</PDRVolume>
          <PDRYear>1997</PDRYear>
          <PDRPages>992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN-CF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1365</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1367</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1443</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 30 TABLES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1519</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1536</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1537</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL SUSPENSION DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1538</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1539</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL FLU LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1540</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1541</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1548</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1549</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1550</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1551</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM HOT LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1552</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1553</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1554</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1555</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1781</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1800</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1852</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>1854</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2061</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO -MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2063</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2159</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2236</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2330</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2420</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2536</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION AND TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION [CHERRY]</TradeName>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ROXILOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2556</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2592</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2597</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2678</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHWARZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2923</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>TEN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS [CIV]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>TEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS [CIII]</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS</TradeName>
                <TradeName>PROPACET 100 TABLETS [CIV]</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/300 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2940</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2978</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2979</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS CAPLETS AND TABLETS</TradeName>
                <TradeName>ACTIFED SINUS DAYTIME/NIGHTTIME CAPLETS AND TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2980</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS MS WITHOUT DROWSINESS CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS</TradeName>
                <TradeName>SUDAFED SINUS MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2981</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>2986</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS &amp; GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS, CAPLETS, AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>3146</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>318</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>320</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL SUSPENSION DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>3211</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>CETA PLUS CAPSULES</TradeName>
                <TradeName>LOBAC CAPSULES</TradeName>
                <TradeName>LOBAC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>3212</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SEATRACE</CompanyName>
              <MarketedTradeNames>
                <TradeName>TENAKE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM HOT LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MEDICATION CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO -MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE, ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>331</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PURDUE FREDERICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>DHCPLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>334</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SCHWARZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>CO-GESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>340</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/300 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>343</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>500</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>701</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>776</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN ANALGESIC CAPLETS &amp; GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>777</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH ANALGESIC TABLETS, CAPLETS, AND GELTABS</TradeName>
                <TradeName>EXCEDRIN P.M. ANALGESIC/SEEPING AID TABLETS, CAPLETS, AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>824</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>825</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>829</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>895</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>DURAMED</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>DURADRIN CAPSULES</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>907</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS USP CII</TradeName>
                <TradeName>HYDROCODONE/ACETAMINOPHEN TABLETS, USP CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>908</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>914</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>920</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>926</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>EVERETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>REPAN-CF TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>937</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>947</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>951</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>952</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>52</PDRVolume>
          <PDRYear>1998</PDRYear>
          <PDRPages>996</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1011</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1020</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1021</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1026</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1027</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1076</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORPAP TABLETS</TradeName>
                <TradeName>PROPOXYPHENE HCL/ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1484</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1486</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1487</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1567</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1649</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANABAR CAPSULES</TradeName>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1666</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYOR</CompanyName>
              <MarketedTradeNames>
                <TradeName>VITAMINOPHEN</TradeName>
                <TradeName>VITAMIST INTRA-ORAL SPRAY DIETARY SUPPLEMENTS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1667</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY- D LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1668</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEW CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1669</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1670</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL FLU LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1671</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SINUS CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1672</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD PLUS COUGH DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1673</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1684</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1685</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ARTHRITIS EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MAXIMUM STRENGTH MEDICATION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1687</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM HOT MEDICATION LIQUID PACKETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1688</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1689</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1690</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1691</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1927</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>1955</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2028</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2029</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2252</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2253</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2362</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>UNISOM WITH PAIN RELIEF-NIGHTTIME SLEEP AID AND PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2450</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2640</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2743</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION AND TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION [CHERRY]</TradeName>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ROXILOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2764</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
                <TradeName>ROXICET TABLETS &amp; ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2806</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>2810</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>307</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3162</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3175</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>318</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>320</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD PLUS COUGH DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>TYLENOL ARTHRITIS EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3214</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER CHILCOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS CAPLETS AND TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS &amp; GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS MS WITHOUT DROWSINESS CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3216</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SINUS MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY- D LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH MULTI-SYMPTOM CHEWABLE TABLETS AND LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEW CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND CHEWABLE TABLETS</TradeName>
                <TradeName>SINE-AID MAXIMUM STRENGTH SINUS MEDICATION GELCAPS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION MULTI-SYMPTOM FORMULA TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD MEDICATION NO DROWSINESS FORMULA CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM HOT MEDICATION LIQUID PACKETS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL COUGH MEDICATION WITH DECONGESTANT, MULTI-SYMPTOM</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH HOT MEDICATION PACKETS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NO DROWSINESS FORMULA, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY MAXIMUM STRENGTH MEDICATION CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3233</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>NOVARTIS</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>329</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>336</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>3400</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>345</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>510</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ALRA</CompanyName>
              <MarketedTradeNames>
                <TradeName>GELPIRIN TABLETS</TradeName>
                <TradeName>GELPIRIN-M TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>815</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>816</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
                <TradeName>EXCEDRIN P.M. CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. GELTABS</TradeName>
                <TradeName>EXCEDRIN P.M. TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>869</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>870</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>871</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>873</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>875</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>960</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>971</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS, USP CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>975</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>984</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>53</PDRVolume>
          <PDRYear>1999</PDRYear>
          <PDRPages>989</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1009</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS, USP CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1028</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1037</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1042</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1066</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIELDING</CompanyName>
              <MarketedTradeNames>
                <TradeName>VITELLE LURLINE PMS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1068</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FLEMING</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALUMADRINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1078</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1083</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1133</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1388</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>HORIZON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZEBUTAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1501</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1502</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1503</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1574</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1658</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANABAR CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1659</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LUNSCO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PACAPS CAPSULES</TradeName>
                <TradeName>PROTID TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1670</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1671</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1673</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1674</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAYOR</CompanyName>
              <MarketedTradeNames>
                <TradeName>VITAMINOPHEN</TradeName>
                <TradeName>VITAMIST INTRO-ORAL SPRAY DIETARY SUPPLEMENTS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1675</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1676</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEW CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1677</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1678</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1680</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1682</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND SOFT-CHEW CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1693</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ARTHRITIS EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1694</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1695</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD COMPLETE FORMULA, MULTI-SYMPTOM TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NON-DROWSY MULTI-SYMPTOM CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1696</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY MULTI-SYMPTOM CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1697</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH POWDER</TradeName>
                <TradeName>TYLENOL FLU NON-DROWSY, MAXIMUM STRENGTH GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1698</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL SORE THROAT, MAXIMUM STRENGTH ADULT LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1699</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NON-DROWSY, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1921</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>1962</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2216</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2217</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2407</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2601</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2705</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION AND TABLETS</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION [CHERRY]</TradeName>
                <TradeName>ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>ROXILOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2762</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>2766</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
                <TradeName>MIDRIN CAPSULES</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3120</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3141</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEURICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3166</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS &amp; GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3167</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SINUTAB SINUS MS WITHOUT DROWSINESS CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3168</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED SINUS MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP CIII</TradeName>
                <TradeName>BUTALBITAL, CAFFEINE, AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP CIII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP CII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP CII</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS, USP CIV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEW CHEWABLE TABLETS, ELIXIR, AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL COATED CAPLETS AND SOFT-CHEW CHEWABLE TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL COLD COMPLETE FORMULA, MULTI-SYMPTOM TABLETS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NON-DROWSY MULTI-SYMPTOM CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY MULTI-SYMPTOM CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH POWDER</TradeName>
                <TradeName>TYLENOL FLU NON-DROWSY, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH CAPLETS AND TABLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SORE THROAT, MAXIMUM STRENGTH ADULT LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS NON-DROWSY, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>329</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>3337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>340</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>344</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>786</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>812</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ASPIRIN FREE EXCEDRIN CAPLETS</TradeName>
                <TradeName>ASPIRIN FREE EXCEDRIN GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>813</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>814</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN P.M. CAPLETS</TradeName>
                <TradeName>EXCEDRIN P.M. GELTABS</TradeName>
                <TradeName>EXCEDRIN P.M. TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>901</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>902</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>906</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>54</PDRVolume>
          <PDRYear>2000</PDRYear>
          <PDRPages>908</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINULIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1077</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1177</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1200</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII</TradeName>
                <TradeName>OXYCODONE/ACETAMINOPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1201</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1211</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1250</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIRST HORIZON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZEBUTAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1253</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FLEMING</CompanyName>
              <MarketedTradeNames>
                <TradeName>ALUMADRINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1263</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1268</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1628</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1629</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1630</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1708</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1809</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1810</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1812</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1814</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEWS CHEWABLE TABLETS AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1815</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1816</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1817</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SINUS SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1818</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1819</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1820</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT-CHEWS CHEWABLE TABLET</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1832</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1833</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1834</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD COMPLETE FORMULA, MULTI-SYMPTOM CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NON-DROWSY MULTI-SYMPTOM CAPLETS AND GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1835</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY MULTI-SYMPTOM CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1836</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NON-DROWSY, MAXIMUM STRENGTH GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1837</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL SORE THROAT, MAXIMUM STRENGTH ADULT LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>1838</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NON-DROWSY, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF, MULTI-SYMPTOM CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2060</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2115</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2397</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2398</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2560</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2710</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2822</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION AND TABLETS</TradeName>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
                <TradeName>ROXICET ORAL SOLUTION</TradeName>
                <TradeName>ROXICET TABLETS</TradeName>
                <TradeName>ROXILOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2868</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>2874</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>CARNRICK</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>KNOLL LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3209</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SOFT-CHEWS CHEWABLE TABLETS AND SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT-CHEWS CHEWABLE TABLET</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
                <TradeName>TYLENOL COLD COMPLETE FORMULA, MULTI-SYMPTOM CAPLETS</TradeName>
                <TradeName>TYLENOL COLD NON-DROWSY MULTI-SYMPTOM CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL EXTRA STRENGTH GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL REGULAR STRENGTH TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY SINUS MAXIMUM STRENGTH CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>TYLENOL ALLERGY SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY MULTI-SYMPTOM CAPLETS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME, MAXIMUM STRENGTH LIQUID</TradeName>
                <TradeName>TYLENOL FLU NON-DROWSY, MAXIMUM STRENGTH GELCAPS</TradeName>
                <TradeName>TYLENOL PM PAIN RELIEVER/SLEEP AID, EXTRA STRENGTH CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NON-DROWSY, MAXIMUM STRENGTH GELTABS, GELCAPS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>TYLENOL SORE THROAT, MAXIMUM STRENGTH ADULT LIQUID</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF, MULTI-SYMPTOM CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3233</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
                <TradeName>NOREL PLUS CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3265</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS CAPLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3266</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS &amp; GELCAPS</TradeName>
                <TradeName>SINUTAB SINUS ALLERGY, MEDICATION MS TABLETS AND CAPLETS</TradeName>
                <TradeName>SINUTAB SINUS MEDICATION MS WITHOUT DROWSINESS TABLETS AND CAPLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3267</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WARNER-LAMBERT</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED SINUS MS CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP CIII</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP CIII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP CII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP CII</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS, USP CIV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS NIGHTTIME, MAXIMUM STRENGTH CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>329</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3303</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>333</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>339</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>340</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>3468</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WYETH-AYERST</CompanyName>
              <MarketedTradeNames>
                <TradeName>WYGESIC TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>539</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>540</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>956</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>55</PDRVolume>
          <PDRYear>2001</PDRYear>
          <PDRPages>992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1025</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1070</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1266</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1316</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS, USP CII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1317</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1326</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1330</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1359</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIRST HORIZON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZEBUTAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1370</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1375</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1907</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1992</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1993</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CODEINE PHOSPHATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1994</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS. USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1996</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>1997</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2009</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2010</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHTTIME CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2011</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME LIQUID</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NON-DROWSY GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2012</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHTTIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NON-DROWSY GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2013</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2014</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2015</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2017</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SINUS SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2225</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2278</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2595</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2597</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLOX CAPSULES</TradeName>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2760</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACTIFED COLD &amp; SINUS CAPLETS</TradeName>
                <TradeName>BENADRYL ALLERGY/COLD TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2761</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY/SINUS HEADACHE CAPLETS &amp; GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2762</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PFIZER CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS ALLERGY MEDICATION MS TABLETS AND CAPLETS</TradeName>
                <TradeName>SINUTAB SINUS MEDICATION MS WITHOUT DROWSINESS TABLETS AND CAPLETS</TradeName>
                <TradeName>SUDAFED COLD &amp; COUGH LIQUID CAPS</TradeName>
                <TradeName>SUDAFED COLD &amp; SINUS LIQUID CAPS</TradeName>
                <TradeName>SUDAFED SEVERE COLD FORMULA MS CAPLETS AND TABLETS</TradeName>
                <TradeName>SUDAFED SINUS HEADACHE CAPLETS AND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2763</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>2929</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROBINS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHENAPHEN WITH CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3056</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION</TradeName>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES USP</TradeName>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
                <TradeName>ROXICET ORAL SOLUTION</TradeName>
                <TradeName>ROXICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3089</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>309</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3094</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SAVAGE</CompanyName>
              <MarketedTradeNames>
                <TradeName>AXOCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL ALLERGY-D LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD PLUS COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL COLD SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SINUS SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS</TradeName>
                <TradeName>INFANTS' TYLENOL COLD DECONGESTANT AND FEVER REDUCER CONCENTRATED DROPS PLUS COUGH</TradeName>
                <TradeName>INFANTS' TYLENOL CONCENTRATED DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHTTIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME LIQUID</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NON-DROWSY GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHTTIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NON-DROWSY GELTABS, GELCAPS, CAPLETS AND TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPSULES</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>330</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>TYLOX CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3317</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>334</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3369</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP CIII</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP CIII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP CII</TradeName>
                <TradeName>PENTAZOCINE HCL AND ACETAMINOPHEN TABLETS CIV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS, USP CIV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>339</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 5/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 7.5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3399</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3424</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3425</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 7.5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3427</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3464</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WOMEN FIRST</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>3613</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>GENEVA</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>516</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>517</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>518</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>577</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>56</PDRVolume>
          <PDRYear>2002</PDRYear>
          <PDRPages>578</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1022</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1065</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1240</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1295</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS CII, USP</TradeName>
                <TradeName>ENDODAN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1296</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1308</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1337</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FIRST HORIZON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZEBUTAL CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1349</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1354</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>LILLY</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP</TradeName>
                <TradeName>ANEXSIA TABLETS</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1908</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1910</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHT TIME COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1911</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME LIQUID</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1912</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS AND CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1913</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>WOMENS TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1914</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS ALLERGY</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1915</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>1917</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS SINUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2134</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2193</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2507</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2508</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2686</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2811</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUID AND LIQUICAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2812</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS 44M COUGH, COLD &amp; FLU RELIEF</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2813</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>2972</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES USP</TradeName>
                <TradeName>ROXICET 5/500 CAPLETS</TradeName>
                <TradeName>ROXICET ORAL SOLUTION</TradeName>
                <TradeName>ROXICET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3011</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
                <TradeName>PHRENILIN WITH CAFFEINE AND CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL-MYERS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS ALLERGY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS SINUS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME LIQUID</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS AND CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHT TIME COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>WOMENS TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3224</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3227</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3270</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP CIII</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND APAP TABLETS, USP CIII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP CII</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP CII</TradeName>
                <TradeName>PENTAZOCINE HCL AND ACETAMINOPHEN TABLETS CIV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS, USP CIV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3302</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>SANOFI-SYNTHELABO</CompanyName>
              <MarketedTradeNames>
                <TradeName>TALACEN CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3327</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 7.5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>336</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 5/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 7.5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3366</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WOMEN FIRST</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>341</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>3503</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AAI PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>509</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>510</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>511</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>567</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>568</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYDROCET CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>571</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN WITH CAFFEINE AND CODEINE CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>572</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>57</PDRVolume>
          <PDRYear>2003</PDRYear>
          <PDRPages>831</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BALLAY</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORTEMP ORAL SOLUTION-CHILDREN'S</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1118</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
                <TradeName>EXCEDRIN TENSION HEADACHE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS, PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1119</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN PM TABLETS, CAPLETS, AND GELTABS</TradeName>
                <TradeName>EXCEDRIN QUICKTABS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1215</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1235</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO GENERICS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS CII, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1236</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1245</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1249</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1297</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1306</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1872</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MAGNA</CompanyName>
              <MarketedTradeNames>
                <TradeName>STAFLEX CAPLETS</TradeName>
                <TradeName>STAGESIC CAPSULES CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MALLINCKRODTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1873</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1889</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND GELCAPS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1890</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1891</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHT TIME COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS. GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SEVERE COLD &amp; FLU NIGHTTIME LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1893</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS, AND CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1894</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1895</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS ALLERGY</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>1896</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MC NEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS SINUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2126</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2194</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2490</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2491</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2701</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACETUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2821</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUID &amp; LIQUICAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2822</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS 44M COUGH, COLD &amp; FLU RELIEF</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2823</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>2996</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES USP CII</TradeName>
                <TradeName>ROXICET ORAL SOLUTION CII</TradeName>
                <TradeName>ROXICET TABLETS USP CII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH CAPLETS</TradeName>
                <TradeName>EXCEDRIN EXTRA-STRENGTH TABLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE CAPLETS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE GELTABS</TradeName>
                <TradeName>EXCEDRIN MIGRAINE TABLETS</TradeName>
                <TradeName>EXCEDRIN PM TABLETS, CAPLETS, AND GELTABS</TradeName>
                <TradeName>EXCEDRIN TENSION HEADACHE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS, PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN EXTRA-STRENGTH GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BRISTOL MYERS PRODUCTS</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXCEDRIN QUICKTABS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>313</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>314</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MC NEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS SINUS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS ALLERGY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>JUNIOR STRENGTH TYLENOL SOFT CHEWS CHEWABLE TABLETS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHT TIME COMPLETE FORMULA CAPLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3233</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3235</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>OCR</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>324</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS. GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SEVERE COLD &amp; FLU NIGHTTIME LIQUID</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS, AND CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE RELIEF CAPLETS</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3250</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACETUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3296</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE PHOSPHATE CAPSULES</TradeName>
                <TradeName>HYDROCODONE AND APAP TABLETS</TradeName>
                <TradeName>OXYCODONE/APAP CAPSULES</TradeName>
                <TradeName>OXYCODONE/APAP TABLETS</TradeName>
                <TradeName>PENTAZOCINE/APAP TABLETS</TradeName>
                <TradeName>PROPOXYPHENE/APAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>330</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3360</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3361</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORCO 10/325 TABLETS CIII</TradeName>
                <TradeName>NORCO 7.5/325 TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3396</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WOMEN FIRST</CompanyName>
              <MarketedTradeNames>
                <TradeName>MIDRIN CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>3522</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>403</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AAI PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>525</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>526</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>528</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>565</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>568</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AMARIN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>804</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BALLAY</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORTEMP SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>58</PDRVolume>
          <PDRYear>2004</PDRYear>
          <PDRPages>991</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BLANSETT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANOLOR 300 CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1192</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1212</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS CII, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1213</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1222</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1226</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1275</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1286</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1287</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1924</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS, USP</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS, USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN CAPSULES</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES, USP</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS, USP</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1925</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1943</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1944</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1945</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1946</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE DAYTIME LIQUID</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE NIGHTTIME LIQUID</TradeName>
                <TradeName>TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1947</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS, AND CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1948</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1949</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD NIGHTTIME SUSPENSION LIQUID</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>1950</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD DAYTIME NON-DROWSY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2197</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2213</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2548</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2549</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2692</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2792</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUID &amp; LIQUICAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2793</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS 44M COUGH, COLD &amp; FLU RELIEF</TradeName>
                <TradeName>VICKS NYQUIL LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>2966</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ROXANE</CompanyName>
              <MarketedTradeNames>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES USP CII</TradeName>
                <TradeName>ROXICET 5/500 CAPLETS USP CII</TradeName>
                <TradeName>ROXICET ORAL SOLUTION CII</TradeName>
                <TradeName>ROXICET TABLETS USP CII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELCAPS, GELTABS, CAPLETS, AND TABLETS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD DAYTIME NON-DROWSY</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD NIGHTTIME SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, AND GELCAPS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS DAY TIME CAPLETS, GELCAPS, AND GELTABS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL ALLERGY SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>MAXIMUM STRENGTH TYLENOL SORE THROAT ADULT LIQUID</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND CAPLETS</TradeName>
                <TradeName>TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS</TradeName>
                <TradeName>TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY GELTABS, GELCAPS, AND CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3238</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3240</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3261</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3266</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VALEANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3276</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VALEANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3296</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE CAPSULES C-III</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS C-ILL</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES C-II</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS C-II</TradeName>
                <TradeName>PENTAZOCINE HCL AND ACETAMINOPHEN TABLETS CLV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS C-IV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3299</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES C-III</TradeName>
                <TradeName>MAXIDONE TABLETS CIII</TradeName>
                <TradeName>NORCO TABLETS CIII</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>VALEANT</CompanyName>
              <MarketedTradeNames>
                <TradeName>CAPITAL AND CODEINE ORAL SUSPENSION</TradeName>
                <TradeName>PHRENILIN FORTE CAPSULES</TradeName>
                <TradeName>PHRENILIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>3418</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>XANODYNE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCET ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>402</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>AAI PHARMA</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET A 500 TABLETS</TradeName>
                <TradeName>DARVOCET-N 100 TABLETS</TradeName>
                <TradeName>DARVOCET-N 50 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>526</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>527</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>528</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>59</PDRVolume>
          <PDRYear>2005</PDRYear>
          <PDRPages>778</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BALLAY</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORTEMP SUSPENSION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1081</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS CII, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1105</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCOMINE COMPOUND TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1114</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1118</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1186</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1198</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1199</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1827</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MALLINCKRODT</CompanyName>
              <MarketedTradeNames>
                <TradeName>ANEXSIA TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1843</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELTABS, CAPLETS, COOL CAPLETS AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1844</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY COMPLETE MULTI-SYMPTOM CAPLETS AND GELCAPS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL ALLERGY COMPLETE NIGHTTIME CAPLETS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1845</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHTTIME CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1846</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1847</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, GELCAPS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1848</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1849</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1850</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1851</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD DAYTIME NON-DROWSY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD NIGHTTIME SUSPENSION LIQUID</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>1853</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2098</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MERZ</CompanyName>
              <MarketedTradeNames>
                <TradeName>SEDAPAP TABLETS 50 MG/650 MG</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2110</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2461</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2462</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2599</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2675</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/ FLU RELIEF LIQUID</TradeName>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUICAPS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2676</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS 44M COUGH, COLD &amp; FLU RELIEF</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>2677</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>303</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; COUGH SUSPENSION LIQUID AND CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD CHEWABLE TABLETS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD DAYTIME NON-DROWSY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD NIGHTTIME SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL GELTABS, CAPLETS, COOL CAPLETS AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD NIGHTTIME CAPLETS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, GELTABS, GELCAPS AND LIQUID</TradeName>
                <TradeName>MULTI-SYMPTOM TYLENOL COLD DAY NON-DROWSY CAPLETS AND GELCAPS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE GELTABS AND CAPLETS</TradeName>
                <TradeName>TYLENOL ALLERGY COMPLETE MULTI-SYMPTOM CAPLETS AND GELCAPS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL ALLERGY COMPLETE NIGHTTIME CAPLETS</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD &amp; FLU SEVERE NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL FLU DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL FLU NIGHTTIME GELCAPS</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS DAY NON-DROWSY GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS NIGHT TIME CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT LIQUID PAIN RELIEVER</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>328</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
                <TradeName>ULTRACET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3315</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB 10/500 TABLETS</TradeName>
                <TradeName>LORTAB 2.5/500 TABLETS</TradeName>
                <TradeName>LORTAB 5/500 TABLETS</TradeName>
                <TradeName>LORTAB 7.5/500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3342</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>MEDIGESIC CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3376</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE CAPSULES C-III</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS C-III</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES C-II</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS C-II</TradeName>
                <TradeName>PENTAZOCINE HCI/ACETAMINOPHEN TABLETS C-IV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS C-IV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3378</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES C-ILL</TradeName>
                <TradeName>MAXIDONE TABLETS C-III</TradeName>
                <TradeName>NORCO TABLETS C-ILL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3379</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES C-ILL</TradeName>
                <TradeName>MAXIDONE TABLETS C-III</TradeName>
                <TradeName>NORCO TABLETS C-ILL</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3497</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>XANODYNE</CompanyName>
              <MarketedTradeNames>
                <TradeName>DARVOCET A 500 TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>3499</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>XANODYNE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCET ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>530</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>531</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>532</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>60</PDRVolume>
          <PDRYear>2006</PDRYear>
          <PDRPages>739</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>BALLAY</CompanyName>
              <MarketedTradeNames>
                <TradeName>NORTEMP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1089</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1110</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ENDOCET TABLETS CII, USP</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1131</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1139</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1182</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1195</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1870</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT RAPID BLAST LIQUID</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL CAPLETS, COOL CAPLETS, GO TABS AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1872</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1873</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD HEAD CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION SEVERE CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1874</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1875</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, VANILLA CAPLETS, GELTABS, GELCAPS AND LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1876</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1877</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1878</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION WITH FLAVOR CREATOR</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1879</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; RUNNY NOSE SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; SORE THROAT SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS MULTI-SYMPTOM COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>1881</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2146</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2391</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2461</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2479</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PAR</CompanyName>
              <MarketedTradeNames>
                <TradeName>TRAMADOL HCI/ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2599</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2678</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUICAPS</TradeName>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2680</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS 44M COUGH, COLD &amp; FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>2681</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL MULTI-SYMPTOM COLD/FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>303</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO LABS</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>312</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; RUNNY NOSE SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; SORE THROAT SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS MULTI-SYMPTOM COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID AND MELTAWAYS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION WITH FLAVOR CREATOR</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT RAPID BLAST LIQUID</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL CAPLETS, COOL CAPLETS, GO TABS AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION NON-DROWSY CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, VANILLA CAPLETS, GELTABS, GELCAPS AND LIQUID</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE CAPLETS</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>326</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>3338</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL SR TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>3385</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE CAPSULES C-III</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS C-III</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES C-II</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS C-II</TradeName>
                <TradeName>PENTAZOCINE HCI/ACETAMINOPHEN TABLETS C-IV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS C-IV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>3388</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES C-III</TradeName>
                <TradeName>MAXIDONE TABLETS C-III</TradeName>
                <TradeName>NORCO TABLETS C-III</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>3496</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>XANODYNE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCET ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>535</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>536</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>61</PDRVolume>
          <PDRYear>2007</PDRYear>
          <PDRPages>538</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1069</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ECR</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUPAP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1125</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1133</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1168</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC CAPSULES</TradeName>
                <TradeName>ESGIC TABLETS</TradeName>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1181</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
                <TradeName>LORCET-HD CAPSULES</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1877</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY &amp; COLD CAPLETS</TradeName>
                <TradeName>BENADRYL ALLERGY &amp; SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1879</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL SEVERE ALLERGY &amp; SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1889</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SINUTAB SINUS CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1890</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED PE COLD &amp; COUGH CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1891</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED PE NIGHTTIME COLD CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1892</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>SUDAFED PE SEVERE COLD CAPLETS</TradeName>
                <TradeName>SUDAFED PE SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1893</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL MELTAWAYS</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION WITH FLAVOR CREATOR</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION LIQUID WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1894</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD HEAD CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION SEVERE DAYTIME CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1896</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; RUNNY NOSE SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; SORE THROAT SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS MULTI-SYMPTOM COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1897</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME CAPLETS WITH COOL BURST AND RAPID RELEASE GELS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE DAYTIME LIQUID WITH CITRUS BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1898</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU SUSPENSION LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1899</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT RAPID BLAST LIQUID</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL CAPLETS, COOL CAPLETS, AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, VANILLA CAPLETS, GELTABS, GELCAPS, LIQUID, AND RAPID RELEASE GELS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1901</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>1903</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2164</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MYLAN</CompanyName>
              <MarketedTradeNames>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS</TradeName>
                <TradeName>PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2365</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2589</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PHARMACEUTICAL ASSOCIATES</CompanyName>
              <MarketedTradeNames>
                <TradeName>ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SOLUTION USP</TradeName>
                <TradeName>ACETAMINOPHEN ORAL SUSPENSION USP</TradeName>
                <TradeName>HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2654</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/ FLU RELIEF LIQUICAPS</TradeName>
                <TradeName>VICKS DAYQUIL MULTI-SYMPTOM COLD/ FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2655</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS FORMULA 44M COUGH, COLD &amp; FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2656</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL MULTI-SYMPTOM COLD/ FLU RELIEF LIQUICAPS</TradeName>
                <TradeName>VICKS NYQUIL MULTI-SYMPTOM COLD/ FLU RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>2657</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>PROCTER &amp; GAMBLE</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICKS NYQUIL D COLD &amp; FLU MULTI-SYMPTOM RELIEF LIQUID</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>303</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>304</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>310</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ENDO</CompanyName>
              <MarketedTradeNames>
                <TradeName>PERCOCET TABLETS</TradeName>
                <TradeName>ZYDONE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>311</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>FOREST</CompanyName>
              <MarketedTradeNames>
                <TradeName>ESGIC-PLUS TABLETS</TradeName>
                <TradeName>LORCET 10/650 TABLETS</TradeName>
                <TradeName>LORCET PLUS TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>319</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL ALLERGY &amp; COLD CAPLETS</TradeName>
                <TradeName>BENADRYL ALLERGY &amp; SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>320</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>BENADRYL SEVERE ALLERGY &amp; SINUS HEADACHE CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>321</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>EXTRA STRENGTH TYLENOL ADULT RAPID BLAST LIQUID</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL CAPLETS, COOL CAPLETS, AND EZ TABS</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL RAPID RELEASE GELS</TradeName>
                <TradeName>REGULAR STRENGTH TYLENOL TABLETS</TradeName>
                <TradeName>SINUTAB SINUS CAPLETS</TradeName>
                <TradeName>SUDAFED PE COLD &amp; COUGH CAPLETS</TradeName>
                <TradeName>SUDAFED PE NIGHTTIME COLD CAPLETS</TradeName>
                <TradeName>SUDAFED PE SEVERE COLD CAPLETS</TradeName>
                <TradeName>SUDAFED PE SINUS HEADACHE CAPLETS</TradeName>
                <TradeName>TYLENOL ARTHRITIS PAIN EXTENDED RELEASE CAPLETS AND GELTABS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>322</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>CHILDREN'S TYLENOL MELTAWAYS</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD &amp; ALLERGY SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; RUNNY NOSE SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS COUGH &amp; SORE THROAT SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS FLU SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL PLUS MULTI-SYMPTOM COLD SUSPENSION LIQUID</TradeName>
                <TradeName>CHILDREN'S TYLENOL SUSPENSION LIQUID</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD</TradeName>
                <TradeName>CONCENTRATED TYLENOL INFANTS' DROPS PLUS COLD AND COUGH</TradeName>
                <TradeName>EXTRA STRENGTH TYLENOL PM CAPLETS, VANILLA CAPLETS, GELTABS, GELCAPS, LIQUID, AND RAPID RELEASE GELS</TradeName>
                <TradeName>JUNIOR TYLENOL MELTAWAYS</TradeName>
                <TradeName>TYLENOL 8 HOUR EXTENDED RELEASE CAPLETS</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL ALLERGY MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL CHEST CONGESTION LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD HEAD CONGESTION SEVERE DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME CAPLETS WITH COOL BURST AND RAPID RELEASE GELS</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COLD MULTI-SYMPTOM SEVERE DAYTIME LIQUID WITH CITRUS BURST</TradeName>
                <TradeName>TYLENOL COLD SEVERE CONGESTION DAYTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL COUGH &amp; SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SEVERE ALLERGY CAPLETS</TradeName>
                <TradeName>TYLENOL SORE THROAT DAYTIME LIQUID WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SORE THROAT NIGHTTIME LIQUID WITH COOL BURST</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>323</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>MCNEIL CONSUMER</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN DAYTIME CAPLETS WITH COOL BURST AND GELCAPS</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN NIGHTTIME CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS CONGESTION &amp; PAIN SEVERE CAPLETS WITH COOL BURST</TradeName>
                <TradeName>TYLENOL SINUS SEVERE CONGESTION CAPLETS WITH COOL BURST</TradeName>
                <TradeName>WOMEN'S TYLENOL MENSTRUAL RELIEF CAPLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>3259</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>UCB</CompanyName>
              <MarketedTradeNames>
                <TradeName>LORTAB TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>326</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ORTHO-MCNEIL</CompanyName>
              <MarketedTradeNames>
                <TradeName>TYLENOL WITH CODEINE ELIXIR</TradeName>
                <TradeName>TYLENOL WITH CODEINE TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>3279</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>U.S. PHARMACEUTICAL</CompanyName>
              <MarketedTradeNames>
                <TradeName>NOREL SR TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>3332</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE TABLETS</TradeName>
                <TradeName>BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE CAPSULES C-III</TradeName>
                <TradeName>HYDROCODONE BITARTRATE/ACETAMINOPHEN TABLETS C-III</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN CAPSULES C-II</TradeName>
                <TradeName>OXYCODONE AND ACETAMINOPHEN TABLETS C-II</TradeName>
                <TradeName>PENTAZOCINE HCL AND ACETAMINOPHEN TABLETS C-IV</TradeName>
                <TradeName>PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS C-IV</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>3335</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>WATSON</CompanyName>
              <MarketedTradeNames>
                <TradeName>FIORICET TABLETS</TradeName>
                <TradeName>FIORICET WITH CODEINE CAPSULES C-III</TradeName>
                <TradeName>MAXIDONE TABLETS C-ILL</TradeName>
                <TradeName>NORCO TABLETS C-III</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>3445</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>XANODYNE</CompanyName>
              <MarketedTradeNames>
                <TradeName>HYCET ORAL SOLUTION</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>510</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>511</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN ES TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
        <PDRReference>
          <PDRVolume>62</PDRVolume>
          <PDRYear>2008</PDRYear>
          <PDRPages>513</PDRPages>
          <PharmaCompanies>
            <PharmaCompany>
              <CompanyName>ABBOTT</CompanyName>
              <MarketedTradeNames>
                <TradeName>VICODIN HP TABLETS</TradeName>
              </MarketedTradeNames>
            </PharmaCompany>
          </PharmaCompanies>
        </PDRReference>
      </PDRReferences>
    </KnownDrugInformation>
    <TextDatasets>
      <TextDatum>
        <Name>ActivityCategory_MCASE_mg_DSS_FDAMDD</Name>
        <Value>Low</Value>
        <Source>dssfdamdd</Source>
      </TextDatum>
      <TextDatum>
        <Name>ActivityCategory_MRDD_mmol_DSS_FDAMDD</Name>
        <Value>Low</Value>
        <Source>dssfdamdd</Source>
      </TextDatum>
      <TextDatum>
        <Name>TherapeuticCategory_DSS_FDAMDD</Name>
        <Value>analgesic; antipyretic</Value>
        <Source>dssfdamdd</Source>
      </TextDatum>
      <TextDatum>
        <Name>Bacterial Mutation</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Salmonella</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA100</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA98</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA1535</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA1537</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA100m</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA98m</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA1535m</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>TA1537m</Name>
        <Value>Negative</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>ivt Chrom. Abs.</Name>
        <Value>Positive</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>ivt Chrom. Abs. CHO</Name>
        <Value>Positive</Value>
        <Source>genetox_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>SAR Form</Name>
        <Value>LS-32</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Neutral Parent Form</Name>
        <Value>LS-32</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Rat_NTP</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Rat_CCRIS</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Female_Rat_CCRIS</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Mouse_NTP</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Mouse_CCRIS</Name>
        <Value>Intermediate</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Female_Mouse_NTP</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Female_Mouse_CCRIS</Name>
        <Value>Positive</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Rat</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Female_Rat</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Male_Mouse</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
      <TextDatum>
        <Name>Female_Mouse</Name>
        <Value>Negative</Value>
        <Source>carc_level_2</Source>
      </TextDatum>
    </TextDatasets>
    <Structure>
      <Molfile>
        <Header>
          <Line1>LS-32</Line1>
        </Header>
        <ConnectionTable><![CDATA[ 11 11  0  0  0  0  0  0  0  0999 V2000
   -2.5950    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5950   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2975   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0025   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0025    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2975    1.4975    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8925    1.5000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.2975   -1.5000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5950   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8950   -1.5000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5950    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  1  6  1  0  0  0  0
  1  7  1  0  0  0  0
  4  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
  9 11  1  0  0  0  0
M  END
]]></ConnectionTable>
      </Molfile>
    </Structure>
  </Compound>
</Compounds>